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 and amoxicillin Kent
®
 capsules 250 mg (left panels) and 500 mg (right 
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pH 6.8 (red). Three setup scenarios were tested: (1) 900 mL, USP II apparatus; (2) 
250 mL, USP II apparatus; (3) 50 mL, mini-paddle apparatus (from top to bottom). 
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 tablets 5 mg (left panels) and 25mg (right panels), in SGFsp 
pH 1.2 (blue), acetate buffer pH 4.5 (green) and phosphate buffer pH 6.8 (red). Three 
setup scenarios were tested: (1) 900 mL, USP II apparatus; (2) 250 mL, USP II 
apparatus; (3) 50 mL, mini-paddle apparatus (from top to bottom). Dotted grey lines 
represent the limit for ‘very rapid dissolution’ classification (> 85 % dissolved 
within 15 min). 







 tablets 5 mg (left panels) and 10 mg (right panels), in SGFsp 
pH 1.2 (blue), acetate buffer pH 4.5 (green) and phosphate buffer pH 6.8 (red) under 
three testing scenarios. Three setup scenarios were tested: (1) 900 mL, USP II 
apparatus; (2) 250 mL, USP II apparatus; (3) 50 mL, mini-paddle apparatus (from 
top to bottom). Dotted grey lines represent the limit for ‘very rapid dissolution’ 
classification (≥ 85 % dissolved within 15 min). 
Figure 6.6. Risk assessment of extending the biowaiver for IR formulations of 3 
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Green and red colours represent if the products would pass or fail, respectively, the 
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The field of paediatric biopharmaceutics is currently evolving, as a result of the 
distinct needs of this population regarding formulation design and performance. 
Age-appropriate biopharmaceutical tools for paediatric formulation development are 
warranted due to their potential in minimising scientific and regulatory risks. 
The aim of this thesis was to develop in vitro predictive tools to aid understanding of 
formulation performance in paediatrics, with emphasis on co-administration of 
medicines with food and drinks (vehicles), and to explore the extension of the 
Biopharmaceutics Classification System (BCS) to paediatrics. Common practices of 
medicine co-administration with vehicles were investigated and compared with the 
relevant guidelines. The possible negative outcomes of this practice were 
highlighted, revealing the need for a unified mandatory guidance on administration 
practices, vehicle selection and assessment. Frequently recommended vehicles were 
selected, and their physicochemical properties and composition were characterised. 
These differences had an impact on the solubility of two poorly soluble drugs, 
montelukast and mesalazine. Age-appropriate in vitro dissolution testing was 
developed to predict the impact of medicine co-administration on drug product 
performance. Drug dissolution was affected by co-administration with food and 
drinks in comparison to direct administration of formulation, and the time between 
preparation and testing of the drug-vehicle mixture. A biorelevant dissolution testing 
setup was developed, which predicted the in vivo formulation performance after 
medicine co-administration with vehicles in infants. Ultimately, the potential of 
dissolution studies with mini-paddle in mimicking paediatric administration 
practices and predicting in vivo drug performance was shown. An extension of 
current BCS-based biowaiver criteria into paediatrics was explored but shown not to 
be feasible due to gaps in knowledge regarding the gastrointestinal tract of paediatric 
patients, which hinder the development of a paediatric-BCS.  
Overall, this thesis provides a useful insight on the critical aspects of paediatric 
biopharmaceutics, with an overview on the possible impact of administration 
practices on paediatric clinical outcomes. This could be a starting point towards 
developing physiologically relevant in vitro biopharmaceutical tools, which can be 
used to assess product drug performance in paediatric subpopulations.  
15 
 
Aims and objectives 
This thesis discusses the benefit of developing appropriate biopharmaceutical tools 
for paediatric formulation development in order to minimise scientific and regulatory 
risks. The overall aim of this project was to develop predictive tools to understand 
formulation performance in the paediatric population, by gaining a 
biopharmaceutical understanding of current paediatric medicine co-administration 
practices and how these may impact therapy, and to identify the gaps in existing 
biopharmaceutical knowledge in this population. Age-appropriate biorelevant in 
vitro dissolution tests were developed to predict the impact of administration 
practices and age factors on drug product performance. 
The specific objectives of each chapter were: 
Chapter 1: To provide a general overview of the current strategies employed to 
overcome administration of a specific dose, acceptability and adherence issues of 
medicines in the paediatric population, with focus on the co-administration of 
medicines with food and drinks (vehicles). More specifically, an insight was given 
on the strategies for the co-administration of medicines with vehicles in the UK, in 
the context of their biopharmaceutical properties. Current administration practices 
reported by healthcare professionals and parents/carers were compared with the 
relevant guidelines, setting the background and experimental challenges of the Ph.D. 
project. 
Chapter 2: To describe the current recommended strategies for paediatric co-
administration of medicines with vehicles. Current administration recommendations 
in different settings were compared in order to obtain a global respective on practices 
and recommendations. A statistical model was developed to understand the rationale 
behind vehicle selection based on drug and formulation properties. 
Chapter 3: To screen the physicochemical properties of a selection of soft food and 
drinks, commonly reported to be mixed with medicines prior to paediatric 
administration, and to evaluate the vehicle-impact on the solubility of two poorly 
soluble drugs, montelukast and mesalazine. More specifically, in this chapter the 
importance of evaluating the possible vehicle-effect on drug solubility and, 
ultimately, product drug performance was highlighted. 
16 
 
Chapter 4: To develop an in vitro dissolution testing setup which could be used to 
evaluate drug dissolution whilst addressing typical dosing conditions, such as the 
effect of medicine co-administration with vehicles. The effect of medicine co-
administration with selected foods and drinks, and of different administration 
practices on drug dissolution was then evaluated. This study was used to demonstrate 
the potential of in vitro dissolution studies in mimicking administration practices and 
predicting formulation performance in the paediatric population. 
Chapter 5: To develop a predictive, biorelevant in vitro dissolution test to investigate 
the impact of practices of medicine co-administration with vehicles on the 
dissolution performance of a poorly soluble compound. To predict in vivo 
formulation performance, paediatric biorelevant media was used in combination with 
the dissolution setup developed in Chapter 4 to simulate the in vivo gastrointestinal 
environment of infants. Based on the in vitro dissolution data and the in vivo data 
available in the literature, in vitro-in vivo relationships were obtained. 
Chapter 6: To assess the risk of extending Biopharmaceutics Classification System 
(BCS)-based biowaiver criteria into paediatric products. Compounds that would 
change drug solubility class in the paediatric population were identified and their 
immediate release formulations were tested. The performance of the formulations 
tested in age-appropriate conditions were evaluated in order to identify 




Chapter 1: Recommended strategies for the oral administration of 
paediatric medicines with food and drinks in the context of their 
biopharmaceutical properties: a review 
Abstract 
Objectives: This review focuses on the recommended strategies for the oral 
administration of paediatric medicines with food in the context of their 
biopharmaceutical properties. 
Key findings: Acceptability of oral medicines in young patients is more challenging 
than in adult patients. Mixing oral dosage forms with foods and drinks is sometimes 
suggested in order to administer a specific dose and enhance compliance in the 
paediatric population. In this review, the strategies for the co-administration of 
paediatric medicines with food and drinks are discussed. Current administration 
practices as reported by healthcare professionals and parents/carers are compared 
with the relevant guidelines. Differences in the type of vehicles recommended to be 
used and actually used in current practice were identified. Correlations of the type of 
food recommended the type of formulation and the drug’s Biopharmaceutical 
Classification System (BCS) class were performed and revealed that 
recommendations should be made on a case-by-case basis.  
Summary: The propensity for physiochemical or bioavailability changes that may 
occur from the co-administration of medicines with food and drinks in the paediatric 
population should be considered and harmonisation of the recommended 








Historically, medicines for children have not been designed and tested for each target 
subpopulation. Medicines developed for adults are commonly administered to the 
paediatric population, usually informally adapted and in the absence of relevant 
evidence (1). It is widely recognised though that ‘Children are not just small 
adults’(2); constant developmental changes, in terms of anatomical and physiological 
aspects until adulthood, need to be considered for an efficient treatment and the 
development of appropriate formulations.  
The use of unlicensed and off-label medicines for children is widespread, with 
healthcare professionals, parents or carers facing the need to manipulate medicines 
designed for adults (3). This manipulation that can range from simple (e.g. tablet 
splitting) to complex methods (e.g. tablet crushing for suspension preparation) 
results in the availability of formulations ready to be administered and appropriate 
for the condition and patient intended. Appropriate oral formulations for young 
patients need to overcome swallowing difficulties or undesirable palatability, which 
could affect adherence in these patients (3-6). 
Acceptability, defined as the overall acceptance of the dosage form regardless of the 
mode of its administration (7), has been identified as an integral part of the paediatric 
formulation development. It depends on several factors, such as suitability of the 
dosage form and palatability of the oral medicine. Palatability, described as the 
overall acceptance of the taste, flavour, smell, dose, volume or size, and texture of a 
medicine to be administered by mouth or to be swallowed, is essential for adherence 
in this population and influences the choice of dosage form and its design (7). Carers 
usually attempt to facilitate administration and improve the acceptance of the patient 
by mixing the dose with food or drinks (8, 9). If this situation is intended/predicted, 
appropriate compatibility studies should be conducted to evaluate possible changes 
in bioavailability and information should be provided in the patient information 
leaflet, by the manufacturer (3). Recent studies have shown that sometimes this type 
of co-administration is performed without following the appropriate procedures, for 
example, by letting the child or carer chose the food or drink used for administration 
without proof of safety and efficacy (8, 9).  
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This review describes the current strategies employed to overcome administration of 
a specific dose, acceptability and adherence issues of medicines in the paediatric 
population, focusing on the co-administration of medicines with food and drinks. 
Current administration practices as reported by healthcare professionals and 
parents/carers are compared with the relevant guidelines in order to assess the 
possible clinical consequences of these practices, in particular changes in the 
bioavailability of the drug. The type of food and drinks co-administrated with 
paediatrics medicines was correlated with the type of formulation and the drug’s 
Biopharmaceutical Classification System (BCS) class in order to reveal the 
biopharmaceutical aspects of the recommended administration strategies. 
  
2. Age classification of paediatric patients 
Children differ from adults from a biological and pharmacological development 
perspective, and these differences should be reflected in the development and use of 
medicines for the paediatric population. Moreover, and although often overlooked, 
due to continuous physiological growth and maturation, the paediatric population is 
not a homogeneous group and can be subdivided accordingly to specific age groups. 
The division of this population in specific age groups is not harmonised between all 
the regulatory authorities, and some differences are observed in the upper age limit 
and in the distinction between young children and older children and premature and 
term newborns (10-12). In this review, the classification identified by the 
International Conference on Harmonization of Technical Requirements for 
registration of Pharmaceuticals for Human Use (10) is followed (Table 1.1). 
 
Table 1.1. Paediatric age sub-groups (10) 
Paediatric sub-group Name used Age 
Preterm newborn infants (‘Prematures’)  <37 weeks gestation 
Term newborn infants (‘Neonates’) Neonates 0-27 days 
Infants and toddlers Infants 28 days-24 months 
Children  Children 2-11 years 
Adolescents Adolescents 
12-16 or 18 years 
(depending on region) 
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3. Paediatric formulations: from regulatory guidance to reality 
3.1 Regulatory status 
Developing paediatric formulations as acceptable dosage forms, with a predictable 
and safe drug release in the patient and ensuring compliance, is scientifically 
challenging due to unique requirements and limitations (1, 13). The paediatric 
population represents a small target group with many short-term illnesses, and the 
development of acceptable formulations can differ significantly from the adult 
formulations in terms of the excipients that can be used and the selected route of 
administration (5, 13).  
New regulations, additional funding opportunities and innovative collaborative 
research initiatives both in the USA (Best Pharmaceuticals for Children Act – 
BPCA, and the Pediatric Research Equity Act – PREA (14, 15)) and the European 
Union (‘Better medicines for children’ concept paper and the Paediatric Regulation 
(EC) N°1901/2006, which introduced Paediatric Use Marketing Authorization – 
PUMA – and Paediatric Investigation Plan – PIP (1, 16)), have affected the 
paediatric formulation development. Novel formulations, such as flexible, 
dispersible, and multiparticulate oral solid dosage forms start to appear. The 
paradigm shift towards oral solid formulations of appropriate size and properties (i.e. 
sprinkles, multiparticulates) has enabled greater dose flexibility, easier 
administration and better acceptability of drug formulations, whilst efficacy and 
safety are maintained. Overcoming swallowability and taste and texture issues of the 
drug formulation is a current challenge in order to achieve paediatric compliance (5). 
Co-administration with food and drinks is often recommended to facilitate ingestion 
but it may have an impact on the solubility and oral bioavailability of the drug, and 
the risk of medication errors is increased (9, 17, 18). 
The European Medicines Agency highlights the need for appropriate testing to 
support formulation changes during paediatric formulation development, the 
importance of changes in bioavailability when extemporaneously manipulating a 
solid dosage form by mixing with food and drinks, and the impact of physiology on 
the absorption potential from modified release formulations (7). Furthermore, any 
formulation changes undertaken for the development of an acceptable and safer or 
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more effective formulation for different paediatric age groups should be included in 
the paediatric investigation plan (19). 
Legislative and regulatory frameworks, which underpin the expectation that children 
will be given the medicines they deserve, have been established in two major 
jurisdictions (EU and USA). However, scientific evidence in order to guide 
paediatric formulation development is still lacking, with data and experience 
acquired by individual pharmaceutical companies during product development not 
being always available in the public domain.  
 
3.2 Use of off-label and unlicensed medicines in the paediatric population 
The frequency of use of off-label and unlicensed medicines in children in the United 
Kingdom (UK) is ~ 11 % in general practice (20), 25 % in hospital general wards 
(21), 40 % in paediatric intensive care units (22) and 80 % in neonatal intensive care 
units (23). This trend is similar in other European countries (24, 25).  
Most of the authorised medicines are intended for adult use and are usually available 
as tablets (single or multiple unit) or capsules. Children are not always able to take 
the dosage forms that are designed for adults; for example, tablets for adults may 
need to be split before being administered to younger children, leading sometimes to 
unevenly tablet splitting and consequent dosage variability when the tablet design is 
not appropriate for this practice. In cases of liquid formulations for adults, their 
concentration may not permit the administration of the correct paediatric dose; for 
example, when the drug concentration of a liquid formulation is high, the volume 
needed to prepare the paediatric dose is extremely low and difficult to measure and 
administer. Dosage flexibility and ease of administration are essential as the dose 
administered throughout childhood relates to body weight, body surface area or age 
and in very young or very sick children inability to swallow and palatability issues 
are observed. Effectiveness and safety of treatment are also affected by the 
dependence on carers and knowledge of use of the medicine by both the carer and 
user.   
Consequently, adult solid oral dosage forms are, in some cases, inappropriate and 
need to be modified prior to administration leading to various practices, such as 
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preparing extemporaneous formulations, crushing tablets, opening capsules and 
adding to food or drinks, giving oral anticonvulsants rectally, utilising intravenous 
formulations for oral use and using ophthalmic preparations in the ear (26, 27). 
Crushing a licensed tablet formulation or opening a capsule are the most common 
forms of manipulation used to prepare extemporaneous products. The resulting 
powder is either dissolved or suspended with various excipients to prepare an oral 
liquid formulation or redistributed in sachets or smaller capsules. Cutting a tablet 
into smaller segments in order to obtain the appropriate dose for the paediatric 
patient is also applied. The manipulated formulations are then mixed with food or 
drinks to facilitate administration and improve acceptability. Even though these 
formulations are relatively quick to prepare and can allow dosage flexibility, their 
physical, chemical and microbial stability and palatability are not guaranteed (3, 25). 
Insufficient data to support practice, expiration dating of compounded formulations, 
unknown bioavailability, and extemporaneous compounding errors are associated 
with this practice. 
 
4. Age-related factors affecting adherence to paediatric medicines 
Adherence to prescribed medication varies between 11 and 93 % amongst the 
paediatric population (median value of 58 %) and is lower than the one reported in 
adults (30-70 %) (28-30). Formulation acceptability facilitates adherence to 
medication in children and the achievement of intended treatment outcomes (5). 
Variability of acceptability of dosage form(s) in young patients relates to individual 
characteristics (age and individual health status, behaviour, disabilities and 
background), difficulties in medicines’ administration (manipulation of medicines 
and taste), medication-taking behaviour (influence of family, school and life 
situation/context), and culture (3, 5, 7). 
a) Individual characteristics 
A paediatric patient cannot be standardised. According to physical development and 
psychological understanding, the ability to use different dosage forms can vary 
greatly. The age at which children can safely swallow solid oral dosage forms 
depends on health status and inter-patient differences (5).  
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b) Disease status  
The type of disease, acute or chronic, as well as the duration of treatment and the 
required number of medicines affect acceptability of medicines. Paediatric patients 
who are acutely unwell may be frightened and less co-operative than usual, 
especially if in pain or with fever. Sometimes medications have to be administered 
during school hours and training of the carer is required. Paediatric patients with 
long-term illness requiring continuing medication can be trained to take solid dosage 
forms from a relatively early age of 3-5 years, whereas for younger children training 
is given to carers (7, 9).   
c) Carers  
Dependence on a carer is common for the majority of the paediatric age groups with 
the exception of adolescents. The willingness and ability of the carer influence the 
acceptability of the medicine and treatment outcome (4). Attention should be given 
to the ease of administration by the carer as it influences dosage form choice and 
adherence (3). Moreover, carers may follow different administration techniques in 
the domiciliary/pragmatic environment than the ones recommended to them by 
healthcare professionals (31). 
d) Adolescence and peer pressure 
Information on handling medicinal products during puberty is scarce (7). 
Adolescents are usually responsible for their own medicine administration and 
capable of taking medication without mixing it with food or drinks. They may be 
rebellious though and reject medicinal products they have previously taken or be 
affected by peer pressure or recalcitrance. Lifestyle changes also may impose the 
need for discrete and portable dosage forms.  
e) Cultural and geographical differences  
The acceptability of medicines can be influenced by the location and/or setting in 
which the administration takes place. Interpretation of colour, form and taste of the 
medicine linked to strength and effect presents sociocultural variability. For 
example, a large pill can be interpreted as stronger than a small one or a bitter tasting 
medicine as more powerful than a sweet one. Traditional homeopathic or herbal 
medicines are preferred in some societies instead of western medicines that are 
24 
 
viewed as ‘too strong’ or with ‘too many’ side effects (32). Traditional beliefs, 
misconceptions and irrational use of medicines, may be more pronounced in 
resource-poor settings (education) and where other services are limited (i.e. access to 
clean water). The preferred method for dispensing extemporaneous preparations 
relates to the country; for example, in the UK, Ireland and Norway oral liquids tend 
to be prepared, whereas in France and Spain capsules are usually chosen, and in Italy 
powders are preferred (25). Differences in the palatability and acceptability of 
different routes of administration in different countries and different religions are 
well recognised, even though data for evaluation of the effect of global sociocultural 
differences on adherence to paediatric medicines is limited (32). 
f) Palatability 
Children have a low tolerance for disagreeable taste, smell and texture which affects 
their adherence to oral formulations. Size, taste and texture have been found to be the 
most significant factors controlling the drug administration to children (8, 9). To 
overcome poor taste, and to improve acceptability to paediatric patients, a wide 
range of drugs are mixed with food prior to administration (9). 
 
5. Improving palatability and acceptability: mixing medication with food 
or drinks 
5.1 Current practice and legislation 
Mixing medication with food or drinks intends to mask the unsatisfactory 
palatability of a formulation, in cases that it cannot be further improved through 
dosage form design, and to enhance acceptability through swallowing facilitation or 
texture improvement. Children often struggle with dysphagia either because the 
tablet or capsule is ‘too large’ to swallow or the liquid is ‘too bitter’ or ‘unpleasant’. 
Therefore, carers mix the medication (usually after manipulation of the initial dosage 
form) with a drink (i.e. fruit juice) or with food (i.e. yoghurt or applesauce) (7-9, 33). 
This is particularly prevalent in children with neurological impairments and mental 
health difficulties, as the majority of psychoactive medicines are unlicensed in 
children and have a bitter taste (8). In a recent study, conducted in a large paediatric 
population suffering from different chronic conditions, manipulation of the 
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formulations in the domiciliary environment reported by almost one third (74/252) of 
respondents was mainly associated with the age of child, socioeconomic status, taste, 
texture, and volume/ or quantity of dosage form. 19 % (94/499) of formulations were 
manipulated with the majority of these (93 %, 87/94) to be manipulated ‘always’ (i.e. 
prior to every dose administration) (31).  
Current legislation highlights that whatever the reason for mixing medicines with 
food or drinks is, the rationale should be discussed and justified, and relevant 
information should be included in the summary of product characteristics (SmPC) 
and patient information leaflet (PIL) (7). Clear instructions on the type of food and 
drinks appropriate for mixing with the paediatric medicine should be given. 
Appropriate warnings in cases when such practice is unsuitable or has not been 
studied must be provided. Any mixing outside the recommendations is responsibility 
of the health care professional or the user (3, 7). Instructions on the quantity of the 
food or drinks to be used and the acceptable time period after mixing based on the 
chemical stability of the drug should be noted. If chewing of the product is expected 
to alter product performance or influence acceptability it must be clearly stated.  
Different food or drinks can have different effects on the paediatric medicine due to 
their properties, such as pH, osmolality and viscosity. For example, pudding and 
applesauce are both considered as a ‘soft food’, but they had a different effect on 
drug’s absorption when mixed with the same drug (34). The possible effect of food 
or drinks on the biopharmaceutical characteristics of the medicinal product and on its 
acceptability, compatibility and stability should be studied. Assessment of the impact 
of food and drinks on drug’s bioavailability may be extrapolated from studies in 
adults, if relevant to the paediatric medicine; for example, adult food effect studies 
and achlorhydria studies. 
  
5.2 Current platforms  
National and/or regional formularies (quite often hospital formularies) are used for 
paediatric medicines, especially in cases where effective adult doses of newly 
approved medicines cannot be down-scaled based on a simplistic body weight 
extrapolation. In the UK, the British National Formulary for Children (BNF-C) was 
established in 2006 in order to compile available information and harmonize 
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practice. The BNF-C lists the correct mode of administration of paediatric 
medicines, with recommendations for mixing the drugs with food or drinks, when 
applicable. In practice, several Hospital Formularies are used with recommendations 
for mixing paediatric medicines with food or drinks, some of which are not recorded 
in the BNF-C.  
For the purpose of this review, both the BNF-C (26) and the Guy’s and St. Thomas, 
King’s College and University Lewisham Hospitals’ Paediatric Formulary (35) were 
consulted, in order to access the drugs recommended to be mixed with food and/or 
drinks prior to oral administration, and compare differences between these 
formularies (Table 1.2). 61 drugs are recommended to be mixed with food or drinks 
prior to administration. Differences in the instructions between the two sources are 
observed and only 30 drugs are included in both formularies although sometimes 
with different recommendations; for example, Sodium Phenylbutyrate is 
recommended to be mixed with meals or milk in the Hospital Formulary but not in 
the BNF-C. A more concerning issue arises in the case of Tenofovir Disoproxil, as 
the BNF-C warns against mixing with liquids whereas in the Hospital Formulary 
mixing of the granules with orange juice or water is advised. The BCS Class of the 
drug was added (information not included in the Formularies). The paediatric age 
subgroups were classified as Neonates, Infants, Children and Adolescents (Table 
1.1). Seven formulation types were identified: tablets crushed prior to mixing, 
opened capsules whose contents are sprinkled on or mixed with the food or drink, 
ampoules for IV administration which are recommended to be diluted and 
administered orally, granules, powder, solutions and suspensions. The type of food 
or drinks recommended were categorized in ‘Soft foods’, ‘Meals’, ‘Juice’, ‘Milk’, 
‘Water’ and ‘Others’. ‘Soft foods’ include yoghurt, applesauce, jam, honey and/or 
ice-cream; ‘milk’ refers to particular types as breast or skimmed milk; ‘juices’ are 
fruit, apple, orange, blackcurrant or squashes and ‘others’ refer to cola or tea. 
Specific vehicles recommended are included in the ‘Notes’ column. Recommended 
administration in water was noted in the cases where water was an alternative 
vehicle to other drinks. Drugs for which it was noted that tablets ‘may be crushed or 




Table 1.2. Drugs recommended to be mixed with food (according to the BNF-C (A) and Guy’s and St. Thomas, King’s College and University 










Meals Juice Milk Water Others 
Acetylcysteine  
(A) (B) 
I (36) N I C A 
Granules; 
ampoule* 
  X   X 
Juices: blackcurrant, orange 
Others: cola, orange or blackcurrant syrup 
Betaine (A) (B) - N I C A Powder X X X X X  Meals: formula, (+) 
Budesonide (A)  
II 
(37) 
A Capsule   X    Juices: apple, orange 
Calcium carbonate 
(A)(B) 
- N Tablet; solution  X   X  
- 




Sulfonate (A) (B) 
- I C A Powder    X X X 
Others: soft drinks 
(should not be given with squash or fruit 
juice) 
Carnitine      
(l-carnitine) (B) 
- N I C A Solution   X  X  Juices: fruit 
Charcoal, activated 
(A) 
- N I C A 
Suspension; 
capsule; tablet 
  X   X 
Juices: fruit 




- N I C A Solution; tablet    X X  - 
Cholestyramine 
(A) (B)  
- I C A Powder X  X X X X 




Clindamycin (B) I (38) N I C A  Capsule X X X  X  - 












Meals Juice Milk Water Others 




- A Granules X  X X X X 
Soft foods: thin soups, pulpy fruits, yoghurt 
Juices: fruit 
Milk: skimmed 
Others: cereals  
Cyclophosphamide 
(B) 





I C A Solution   X    
Juices: orange, apple, squash 
(should not be mixed with blackcurrant 
juice) 
Deferasirox (A) (B)  
II 
(40) 
I C A 
Dispersible 
tablet 
  X  X  Juices: apple, orange 
Didanosine (A)  
III 
(38) 
I C A Chewable tablet   X  X  Juices: apple 
Docusate sodium 
(A) (B)  
- I C A Solution   X X   
Juices: squash 




C A Capsule X X     - 








C A Capsule   X   X 
Juices: blackcurrant 
Others: strong tasting liquid 




Capsule (IR or 
MR) 

















I C A Tablet   X  X  Juices: apple 








I C A 
Solution; 
powder 
 X X  X  
Juices: fruit 
(Mix with food/drinks to reduce nausea) 
Lisdexamfetamine 
mesilate (A) 
-  C A Capsule X  X  X  




- I C A 
Powder; 
granules 











- I C A Solution   X  X  Juices: fruit 
Mercaptamine (A) 
(B) 
- N I C A Capsule X X Ѵ   Ѵ 
Strongly flavoured drinks or food at a 
temperature suitable for eating 
(should avoid acidic drinks) 
Mesalazine (A) (B)  
IV 
(45) 
C A Granules   X  X  Juices: orange 
Mesna (A)(B) - C Ampoule*   X   X 
Juices: orange, (+)  























I (45) C A Capsule (MR) X      Soft foods: applesauce 
Midazolam (A)(B) I (48) I C A Ampoule*   X   X 
Juices: apple, blackcurrant 





C A Granules X      
Soft foods: cold or at room temperature (not 
liquid) 








  X X X X 





N I C A 
Tablet (GR); 
Capsule 
X  X  X  
Soft foods: yoghurt 
Juices: fruit 
Pancreatin (A)(B)  - N I C A 
Granules (GR); 
Capsule 
X X X X  X 
Soft foods: acidic, jam, (+) 
Meals: formula 
Juices: apple 




N I Capsule   X X   - 









C A Solution   X X X X 
Juices: fruit, orange 
Water: mineral 
Others: coffee, tea 
Ritonavir (A) (B) 
IV 
(38) 
C A Solution X   X   
Soft foods: ice cream 
Milk: chocolate 
(should not be mixed with water) 












Meals Juice Milk Water Others 
Senna with 
ispaghula husk (A) 









I C A Solution   X  X  
Juices: orange 
(should not be mixed with other liquids) 
Sodium benzoate 
(A)(B) 
- N I C 
Solution; 
powder 





I (45) N Tablet (MR)  X  X   





- N I C A Granules; tablet  Ѵ X Ѵ   Juices: fruit 
Sodium valproate 
(A)(B) 
I (38) N I C A 
Granules (MR); 
capsule (MR) 
X  X X X X 
Soft foods: cold 




N I C A Capsule X X     - 
Sterculia (A) - C A Granules; tablet X      Soft foods: yoghurt, (+) 






C A Granules X  Ѵ  Ѵ  
Soft foods: yoghurt, applesauce, (+) 
Juices: orange 
(should not be mixed with liquids (A)) 
Theophylline 
(A)(B) 






Capsule X      
 
Tablet (B)  Ѵ Ѵ  Ѵ Ѵ 
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(A) BNF-C                                     A      adolescents                            Ѵ  recommendations from (B) but not (A)              
(B) Paediatric formulary                *       solution for injection            (+)  others                                                            
N   Neonates                                   GR    Gastro-resistant                     †    Predictive values 
I     Infants                                      MR   Modified-release                    ** Unlicensed medicine (no age is specified)                                                                    










Meals Juice Milk Water Others 
Vigabatrin (A)(B) I (53) C A Powder; tablet X  X X X X 
Juices: fruit, squash 
Others: soft drinks 
Vitamins with 
minerals and trace 
elements (A) 





5.3 Biopharmaceutical properties of drugs and mixing with food and drinks 
The biopharmaceutical characteristics of the medicinal product will be affected by its 
mixing with food or drinks. Analyses were performed to reveal potential correlations 
of the biopharmaceutical properties of the drugs with the age group, the type of 
formulation administered, and the type of food and drinks used for the mixing with 
the drug. 
The Biopharmaceutics Classification System (BCS) established by Amidon et al. 
(1995), which categorises drugs based on their solubility and permeability, is a 
regulatory framework for oral drug products for adults (54). Out of the 61 drugs 
listed (Table 2.2), 44% could not been assigned to a BCS class based on the 
published information regarding their solubility and permeability (and were denoted 
as ‘BCS unclassified’), 25% belong to BCS class 1, 20% to BCS class 2, 8% to BCS 
class 3 and 3% to BCS class 4 (Figure 1.1). It is worth noting that the majority of 




Figure 1.1. BCS classification of the drugs recommended to be mixed with food and/or 
drinks 
 
a) BCS class of the drug vs age group 
The relationship between the paediatric age group and the BCS class of the drug is 
presented in Figure 1.2. The majority of drugs recommended to be given with food 
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or drinks to neonates are BCS class 1 drugs. From the drugs identified from the two 
formularies studied, there are no drugs belonging to BCS class 3 or 4 suggested to be 
mixed with foods or drinks to neonates. For infants, drugs recommended to be mixed 
with food or drinks are drugs belonging to all BCS classes with the exception of 
BCS class 4 drugs. Regarding the other two subpopulations (children and 
adolescents), from the analysis performed, it can be observed that drugs from all four 
BCS classes are indicated to be mixed with foods or drinks (Figure 1.2). 
 
 
Figure 1.2. Percentage of drugs of each BCS class in relation to the paediatric age group 
 
b) BCS class of the drug vs type of formulation 
In Figure 1.3, the relationship between the drug’s BCS class and the type of 
formulation administered and mixed with food or drinks is shown. Capsules and 
tablets are the most common formulations used in this practice for BCS class 1 and 
BCS class 3 drugs and solutions, capsules and tablets for BCS Class 2 drugs. BCS 
class 4 compounds formulated as granules and solutions are the prevalent dosage 




Figure 1.3. Percentage of the formulation type in relation to the BCS class of the drugs 
 
c) BCS class of the drug vs type of food 
As illustrated in Figure 1.4, juice is the most prevalent type of vehicle used for drugs 
belonging to all the BCS classes. Soft foods are commonly recommended for mixing 
with BCS class 1 and 2 drugs, milk with BCS class 4 drugs, whereas meals are the 
less commonly suggested vehicles to be mixed with paediatric medicines. The 
characteristics of the vehicles may have an impact on drug’s stability and solubility 
compromising its bioavailability and therapeutic outcomes. For example, most fruit 
juices and cola due to their low acidic pH can affect the stability of certain API’s. 
Mixing soft foods such as ice cream, with BCS class 2 drugs (lipophilic drugs) could 
have an effect on drug’s solubility due to partitioning into the lipophilic phase. 
Variability on the outcome would be expected when drugs are mixed with different 
food or drinks belonging in the same food or drink ‘type’ due to the intra-variability 





Figure 1.4. Percentage of the vehicle type in relation to the BCS class of the drugs 
 
d) Type of food vs type of formulation 
The relationship between the type of vehicle and the type of formulation is presented 
in Figure 1.5. Ampoules are recommended to be mixed either with juice or other 
types of drinks (tea or cola). When this practise is followed, the risk of precipitation 
due to dilution or pH of the liquid vehicle should be considered. Even though 
paediatric patients do not typically drink hot liquids, the effect of temperature when 
preparing a formula or tea on the stability of the drug should be studied. Soft foods 
or meals are suggested for the mixing with suspensions, and soft foods and juice for 
capsules and granules. All vehicles with the exception of soft foods are reported for 
the mixing with solutions, whereas tablets and dispersible tablets, are recommended 
to be mixed with all the vehicles, without preference. Based on the drug’s and 
vehicle’s characteristics’ the potential impact of the mixing practise on drug’s 
solubility and dissolution and subsequently on drug’s absorption should be explored. 
Viscosity, fat and dairy-protein content are other characteristics which apart from 
their effect on gastric emptying rate, may also interfere with the drug’s behaviour 





Figure 1.5. Percentage of the vehicle type in relation to the formulation 
 
e) Type of formulation vs age group 
The relationship between the formulation type and the age group is shown in Figure 
1.6. For neonates, from the seven types of formulations identified in in this study, 
only ampoules, capsule contents and suspensions are recommended to be mixed with 
food and drinks. For all the other groups, all the formulation types are accepted.  
 
 
Figure 1.6. Percentage of formulation type in relation to the paediatric age subgroup 
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6. Administration techniques reported by healthcare professionals and 
parents/carers 
Mixing medication with food and/or drinks is a common practice on paediatric wards 
with nurses being usually responsible for administering medication (8, 9). In a recent 
study, it was found that the majority of paediatric nurses modify oral dosage forms 
or mix medication with food or drinks prior to administration (8). The most common 
food/drinks reported to be used were fruit yoghurts, crushed bananas, and diluted and 
concentrated fruit juices. Co-mixing was perceived as a time-consuming process and 
preference was expressed for mixing the powdered dosage form(s) into juice or a 
liquid rather than into solid foods. The actual method used to mix the medication 
with the food/ drinks was not consistent, with some interviewees reporting that they 
‘poured the contents of the capsule/crushed tablet onto a spoon and added the food 
item to it’, whilst others reported that they ‘dispersed the powdered medicine directly 
into the food’ (8). In a survey performed in a hospital in Cape Town (South Africa) 
to investigate carers’ practices and perceptions regarding tuberculosis (TB) treatment 
of children, about two thirds of the interviewees reported that TB medication was 
given after meals (33). The medication was crushed, dissolved and/or mixed with 
food or drinks in over half of the cases, while 30 % reported that medication was 
swallowed or chewed. It should be noted though that among the drug formulations 
commonly used for TB, only one brand of tablets can be chewed or dispersed in 5 
mL of water. All other tablets are not dispersible, and for one of the tablet 
formulations crushing has been associated with treatment failure due to reduced 
bioavailability of the drug (33, 55). Moreover, parts of crushed or dissolved tablets 
or contents of capsules may not be swallowed, resulting in administration of a lower 
dose than the intended one. 
In another study, the ad hoc techniques that parents and carers had reported to 
healthcare professional groups, as well as the techniques that the healthcare 
professionals recommended to them for the paediatric medicine administration were 
reviewed (9). Nurses gave examples of what is actually done in the wards with 
yoghurt being the vehicle of preference, whereas medical practitioners described in 
detail the practice that the parents follow which does not always correspond to the 
practice on the wards. The majority of nurses were unaware of the potential drug 
stability and degradation issues when performing ad hoc administration techniques. 
39 
 
Some of them were not conscious of the possible impact upon clinical outcome, with 
one nurse even saying “just try whatever the child likes”. Pharmacists expressed 
their concern regarding the impact of these techniques on drug’s pharmacokinetics, 
for example the effect of acidic juice on drug’s solubility and absorption. The 
participating healthcare professionals were unaware of the level of evidence 
supporting the various drug/ formulation manipulation techniques. The need for 
more information about drug-food compatibilities were revealed and training issues 
were identified, as few nurses were aware of the pharmaceutical implications of this 
practice.  
Parents/carers may not always follow the administration techniques recommended to 
them by healthcare professionals in the domiciliary environment, and it is not clear if 
healthcare professionals are always aware of these practices (31).  
 
7. Effect of mixing medicines with food and drinks on drug’s 
bioavailability  
Combination of medication with food or drinks to mask the taste of the drug, can 
have an effect on drug’s safety and efficacy. Even though potential treatment issues 
related to the crushing of modified release tablets or capsules are well recognised 
and understood, this doesn’t seem to apply for issues associated with the crushing of 
other formulation types (for example immediate release formulations) (56, 57). 
Increased bioavailability or sub-therapeutic drug levels due to loss of the dose during 
crushing and transfer of immediate release tablets have been observed (55, 58-60). 
Crushing of tablets or opening of capsules with enteric coating could result in 
decreased drug absorption and efficacy or in irritation on gastrointestinal mucosa 
depending on the drug formulated (18). Drug loss through the crushing process is 
also a concern as children may receive reduced and variable dosing. Contamination 
issues may occur if a previously uncleaned vessel is used for the paediatric medicine 
administration. Assessment of drug pharmacokinetics in children with crushed 
tablets is performed under a ‘standardised’ method, i.e. using water for dissolving 
the drug and may not represent accurate, realistic daily preparation practices. 
Delivering medications with fruit juices such as grapefruit, orange or apple juice 
affects absorption of several drugs possibly due to their acidic pH and increased 
40 
 
potential for drug precipitation or degradation (61, 62). Alterations of physiological 
conditions such as gastric emptying, and of gastrointestinal contents’ properties such 
as viscosity, osmolality and calorific content after food administration can affect 
drug’s pharmacokinetics (63, 64). In some cases, crushing tablets or opening 
capsules and mixing with a small volume of soft foods did not alter bioavailability 
significantly (17, 65). In other cases though, absorption was impaired when crushed 
tablets were mixed with pudding compared to the use of applesauce (34) and 
absorption was delayed after mixing enteric-coated beads with yoghurt or applesauce 
(66). Comparative release and dissolution studies of four drugs from crushed and 
whole tablets in six different foods and drinks frequently used in the clinical setting 
revealed that the impact on drug’s dissolution depends on the drug properties and the 
vehicle properties (18). Furthermore, stability issues can arise when/if there is a 
delay between preparation and administration. 
Food–drug interaction studies are widely reported in adult populations, with 
dedicated regulatory guidance on the conduct of food effect clinical studies (67, 68). 
For paediatric populations the guidance surrounding food effect is limited (17). In 
the USA, the “Pediatric Study Decision Tree” (67) allows extrapolation from adult 
data sets if there is sufficient similarity of both the disease progression and the 
response to intervention between source and target population. If the exposure-
response relationship of the medicinal product is similar, the only PK studies 
required in paediatric populations are those for dose determination and safety 
evaluation. Similarly in the EU, EMA guidance states that relative bioavailability 
comparisons of paediatric formulations with the adult oral formulations should 
typically be conducted in adults with only dose selection PK studies required in 
paediatric populations (7, 69). Therefore, the majority of paediatric pharmacokinetic 
studies are conducted in the fasted state with very limited pharmacokinetic studies in 
the fed state in which milk or standardised breakfasts are mainly used (17). 
The extrapolation of food effects observed in adults into paediatric populations is an 
unexplored and complex area as there are key differences between both populations, 
namely:  
 Biological and anatomical differences in the gastrointestinal tract; 
41 
 
 Different feeding patterns, both in terms of food composition and feeding 
frequency;  
 Reduced volume ingested by younger patients that affects the gastric 
emptying rate and differences to the emptying rate observed in adult studies 
are expected. 
The nature of the food utilised in common practice by carers in paediatric patients 
adds complexity to the extrapolation of the food effect from adult studies (33). Food 
effect can be different between paediatric and adult studies (17); for example, food 
effect was more marked in children compared to adults for sustained-release 
theophylline formulations with bioavailability in the fed state being lower in children 
than in adults (34).  
 
8. Conclusions  
A global effort to improve paediatric accessibility to medicines is observed, which in 
turn has increased the number of drugs tested in and labelled for use in children (1). 
Healthcare professionals, parents or carers face the need to manipulate an adult 
medicine and mix it with food and/or drinks prior to administration in order to 
improve palatability. Although there is some information available regarding drug 
manipulation and the subsequent effect on drug stability/degradation, until recently 
this information had limited relevance as it mainly considered administration via 
PEG (percutaneous endoscopic gastrostomy) tubes and not mixing with food (70). 
Points to consider would relate to the type of food used in the study in terms of 
acceptance from the paediatric population and its uniform composition in different 
countries. For example, studies have been performed with applesauce which is not 
very well accepted amongst the paediatric population and may differ in sugar content 
in different countries (71). Furthermore, viscosity of the vehicle affects dissolution 
and release aspects from crushed tablets (18). The pH of the vehicle affects drug’s 
stability. For example, the pH of fruit yoghurts that are commonly used vehicles 
could compromise the chemical stability of drugs that are acid sensitive, particularly 
in the case of manipulation of enteric-coated dosage forms (8, 9, 72). 
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The European Committee on Pharmaceuticals and Pharmaceutical Care (CD-P-PH) 
and the European Directorate for the Quality of Medicines & HealthCare (EDQM) 
have recently launched an initiative to make a European Paediatric Formulary (73). 
This Formulary will give easy access to hospital and retail pharmacies across Europe 
to monographs for the preparation of extemporaneous formulations for paediatric 
medicines, and the practice amongst all countries and regions can be harmonized. 
The inevitable use of deduction as a means to obtain what is ‘probably’ the best 
therapy for a child will gradually disappear, and the continuous production and 
availability of evidence-based information for health professionals and carers will 
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Chapter 2: Co-administration of paediatric medicines with food 
and drinks in the context of their physicochemical properties – 
a global perspective on practices and recommendations  
Abstract 
Objectives: The aims of this review were (i.) to describe the current recommended 
strategies for co-administration of paediatric medicines with food and drinks 
(vehicles); (ii.) to compare current administration recommendations from different 
countries; and (iii.) to obtain a global perspective on the rationale behind the choice 
of recommended vehicle, in the context of the physicochemical properties of the 
drug and formulation. 
Methods: This study used a defined search strategy on the practices of paediatric 
medicine co-administration with vehicles, recommended in a commonly used 
paediatric and neonatal handbook, in addition to the information previously gathered 
from UK formularies. Multinomial logistic regression analysis was performed to 
further understand the biopharmaceutical basis of the choice of recommended 
vehicle for medicine co-administration. 
Key findings: In this review, the recommended strategies for the co-administration of 
paediatric medicines with food and drinks were discussed and compared with 
relevant regulatory guidelines, according to globally used sources. Differences were 
identified in the type of vehicles globally recommended for medicine co-
administration. Ultimately, a statistical model was developed which provided an 
understanding on which vehicle is recommended for use with drugs/formulations, 
with basis on their biopharmaceutical properties. 
Conclusions: Overall, this review highlights the areas where further information is 
needed to support standardised procedures and guide the recommendation of age-
appropriate and acceptable vehicles for use in the co-administration of paediatric 
medicines. Approaches such as the statistical model  developed in this study could 
be used towards the creation of unified guidelines, where vehicle selection can be 
made based on biopharmaceutical characteristics. Ultimately, unified requirements 




A shift has been observed towards the development of user-friendly, preservative-
free, taste-masked formulations (e.g. multiparticulate single-use solid dosage forms) 
for the paediatric population (1-4). However, the heterogeneity of the paediatric 
population hinders medicine development (2, 3). Consequently, lack of medicines 
designed and studied for use in paediatrics is still an issue, and in many therapeutic 
areas the need for authorised paediatric formulations remains (2). When age-
appropriate licensed formulations are not available, there are several options for 
providing paediatric patients with suitable treatments. These include: (i.) seeking a 
licensed therapeutic alternative, (ii.) importing products authorised in other countries 
(which can be costly, time-consuming, and often subject to strict regulations), (iii.) 
compounding medicines within the pharmacy (i.e. preparing an unlicensed medicine 
to meet specific patient needs) or (iv.) manipulating licensed dosage forms (5-7).  
Drug manipulation is a widely spread, common practice for drug administration and 
refers to handling of medicines to make them suitable for intended administration, 
for example when a specific dose not available is needed, to improve taste and/or 
patient acceptability and compliance (5). Examples of medicine manipulation 
include dividing/crushing a tablet, opening a capsule and emptying its contents, 
making serial dilutions, mixing syrup into a crushed tablet to prepare an 
extemporaneous preparation, and mixing a medicine with food or drinks (vehicles) to 
aid administration. Several risks have been associated with drug manipulation 
practices, including inconsistent results in terms of dose accuracy and possible 
effects on drug stability, solubility and bioavailability (7-10). Ultimately, these 
practices may lead to sub therapeutic or even toxic drug levels and/or increase the 
risk of side effects, which raises safety concerns (1, 7, 11, 12). Therefore, there is a 
need to evaluate the impact of drug manipulation practices and standardise 
recommendations and administration procedures to reduce the risks associated with 
medicine manipulation.  
The most practiced manipulation technique to facilitate paediatric administration is 
to mix a dosage form with vehicles (12, 13). Small amounts of food or drinks can be 
used as vehicles for oral administration of medicines, provided they do not alter 
formulation performance, and are compatible and suitable for use in the targeted 
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patient age group (5, 14). Therefore, when this practice is intended, assessment of 
quality attributes of the mixture formulation-vehicle should be performed (e.g. 
potency assay, and in vitro dissolution/release studies) (5, 14).  
Clear instructions on the optional use of vehicles to facilitate medicine 
administration, should be included in the labelling, summary of product 
characteristics (SmPC) and patient information leaflet (PIL) of the commercial 
formulation (5, 14). However, many factors such as seasonal, regional and climate 
conditions as well as age-related characteristics will influence vehicle composition or 
preference, respectively (7). For example, diet preferences will change depending on 
the age group (e.g. younger age groups have mostly a liquid diet and so mixing with 
a solid food would not be an option), country and physiologic characteristics (e.g. 
swallowability problems in very young ages) (6). Thus, the best candidates for use in 
practice are vehicles with relatively small fluctuations in their macronutrient 
composition and physicochemical characteristics, such as vehicle viscosity and pH, 
and binding/chelation characteristics. Moreover, vehicle candidates should be 
screened concerning their interaction with drug and formulation properties and their 
adequacy to the target age group (5, 14). 
To standardise quality and availability of paediatric medicines, global initiatives 
have been undertaken. In the EU, the European Committee on Pharmaceuticals and 
Pharmaceutical Care (CD-P-PH) and the European Directorate for the Quality of 
Medicines & HealthCare (EDQM) have recently launched an initiative towards the 
compilation of a pan-European Paediatric Formulary, consisting of monographs for 
extemporaneous formulations, based on national or regional information (15, 16). 
This Formulary is intended to give indications on the preparation of extemporaneous 
formulations for paediatric medicines and harmonise medicine administration 
practices. It should be noted though that information regarding formulation co-
administration with food and drinks is not included in the pilot monographs available 
(15, 17).  
In practice, recent studies have shown that medicine co-administration with vehicles 
is often performed without following recommended procedures (7). Parents, carers 
and healthcare professionals often choose or let the child choose the food or drink 
used for medicine co-administration, without following the recommendations stated 
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on the PIL or SmPC of the medicine (7, 12, 13). The implications of the uninformed 
use of vehicles for medicine co-administration on drug safety and efficacy are often 
not taken into consideration.  
Recommendations for mixing oral drugs with vehicles for paediatric administration, 
as described in national and hospital formularies from the UK, have been recently 
reviewed (7). Differences in the type of vehicles recommended and used in current 
practice were identified, and it was also revealed that vehicle recommendations are 
made on a case-by-case basis, without a clear scientific rational behind the choice of 
vehicle and/or depending on the patient and/or administration setting (e.g. hospital or 
home). The importance of considering the possible physicochemical or 
bioavailability changes that may occur from the co-administration of medicines with 
vehicles in the paediatric population were highlighted. 
In this review, the vehicles currently recommended to be used for medicine co-
administration to paediatric patients are discussed on a global perspective. Firstly, 
vehicle recommendations as reported in a paediatric handbook frequently used in 
clinical practice (in the US and other countries) were compared to previously 
gathered information from other formularies. Secondly, differences between 
recommendations were evaluated. Similarly to our previous review (7), the type of 
vehicles recommended to be mixed with medicines were correlated to the type of 
formulation and the BCS class of the drug, in order to reveal the biopharmaceutical 
aspects of the recommended administration strategies. Current administration 
practices were also compared with the relevant regulatory guidelines in order to 
assess possible differences and clinical consequences. Finally, a statistical model was 
developed in order to understand the choice of vehicle type recommended, based on 
the characteristics of the drug/formulation. 
 
2. Methods  
A focused search was performed on the vehicles that are globally used for mixing 
with dosage forms for paediatric administration. The Lexicomp Neonatal and 
Paediatric Dosage Handbook (18) (referred to as Lexicomp Handbook in this review) 
was identified as a source of information. In clinic, it is a valuable point-of-care 
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dosing resource, designed to support medical professionals managing paediatric and 
neonatal patients. For the purpose of this study, the drug monographs included in this 
handbook were screened, with emphasis on the ‘mode of administration’ section. 
Drugs were included in the review if co-administration dosage forms with food, 
drinks or meals were suggested. Drugs for which recommendations were to take the 
formulations ‘with or without food/meals’ or ‘without regards to food/meals’ were 
also included. Because this review focuses on a specific type of medicine 
manipulation (i.e. mixing the drug with vehicles), drugs for which only manipulation 
techniques were referred and/or drugs for which only water was included as an 
administration vehicle were not included. The information gathered from this new 
source was combined with information previously gathered, for a global evaluation 
of practices and vehicle recommendations (7, 19, 20).  
Multinomial logistic regression analysis was performed to further understand the 
biopharmaceutical basis of the choice of recommended vehicle for medicine co-
administration, using XLSTAT
®
 software (an Add-In for Excel, Microsoft
®
). This 
statistical method is used to understand the effect of a series of variables on an 
unordered qualitative response variable (a variable which can take at least two 
values) (21). The statistical analysis was performed to predict the effect of drug and 
formulation characteristics (namely, drug logP, drug aqueous solubility, drug 
Biopharmaceutical Classification System [BCS] class and formulation type) on the 
choice of vehicle type (response variable; drinks or soft foods) recommended to be 
mixed with paediatric medicines. The explanatory variables used were: high/low 
drug solubility (presented as HighSol and LowSol, respectively), formulation type 
(Solid/Liquid), and drug logP (presented as Hydrophilic for logP < 3 and Lipophilic 
if logP > 3). The statistical analysis was described by an equation, which was built 
relatively to the response variable chosen as reference category (in this case, drinks 
as the vehicle type recommended for drug administration). The obtained equation 
was a model of the probability associated to the type of recommended vehicle being 
‘drinks’, depending on the values of the explanatory variables (21). If the estimated 
probability of the event occurring is greater than or equal to 0.5 (better than even 
chance), the event is classified as occurring. If the probability is less than 0.5, the 
event is classified as not occurring (in this case, the vehicle type recommended is not 
drinks, but soft foods). To build and validate the analysis, a total of 430 drug-
56 
 
formulation-vehicle combinations were considered; these were divided into two 
groups: 300 combinations were used for the construction of the model, and 130 for 
the validation of the model.  
 
3. Results 
3.1 Mixing medicines with food and drinks in the context of their 
physicochemical properties  
The Lexicomp Handbook lists recommendations for the administration of paediatric 
medicines, providing information on which food or drinks to use for medicine co-
administration, when applicable (18). Appendix I lists the 407 drugs (out of 1054) 
included in this handbook that are recommended to be mixed with food and drinks 
prior to oral administration, in addition to the recommended vehicles for 
administration. The BCS class of the drug, aqueous drug solubility and drug 
ionisation characteristics were added to the information collected from the Lexicomp 
Handbook. Eight formulation types were identified: tablets, capsules, ampoules, 
granules, powder, solutions, syrup and suspensions. The type of vehicles 
recommended were categorized into Soft foods (e.g. yoghurt, applesauce, fruit 
puree), Drinks (e.g. milk, juices, formula) and Others (e.g. meals, food, suspending 
agents/syrups). Recommendations for administration with water were only noted 
when it was an alternative to other drinks. Specific recommendations included in the 
drug monographs were noted, such as unsuitable vehicles, further examples of 
suitable vehicles for mixing, and/or the acceptable amount of vehicle to administer. 
Drugs for which simple manipulation techniques were given without specific 
suggestions for mixing with vehicles (e.g. tablets ‘may be crushed or dissolved’) 
were not included. Drugs for which recommendations were to take the formulations 
‘with or without food/meals’ or ‘without regards to food/meals’ were included; for 
simplification, these recommendations will be denoted as ‘with or without food’ in 
this review. It is worth noting that improving palatability/taste was indicated in 2 
cases, lopinavir/ritonavir tablets and ritonavir liquid, as a reason for co-
administration with a vehicle. However, this information was not revealed for the 
remainder of the drugs. Similarly, decreasing gastrointestinal (GI) distress was 
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indicated in 23 % (94/407) of the cases as a reason for medicine co-administration 
with food/drinks. 
The drugs previous previously collected from other sources (19, 20) were added to 
the database for further analysis, in order to obtain a global understanding of the 
vehicle recommendations. The database used for analysis encompassed 428 drugs, of 
which 77 % (331/428) were included only in the Lexicomp Handbook, 5 % (21/428) 
only in the UK formularies and 18 % (76/428) in sources from both settings, 
although sometimes with different recommendations.  
The BCS is a regulatory framework for oral drug products for adults, which 
categorises drugs based on their solubility and permeability (22). 61 % of the 428 
drugs gathered were classified into one of the four BCS classes, based on 
information (published studies or predictive values) regarding the solubility and 
permeability of the drugs (Figure 2.1). It was shown that most drugs suggested to be 
co-administered with food and drinks were drugs with high permeability (19.6 % and 
20.1 % belong to BCS class I and II, respectively), whereas only 14.5 % of the drugs 
belonged to BCS class III and 6.8 % to BCS class IV. It should be noted that 
unclassified drugs (in terms of BCS class) were not considered for further analysis.  
 
 
Figure 2.1. BCS classification of the drugs recommended to be mixed with food and drinks 
 
Mixing a paediatric medicine with food and drinks has been shown to affect its 
biopharmaceutical characteristics (7). To further investigate this, analyses were 
carried out to reveal potential correlations between the BCS class of the drugs, the 
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type of formulation administered, and the type of vehicles recommended for mixing 
with the drug.   
 
3.1.1 BCS class of the drug vs formulation type 
The relationship between drug BCS class and the type of formulation co-
administered with food or drinks is shown in Figure 2.2. Tablets and capsules were 
shown to be the predominant dosage forms mixed with foods or drinks, for drugs of 
the four BCS classes. BCS class I products formulated as solutions and BCS class IV 
products formulated as suspensions are also commonly recommended to be mixed 
with foods or drinks. 
 
 
Figure 2.2. Percentage of type of formulation in relation to the BCS class of the drug 
recommended to be mixed with food and drinks 
 
3.1.2 BCS class of the drug vs type of vehicle 
Figure 2.3 shows the prevalence of the type of vehicle used for drugs belonging to 
each BCS class. Vehicles of all types are recommended for mixing with all BCS 
classes. Soft foods are the least commonly suggested to be mixed with paediatric 
medicines, particularly with BCS class III and IV drugs. Meals/foods and syrups 
(classified as others) are the most commonly recommended vehicles for co-
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administration with drugs belonging to BCS class I, II and IV. Despite this, 
recommendations are often not clear on the mixing process, the type and the amount 
of food/meal to use. For BCS class III drugs, the most commonly suggested 
recommendation is to mix ‘with or without foods/meals’, which is a dubious 
recommendation regarding whether it is possible to mix the drug with vehicles. 
Drinks are commonly suggested to be mixed with paediatric medicines for drugs of 
all BCS classes. 
Recent studies have assessed the physicochemical properties of vehicles commonly 
reported to be mixed with paediatric medicines for co-administration (23, 24). 
Distinguished differences between the physicochemical properties (e.g. pH, surface 
tension, osmolality, viscosity, buffer capacity) and macronutrient composition of 
different food and drinks were observed, both among vehicles of different types 
(drinks vs soft foods) and within vehicles of the same subtype (e.g. different 
formulas). These differences between vehicle properties affect drug solubility and 
dissolution properties, particularly of poorly soluble drugs (25-27). For example, 
solubility studies of mesalazine and montelukast, performed in drinks and soft foods, 
resulted in considerably different drug solubility values in each vehicle, being 
significantly affected by the physicochemical properties and macronutrient 
composition of the vehicles (25-27). This vehicle-dependent impact on drug 
properties could compromise drug bioavailability and should be taken into 





Figure 2.3. Percentage of the type of vehicle in relation to the BCS class of the drug 
recommended to be mixed with food and drinks 
 
3.1.3  Type of vehicle recommended vs type of formulation 
The relationship between the type of vehicle recommended for medicine co-
administration and the type of formulation is presented in Figure 2.4. Ampoules for 
IV administration are mainly recommended to be mixed/diluted with drinks and 
administered orally. In some cases, such as for topotecan ampoules, the 
recommendation is to mix with acidic drinks (e.g. apple juice); however, this type of 
recommendation should not be generalised since depending on the drug this practice 
might affect drug stability. Soft foods are mainly suggested for mixing with capsule 
formulations. All vehicle types are reported for mixing with liquids, solutions and 
suspensions. Apart from soft foods, all vehicle types are recommended to be mixed 
with syrups. Tablets are recommended to be mixed with all vehicle types, with a 
high prevalence of mixing with meals/food and with suspending agents/syrups for 
extemporaneous preparations. Mixing ‘with or without foods/meals’ is reported for 
all formulation types, except granules and caplets. It should be noted that for several 
cases, recommendations were made to mix the suggested vehicles with oral dosage 
forms, and so all the oral drug formulations listed in the Lexicomp Handbook as 
available were considered. This suggests that recommendations were possibly made 





Figure 2.4. Percentage of the type of vehicle recommended in relation to the type of 
formulation. 
 
3.2 Effect of drug/formulation properties on the choice of the recommended 
vehicle 
Although there have been many reports on the use of food and drink vehicles to 
facilitate administration of paediatric medicines, there are still major gaps in the 
knowledge of the scientific rationale for choosing which vehicle is appropriate (7, 
14).  
Multinomial logistic regression analysis was performed to investigate the 
relationship between drug/formulation variables and the type of vehicle 
recommended (drinks, soft foods). The statistical model is described by the 
following equation (Eq. 2.1):  
             [   
                                                     ]  (Eq. 2.1) 
where,            is the probability of the vehicle type recommended to be drinks, 
and LowSol, Solid and Lipophilic can take the values of 1 or 0 depending on 
whether the drug/formulation has those characteristics or not, respectively.  
For example, for a lipophilic drug (Lipophilic = 1), with high solubility (LowSol = 
0) and formulated as a tablet (Solid = 1), the probability of the vehicle type 
recommended to be drinks is  0.59.  
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Model validation was performed by comparing the type of vehicle recommended in 
the formularies and the vehicle type predicted by the model equation, using 130 
drug-formulation-vehicle combinations as validation sample. In 60 % of the cases, 
the multinomial logistic regression model could predict correctly the vehicle type 
recommended, according to drug and formulation characteristics. 
 The standardised coefficients of each studied variable are presented in Figure 2.5 
and reveal that formulation type is the variable with most impact on the choice of 
vehicle type recommended (p < 0.05).  
 
 
Figure 2.5. Standardised coefficients corresponding to the variables studied for the 
multinomial logistic regression model constructed. 
 
Overall, this analysis was a first approach towards defining a correlation/rational 
between the type of vehicle suggested for mixing and the drug and formulation 
properties. The developed model provides an insight on which vehicle type is 
recommended for use with basis on the biopharmaceutical properties of the 
drugs/formulations. It has a reasonably good predictive ability, with predicted and 
calculated vehicle recommendation in the test set showing good agreement. 
Nevertheless, given that the model is currently based on a dataset comprising a 
limited number of sources, further work is required to verify and extend the 
approach. Despite its limitations, the analysis described provides information to 
generate awareness and discussion towards co-administration practices of paediatric 
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medicines, within the clinical and scientific communities. In the future, it would be 
useful to include information from other formularies not identified in this review to 
further refine and validate the model constructed. 
 
4. Discussion  
4.1  Discrepancies in recommendations reported    a global perspective  
In this review, the availability of drug products recommended to be mixed with food 
and drinks was assessed using two datasets: (i.) the list of drugs gathered after 
consulting the Neonatal and Pediatric Dosage Handbook (18), and (ii.) the database 
previously collected in Chapter 1 from two sources (British National Formulary for 
Children (19) and a Hospital Formulary (20)). Over half of the drugs for which 
mixing with a vehicle was suggested in the Lexicomp Handbook were not included 
in the UK formularies. Although it is not completely clear how the recommendations 
were established, a possible explanation for this is the discrepancy observed in the 
number of drugs included in the sources (e.g. the Lexicomp Handbook included 
1054 drug monographs whereas the UK formularies included less than half that 
number). In addition, 47 % of the drugs were included in both datasets, but with no 
vehicle suggestions for medicine co-administration in the UK. For example, 
terbinafine is recommended to be mixed with non-acidic foods in the Lexicomp 
Handbook, but not in the UK formularies even though it was included in the 
formularies consulted. A more concerning issue arises in the cases of tenofovir 
disoproxil fumarate, sodium phenylbutyrate and risperidone (Table 2.1). In the first 
case, the BNF-C and Lexicomp Handbook warn against mixing with liquids, 
whereas mixing of the granules with orange juice or water is advised in the Hospital 
Formulary. In the case of sodium phenylbutyrate, the Lexicomp Handbook advises 
against mixing with acidic drinks whereas fruit juices are recommended in the UK 
formularies. Similarly, risperidone formulations are suggested to be mixed with 
coffee in the formularies, whereas this drink is advised against mixing with the drug 




Table 2.1. Differences in recommendations between the different sources consulted 
Drug 
Sources 
Lexicomp Handbook (18) 
BNF-C (19) and Hospital 
Formulary (20) 
Risperidone Mix with water, orange juice, or 
low-fat milk 
Do not mix with coffee or tea 
Mix with milk, juice, coffee, tea, 
fruit juice, orange juice (20);  
Mix with non-alcoholic drinks 
except tea (19) 
Sodium phenylbutyrate Avoid mixing with acidic 
beverages e.g. most fruit juices or 
colas, food, meal or feeding 
Mix with fruit juice (19), 
meals, milk (20) 
Tenofovir disoproxil 
fumarate 
Do not mix with liquids 
Mix with 2-4 ounces of 
applesauce, baby food, yoghurt 
Mix with soft foods e.g. yoghurt, 
applesauce (19);  
Mix with orange juice (20) 
 
4.2 Medicine co-administration with food and drinks – from regulatory 
guidance to reported recommendations and practices 
The widespread use of off-label and unlicensed medicines for the paediatric 
population confirms that the currently available commercial products do not meet the 
needs of this population. Medicines are often manipulated prior to administration due 
to unacceptability of the dosage form to the patient or unavailability of the needed 
dose. Medicine co-administration with vehicles is the most practiced manipulation 
strategy in paediatrics; however, no recommended testing methodology or uniform 
criteria to define what is classed as globally acceptable vehicle for the different 
paediatric age groups (e.g. in terms of flavour, texture and composition) have been 
set to predict the possible impact of medicine co-administration with vehicles on 
drug product performance (6, 10, 28).  
Current guidance has begun addressing the recommended strategies for paediatric 
medicine development, acceptability and administration, with special emphasis on 
co-administration of medicines with food and drinks (5, 14, 29). The most recent 
example is the Food and Drug Administration (FDA) draft guidance released in 
2018, which recommends vehicle selection approaches and in vitro testing for co-
administration of paediatric medicines (14). The three main purposes of this draft 
guidance are: (i.) to give recommendations on vehicle selection, (ii.) to describe 
standardised in vitro methods for evaluating vehicle compatibility, and (iii.) to 
provide suggestions on product labelling for communication of acceptability (or 
unacceptability) of vehicles intended for mixing with the medicine.  
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In the following subsections, the considerations provided in current regulatory 
guidance, regarding vehicle selection and testing, will be discussed and compared to 
reported recommendations gathered from the sources consulted and reported 
healthcare practices (5, 14, 29). 
 
4.2.1 Vehicle selection: in vitro assessment of drug product-vehicle 
compatibility and use in practice 
Regulatory guidance states that in vitro compatibility studies should be performed 
when co-administration of medicines with food or drinks is intended. It is 
recommended that comprehensive suitability determinations are conducted to 
evaluate the potential impact of the proposed vehicle on drug behaviour and provide 
guidance on the appropriate vehicle to use in the target age group. These assessments 
include: (i.) potency assays, to quantify the amount of drug in the drug product-
vehicle mixture, evaluate drug product performance and support the recommended 
use time of the mixture after preparation; (ii.) integrity testing, to verify if the drug 
substance quality attributes are maintained after mixing with a vehicle; (iii.) stability 
assessments, to support instructions for the mixture preparation and labelled use time 
of the mixture; (iv.) dose uniformity/homogeneity testing; and (v.) drug 
release/dissolution testing, to determine possible changes in drug behaviour (i.e. 
release/delivery from the drug product and drug dissolution).  
Ideally, food and drinks which have been proven to cause no appreciable effect on 
medicine performance should be proposed as vehicles. It is advised that drug product 
information (product labelling, SmPC, PIL) should also include instructions on 
vehicles found unacceptable, including the rationale for avoiding their use as 
vehicles for medicine co-administration (14). For example, a soft food like 
applesauce should be deemed inappropriate if the targeted patient population are 
infants still consuming a liquid diet, even if the mixture vehicle-drug product is 
physicochemically stable (14).   
In practice, according to the administration techniques reported by healthcare 
professionals, carers and parents, it is common to mix formulations with foods and 
drinks that have not been evaluated (i.e. not mentioned in the SmPC, PIL or product 
labelling) (12, 13, 30). Consequently, an unsuitable vehicle might be used, which 
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may lead to possible changes in drug performance in vivo. This might be critical 
since different food and drinks can have dissimilar effects on a paediatric medicine 
due to their physicochemical properties and might significantly impact drug 
bioavailability and, consequently, therapeutic efficacy (8, 31). For example, crushing 
of gastro resistant dosage forms, such as NSAID drugs, to mix with a vehicle can 
alter drug absorption and efficacy and/or cause irritation of the gastrointestinal 
mucosa and, ultimately, may increase the risk of side effects, such as formation of 
gastrointestinal ulcers. Stability and compatibility studies of tegaserod from crushed 
tablets in soft food and drinks (water, apple juice, orange juice, and applesauce) 
revealed that while the drug was stable in and compatible with these vehicles, the 
dissolution profiles of the crushed tablets in orange juice and applesauce were not 
comparable with those of intact tablets (32).  
The FDA draft guidance provides a list of 27 vehicles commonly used for medicine 
co-administration (reproduced in Table 2.2), which includes the most predominant 
vehicles used in both inpatient and outpatient settings, such as drinks (e.g. fruit 
juices), yoghurts and banana purée (13, 30). In the formularies consulted (18-20), a 
predominant vehicle type is not recommended, probably due to the lack of rational 
behind vehicle selection. When comparing the information gathered from the 
consulted formularies/handbooks with reports from healthcare professionals and the 
FDA draft guidance, several discrepancies were found in recommendations (7, 14, 
18). For example, only 44 %  (12/27) of the vehicles listed in the FDA draft 
guidance were referenced more than 5 times in the sources consulted, 15 % (4/27) of 
vehicles are referenced between 1 and 3 times in the sources consulted, and 41 % 
(11/27) are not specifically mentioned as recommendation vehicles. Banana purée is 
one of the vehicles included as being frequently used in practice (both according to 
reports from healthcare professionals and the FDA guidance) but is not clearly stated 
as an example in any of the sources consulted (13, 18-20). Concerning issues may 
arise from these differences; for instance, juices are frequently used vehicles in 
practice but, in the formularies consulted, using fruit juices for medicine co-
administration is advised against in the cases of several drugs (e.g. bosentan tablets, 
ethambutol tablets and etravirine tablets) (Appendix I). Moreover, although vehicles 
with higher viscosity are frequently used (e.g. banana puree, yoghurt), vehicle 
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viscosity has been shown to negatively affect the dissolution of different drugs (26, 
27, 33).   
 
Table 2.2. Commonly used soft foods and drinks (reproduced from (14)) 
Soft foods Drinks 
Apples (puree) Apple juice 
Applesauce Buttermilk 
Baby food (unstrained) Coconut milk 
Bananas (puree) Cranberry juice 
Carrots (puree) Water  
Chocolate pudding Grapefruit juice 
Fruit jellies Infant formula 
Fruit jam Milk 
Honey Orange juice 
Maple syrup Pineapple juice 
Orange marmalade Soybean milk 
Peanut butter  
Rice pudding   
Strawberries (puree)  
Strawberry jam  
Yoghurt   
 
Overall, in practice there seems to be no clear rational behind vehicle selection for 
use in medicine co-administration. For most drugs, information of possible co-
administration with vehicles is not included in the product information (labelling, 
SmPC nor PIL); therefore, the possible impact of this practice on drug performance 
is often unaddressed (6, 7, 10, 34). Recognising this, the FDA draft guidance 
establish a clear rationale on the most correct approach for vehicle selection and 
standardised age-appropriate testing methodologies. Vehicle selection and age-
appropriate compatibility methodologies of drug-formulation-vehicle should be 
addressed during paediatric product development, to understand the vehicle impact 
on the drug product and the implications of medicine co-administration on drug 
clinical outcomes. In this context, a decision tree for vehicle selection is available on 
the FDA draft guidance, presented as a recommendation and not a mandatory 
requirement during paediatric drug development (14). A complicating factor for the 
establishment of uniform practices are the absence of a correct assessment of the 
acceptability of the product-vehicle mixture, in terms of flavour, texture, mouthfeel, 
and age-related responses to physical characteristics of the mixture (34). For 
example, pharmacokinetic studies have been performed with applesauce, which is 
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not always well accepted among the paediatric population (e.g. in younger age 
groups whose diet consists mostly of liquids) (23). Therefore, the potential 
acceptance of the paediatric population and vehicle uniform composition in different 
countries should be a focus point in the recommendations. Ultimately, it is necessary 
to fully establish and regulate assessment criteria and perform appropriate studies to 
provide better guidance for healthcare practitioners, patients and carers regarding 
medicine co-administration with vehicles in the paediatric population. 
 
4.2.2 Volume of vehicle 
The suggested volume of vehicle to use for mixing with solid oral dosage forms 
should take into consideration the age, size, and average consumption of the vehicle 
by the targeted patient population. For example, children younger than two years old 
may not be able or willing to ingest large volumes of drinks or soft foods at one 
time. Regulatory guidance from both the FDA and the European Medicines Agency 
(EMA) states that the typical volume of vehicle administered to a paediatric patient 
should be ‘swallowable in one unit’ to ensure administration of the complete drug 
dose, whilst facilitating swallowing and providing acceptable taste-masking (14, 29). 
Volumes between 5 and 15 mL have been proposed as acceptable and are normally 
preferable, which means that exploring alternate vehicles should be considered if a 
large volume is required (34). However, in adult studies recently conducted to 
investigate the administration of paediatric formulations mixed with vehicles, the 
volume of vehicles used varied between one tablespoon and 120 mL (6). Moreover, 
when looking at the recommendations gathered (Appendix I), it is observed that very 
different volumes of vehicles (ranging from 5 mL to 200 mL) are suggested to be 
mixed with the different drugs, although no justification is provided for the 
suggestions. For example, imatinib tablets 100 and 400 mg can be mixed with 50 
and 200 mL of water or apple juice, respectively; lansoprazole capsules can be 
opened and mixed with 60 mL of juice or 1 tablespoon of soft foods; topotecan 
capsules can be opened and mixed with 30 mL of juice; and pantoprazole suspension 
can be mixed with 5 mL of juice.  
The use of different volumes of vehicles can be prejudicial for the clinical outcome. 
For example, using a large amount of vehicle (e.g. one pot of yoghurt) might lead to 
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decreased accuracy in dose delivery, especially if the whole product is not 
consumed; conversely, use of a very small volume of vehicle (e.g. less than 5 mL) 
might not properly improve the palatability of the medicine and result in the patient 
refusal to consume it. Thus, further studies should be conducted towards defining 
age-appropriate volumes to consume, and a mandatory regulatory statement 
concerning the appropriate volumes for product testing should be provided to ensure 
a more unified approach. 
 
4.2.3 Mixture preparation and handling 
Standardisation of the preparation and use instructions for the drug product-vehicle 
mixture is important, as ambiguity in instructions or incomplete information can lead 
to unintended outcomes, including decreased accuracy in dose delivery and/or 
misuse of the drug product. Therefore, the FDA draft guidance states that the 
complexity of the preparation, homogeneity of the mixture, and handling procedures 
should be considered by the manufacturer (14). One idea that has been proposed to 
facilitate administration, whilst ensuring dosing accuracy, is to include an oral 
syringe or measuring spoon with the drug product along with clear use instructions 
to avoid administration errors (14).  
In practice, no standardised rational seems to be used for administration practices of 
medicines to paediatrics. Drug manipulation practices as reported by parents, carers 
and healthcare professionals in inpatient and outpatient settings have been recently 
evaluated (12, 30, 35). For example, in a study recently conducted in the 
Netherlands, it was revealed that only 55 % of medicines were manipulated 
according to the instructions or recommendations of the SmPC or PIL (30). The 
main reasons for drug manipulation were found to be dose adjustment, taste 
improvement or feeding tube administration, with 52.3 % of the nurses interviewed 
admitting to having deviated from hospital protocols for manipulation (30). 
Similarly, manipulation of oral dosage forms has been shown to be common practice 
among parents, carers and healthcare professionals in other paediatric hospitals of 
different countries (e.g. UK, Australia) (12, 13, 35).  
In general, the predominant reasons for manipulation have been shown to differ 
between the inpatient and outpatient settings. Manipulation by parents and carers is 
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usually performed for taste and dose adjustment, whilst healthcare professionals 
most often use manipulation for administration through a feeding tube, or for dose 
reduction (30, 36, 37). This difference probably results from: (i.) the more extensive 
formularies of inpatient pharmacies, which allow a more precise dosing with 
compounded dosage forms of different strengths, clinically supported by vehicle 
recommendations and (ii.) the higher prevalence of feeding tubes in the inpatient 
setting (30, 36). Regardless of the setting, the method used for mixture preparation 
and handling can differ depending on the person performing it, which can lead to 
dose accuracy inconsistencies (7). The risk of errors related to the drug manipulation 
will also increase if incorrect information is transferred from the healthcare 
professional to the parent and carer.  
Overall, differences are still observed between current guidance recommendations 
and reported administration practices. This highlights the need for additional in-
service training of the healthcare professionals, and consequently of parents and 
carers, regarding drug manipulation in order to fully harmonise medicine co-
administration practices and avoid potential issues in drug product performance.  
 
4.2.4 Time between preparation and administration of the mixture 
The FDA draft guidance states that the drug product-vehicle mixture should exhibit 
no change in potency (as determined by a validated assay) nor in drug release 
characteristics over the time period proposed in the product information (14). It is 
generally recommended that prepared drug product-vehicle mixtures should be 
administered immediately or as directed in the product information, in order to avoid 
potential dosing errors and/or microbiological contamination of the mixture (14). 
The proposed time frame for administration of the mixture should be supported by 
product quality assessments in which the physicochemical stability of the mixture is 
ensured. If the mixture is intended to be used more than 2 h after preparation, 
microbiological testing should be also carried out (14).  
In practice, information regarding the time frame for use of the mixture is often not 
indicated. Analysis of the recommendations gathered in the sources consulted, as 
well as recent reports on common practices in healthcare settings, revealed that 
information regarding the importance of immediate preparation is not provided for 
71 
 
most of the drugs suggested to be mixed with vehicles (7, 18). For example, this 
information was only available for 2 of the 408 drugs collected from the Lexicomp 
Handbook (Appendix I) (7, 18). These were: amoxicillin tablets (mixture should be 
administered ‘immediately’), and ivacaftor granules (mixture should be consumed 
‘within 1 h’).  
The time between the preparation and administration of the mixture may influence 
drug stability, solubility and dissolution and, subsequently, its oral absorption. In 
recent studies, we have assessed the effect of delaying the testing of drug product-
vehicle mixtures (by 4 h after their preparation) on the stability and dissolution of 
two poorly soluble compounds (mesalazine and montelukast) and their formulations 
(26, 27, 38). It was revealed that drug loss could occur to a small extent (< 15 %) in 
a time dependent manner and, consequently, concluded that administration of the 
mixtures should ideally be performed immediately after preparation, or at least 
within 4 h of preparation. An immediate administration of the mixtures would not 
only avoid potential drug/formulation stability issues and increased risk of drug 
precipitation, but also prevent other vehicle-effects on drug dissolution (e.g. 
increased solubilisation and wetting of the formulation). Other potential 
consequences are the increase of risk of adverse side effects, depending on the 
pharmacological category of the drug (33, 39). 
Overall, when mixing with a vehicle is intended, information on the time for 
administration of the mixture should be provided to ensure proper administration of 
the manipulated dosage form, while guaranteeing drug safety and efficacy. The 
establishment of unified, global practices would be helpful in avoiding possible, 
significant clinical outcomes.  
 
4.2.5 Information required for clinical practices of co-administration with 
food and drinks 
PILs should provide enough information to ensure that the healthcare provider, 
patient, parent or carer have the essential knowledge required for appropriate use of 
the recommended vehicles. In regulatory guidance, a list of recommended 
information to include in the product information is given, and includes: (i.) 
recommended vehicle type, (ii.) detailed information on the vehicle to use, including 
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volume and temperature, (iii.) recommended critical manipulations (e.g. opening a 
capsule and emptying its contents or crushing a tablet), (iv.) information on vehicle 
compatibility and mixture administration (including a succinct summary of 
compatibility/suitability data), and (v.) a rationale for avoiding certain vehicles (5, 
14, 29).  
In reality, this information is scarce for most drugs, hindering the informed 
administration of acceptable vehicle-medicine mixtures to paediatric patients (7, 30, 
34). In addition, even when food-drug interactions are known to the healthcare 
professional, it is not always possible to administer the drug with acceptable vehicles 
due to limitations on which vehicles can be used for administration through enteral 
feedings (36, 40).  
 
4.2.6 Clinical evaluation of medicine co-administration practices  
Although regulatory bodies acknowledge the importance of conducting paediatric 
studies and their benefit for the patients, these are not considered necessary (4). In 
the EU, an optional in vivo study to evaluate this practice is suggested in the EMA 
guideline on pharmaceutical development of paediatric medicines (29). This can be a 
separate bioequivalence study in adults or, alternatively, paediatric clinical trials can 
be conducted with the vehicle of choice. Extrapolation of food-effects observed in 
adults into paediatric subpopulations is an unexplored and complex area due to 
physiological and anatomical differences between the two populations. This may 
result in different food effects in the paediatric population compared to adults (41, 
42). Paediatric clinical trials conducted for vehicle assessment are limited; for 
example, suitability tests were performed on the co-administration of montelukast 
paediatric formulations with formula and applesauce (6). Paediatric clinical studies 
are generally conducted to investigate PK do not always reflect paediatric 
administration practices and, consequently, the clinical impact of the administration 
of paediatric medicines with food and drinks is often not evaluated (43).  
In the USA, the practice of mixing medicines with foods is described in the FDA 
guidance on Food-Effect Bioavailability and Fed Bioequivalence Studies; studies in 
healthy adult volunteers are usually requested and accepted and, additionally, in vitro 
and in silico tests can be accepted as supportive evidence (10, 43, 44). In this 
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context, a recent study described how in vivo, in vitro and in silico investigations 
were adjusted to existing knowledge available for two model drugs (one poorly and 
one highly soluble) (10). Drug stability when mixed with different vehicles was 
confirmed and suitable vehicles for co-administration were selected, following a 
combination of in vitro dissolution and drug solubility studies and in silico 
modelling (10).  
Overall, investigation of vehicle suitability as part of paediatric clinical trials would 
provide the highest reliability in terms of product safety and efficacy. However, 
introduction of additional drug administration conditions and patient recruitment 
difficulties might further complicate the design, execution, interpretation of results, 
and, ultimately, the outcome of clinical studies. The use of in vitro and/or in silico 
age-appropriate predictive tools to aid understanding of formulation performance in 
paediatrics would be beneficial to understand the impact of medicine co-
administration with vehicle, and age-related factors on drug behaviour. Furthermore, 
these tools could be used to predict in vivo clinical outcomes. Ultimately, the 
development and establishment of in vitro and/or in silico testing during paediatric 
drug development could help reduce the number of in vivo studies required for 
paediatric formulation development, and tackle ethical issues related to clinical 
research in the paediatric population (2).  
 
5. Conclusions 
In view of the prevalence of the practice of medicine co-administration with food 
and drinks in paediatrics, efforts should be made to reconcile the information 
available and provide clear, easily accessible information on vehicle suitability. 
However, information on the appropriate vehicle to use is still not available for many 
medicines, and no clear rational seems to guide vehicle recommendations. Published 
sources reporting this practice show a lack of standardisation in terms of vehicle 
recommendations, criteria defining vehicle acceptability, administration practices, 
and evaluation assessments. Moreover, the absence of mandatory status leads to 
differences between practice and recommendations, further hindering the 
establishment of uniform, acceptable administration techniques.  
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In this study, with the information gathered from available paediatric formularies, a 
statistical model was developed. This model provides an understanding on which 
vehicle type is recommended for use in medicine co-administration practices, based 
on the physicochemical and biopharmaceutical properties of the drug/formulation. 
The developed model has a reasonably good predictive ability, with predicted and 
calculated vehicle recommendations in a test set showing a good agreement. 
However, as the model is currently based on a dataset comprising a limited number 
of sources, further work is required to verify and extend this approach. This could 
serve as a starting point towards the development of unified guidelines, where 
selection of a vehicle can be made based on drug/formulation characteristics.  
Overall, it is recognised that healthcare professionals would benefit from obtaining 
complete training on this practice in order to be informed on possible clinical 
outcomes and correctly train parents and carers. A consensus agreement between 
academia, the pharmaceutical industry and regulators would be welcomed to 
harmonise and standardise the methodology for vehicle compatibility assessments, 
and provide uniform and established, scientifically-based guidance.  
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Chapter 3: Assessing the impact of paediatric medicine co-
administration with food and drinks on the solubility of poorly 
soluble drugs 
Abstract 
Objectives: Based on the recommended strategies for the oral administration of 
paediatric medicines with food and drink vehicles, the aims of this study were: (i.) to 
measure the physicochemical properties of a selection of (soft) food and drink 
vehicles, commonly reported to be mixed with paediatric medicines prior to 
administration; (ii.) to assess the impact of the co-administered vehicle on the 
solubility of two poorly soluble paediatric drugs. Montelukast (sodium) and 
mesalazine were selected as the model compounds. 
Methods: 26 vehicles commonly used for paediatric medicine co-administration 
were selected; their physicochemical properties (pH, buffer capacity, surface tension, 
viscosity and osmolality) and macronutrient characteristics (sugar, protein and fat 
content) were measured/recorded. Solubility studies of two poorly soluble drugs 
were then performed in selected vehicles and in three USP buffers (pH 1.2, 4.5 and 
6.8). Partial least square regression was performed to assess the impact of the 
physicochemical properties and content characteristics of the vehicles, as well as 
their interactions, on drug solubility.   
Key findings: Distinguished differences were observed between the physicochemical 
properties and macronutrient composition of the different vehicles, not only among 
vehicle type but also within vehicles of the same subtype. Solubility studies of the 
two model compounds in selected drinks and soft foods, resulted in considerably 
different solubility values in each vehicle. Drug solubility was significantly affected 
by the vehicle physicochemical properties and macronutrient composition, with the 
solubility of montelukast being driven by vehicle pH, fat and protein content and the 
solubility of mesalazine by vehicle osmolality, viscosity and sugar content.  
Conclusions: The observed vehicle-dependent impact on drug solubility could 
compromise its bioavailability, ultimately affecting the safety and/or efficacy of the 




Paediatric formulation development has been affected by new regulations, additional 
funding opportunities and research initiatives in both the USA and Europe. 
Nevertheless, development of acceptable, age-appropriate dosage forms, whilst 
maintaining safety and efficacy and ensuring compliance, remains a challenge due to 
the unique requirements and limitations of this heterogeneous population (1, 2).  
Healthcare professionals, parents and carers still face the need to manipulate 
medicines designed for adults in order to adapt dosage forms to give smaller doses, 
improve palatability and enhance compliance amongst paediatric patients (3). This 
manipulation can range from simple (e.g. tablet splitting) to more complex methods 
(e.g. tablet crushing for suspension preparation), and results in availability of patient-
tailored medicines. A common practice is to mix medications with food or drink 
vehicles to mask the unsatisfactory palatability of a formulation, in cases that it 
cannot be improved through dosage form design, and/or to enhance acceptability 
through swallowing facilitation or texture improvement (4-6).  
When this practice is intended, appropriate compatibility studies should be 
conducted in order to assess compatibility issues and evaluate the possible impact on 
drug bioavailability (7). Clear instructions on the type of vehicles appropriate for 
mixing with the medicine should be provided in the patient information leaflet (PIL), 
summary of product characteristics (SmPCs) and product labelling (7, 8). Similarly, 
appropriate warnings should be provided in cases that such practice is unsuitable, or 
has not yet been studied, with any mixing outside the recommendations being of the 
responsibility of the health care professional, patient, parent or carer (8).  
In practice, the scientific rationale for co-administering a particular type of vehicle is 
often not evident (4). Most of the vehicles that appear in the paediatric dosing 
recommendations of SmPCs and PILs are chosen based on their taste and texture 
being child-friendly, and there is no general rule on how to administer oral medicines 
to the paediatric population in a safe and effective way (5, 9). Moreover, due to 
cultural differences in flavour preferences and accessibility of foods around the 
globe, different vehicles may be used to achieve adequate patient acceptability.  
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Carers often overlook the recommendations given in SmPCs and PILs, however, the 
clinical implications of this practice of medicine co-administration on drug 
behaviour and, subsequently, oral drug bioavailability are often not studied. Previous 
studies have shown that different foods or drinks can have dissimilar effects on the 
paediatric medicine in vivo performance due to their physicochemical properties. For 
example, the pH of pudding (pH 5.6), damaged the enteric coating of duloxetine 
pellets and affected its absorption compared to when the pellets were mixed with 
applesauce or apple juice (10); and the viscosity of applesauce, affected dissolution 
from warfarin crushed tablets in comparison to when these were mixed with orange 
juice (11).  
In an effort to provide guidance on medicine co-administration, the FDA has 
recently launched a draft guidance entitled ‘Use of liquids and/or soft foods as 
vehicles for drug administration: general considerations for selection and in vitro 
methods for product quality assessments’ (7). It is stated that the best vehicles to use 
for this clinical practice are those with relatively small fluctuations in their 
macronutrient composition and physicochemical characteristics, such as vehicle 
viscosity and pH. Furthermore, vehicle candidates should be screened concerning 
their interaction with drug/formulation and their adequacy to the target age group. 
This could guide an appropriate use of the vehicle and avoid possible clinical 
implications (7). 
Knowledge of the composition and properties of the food and drinks will aid 
understanding of their in vivo impact on the drug product behaviour. Oral drug 
performance is influenced by drug bioavailability, which in turn is largely dependent 
on the drug available in the GI tract to undergo absorption (12). For poorly soluble 
compounds, oral drug absorption will be limited by drug solubility. Therefore, it is 
important to understand the impact of medicine co-administration with food and 
drinks on the behaviour of different drugs. The solubility of a drug serves as a 
surrogate indicator of oral biopharmaceutical performance and is one of the two 
factors that are used in the Biopharmaceutics Classification System (BCS) (13). It 
depends on the physicochemical properties of the drug and the composition of the 
dissolution medium the drug is exposed to; thus, it can be affected by the co-
administered vehicle. To our knowledge, little attention has been devoted to 
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characterising soft foods and drinks commonly used in practice as well as identifying 
the impact of these properties on drug solubility. 
The aims of the present study were: (i.) to measure the physicochemical properties of 
a number of food and drink vehicles that are commonly co-administered with 
paediatric medicines, and (ii.) to investigate the impact of the type of co-
administered vehicle on the solubility of two poorly soluble paediatric drugs.  
The characteristics of the model drugs to study were restricted to include a poorly 
soluble compounds, with pH-dependent solubility, documented usage in both 
children and adults, and recommended to be mixed with food or drink vehicles to 
facilitate administration in the paediatric population. Based on these criteria, 
montelukast (sodium) and mesalazine were selected.  
Montelukast is a BCS class II compound with low aqueous solubility (0.2-0.5 µg/mL 
at 25 
o
C (14)), two pKas - 2.7 (strongest basic) and 5.8 (strongest acidic) (15), a 
clogP of 8.79 (16). The structure of montelukast sodium is shown in Figure 3.1. 
Instructions about the use of a paediatric montelukast formulation (Singulair
®
 
granules) report that the granules can be mixed with one teaspoonful of soft food 
(cold or at room temperature) (17). 
 
 
Figure 3.1. Structure of montelukast sodium (ChemDraw Professional 18.1) 
 
Mesalazine has been classified as a BCS class IV drug, having an aqueous solubility 
of 0.84 mg/mL at 25
o
C and a clogP of 0.98 (18). It is a zwitterion having a carboxyl 
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group (–COOH) with a pKa value of 2.3 and an amino group [(NH3
+
)−] with a pKa 
of 5.69 (19). The structure of mesalazine is shown in Figure 3.2. A commercially 
available mesalazine formulation (Pentasa
®
 granules) is recommended to be mixed 
with juice or water to facilitate administration (17). 
 
 
Figure 3.2. Structure of mesalazine (ChemDraw Professional 18.1) 
 
2. Materials and methods 
2.1 Materials  
Ammonium acetate [High Performance Liquid Chromatography (HPLC) grade], 37 
% hydrochloric acid, sodium hydroxide, sodium chloride, sodium acetate trihydrate, 
glacial acetic acid, sodium phosphate anhydrous, acetonitrile (HPLC grade) and 
methanol (HPLC grade) were purchased from Fisher Scientific (UK). Trifluoroacetic 
acid [TFA] (HPLC grade), montelukast sodium and mesalazine were obtained from 
Sigma-Aldrich Company Ltd. (UK). Water was ultra-pure (Milli-Q) laboratory 
grade.  
Polytetrafluoroethylene [PTFE] filters (0.45 µm), RC filter papers (0.45 µm) 
(Whatman
®
, UK) and regenerated cellulose [RC] membrane filters (0.45 µm) 
(Cronus
®
, UK) were used.  
Based on the recommendations gathered from the UK National (BNF-C (17)) and 
Hospital (20) formularies and taking into consideration the availability in a clinical 
setting, twenty-six different vehicles were selected and characterised. The origin, 
description, nutritional factors and manufacturer’s preparation instructions of the 
vehicles studied are described in Table 3.1. Honey, jam, Coca-Cola as well as all 
squashes, milks, yoghurts, Bramley’s applesauce (Bramley applesauce Colman’s of 
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Norwich, UK) and juices were purchased from The Co-Operative (UK). Three infant 
formulas were used in the study: First Infant Milk (cow’s milk-based formula) and 
Infasoy (soya-based formula) (Cow & Gate, UK), and Wysoy (soya-based formula) 
(SMA - Nestlé, UK). Vehicles with considerably different compositions available in 
different countries were also analysed. Mott’s natural applesauce (Mott’s LLP, USA) 
and Bauck Hof applesauce (Bauck Hof Apfelmark, Germany) were purchased from 
Amazon (UK) and were specifically chosen due to their different composition and 
region of origin. 
 
Table 3.1. Identification, origin, nutritional facts and instructions for preparation 
(when applicable) of the vehicles studied. The vehicles, divided in two categories – 
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< 0.5 < 0.5  49.0  N/A 
(N/A: not applicable) 
 
2.2 Methods 
2.2.1 Preparation of vehicles and media  
USP simulated gastric fluid sine pepsin (SGFsp) pH 1.2, acetate buffer pH 4.5 and 
phosphate buffer pH 6.8 were prepared following the USP 27 (21). 
Prior to all analysis, squashes and formulas were prepared as per manufacturer’s 
instructions (Table 3.1) and Coca-Cola was degassed. The dilution of the prepared 
squashes was not the same (blackcurrant: diluted 1/5 with water; orange: diluted 1/10 
with water; Table 3.1). To evaluate if these differences in dilution had an effect on 
the physicochemical characteristics measured, confirmatory studies were performed 
with orange squash diluted on a 1/5 (concentrated squash/water) ratio. Results 
showed that the dilution of the squashes did not have a significant effect on the 





2.2.2 Physicochemical characterisation of the vehicles 
Physicochemical characterisation of all vehicles included measurement of pH, buffer 
capacity, osmolality, surface tension and viscosity. All experiments were run in 
triplicate and results are expressed as mean values ± standard deviation (S.D.).  
2.2.1.1 pH  
The pH of each vehicle was measured, at room temperature, using a pH meter 
(Mettler Toledo S220 Seven Compact pH/Ion meter, Schwerzenbach, Switzerland). 
pH measurements took place immediately after opening the soft food/drink container 
or after vehicle preparation (in the cases of the formulas, squashes and Coca-Cola), 
and agitating the vehicle with a spatula for 5 s.  
2.2.1.2 Buffer capacity 
Buffer capacity was quantified by dropwise addition of 0.1 N sodium hydroxide or 
0.1 N hydrochloric acid, measuring the volume required to change the pH by one 
unit, under constant agitation. Buffer capacity was then calculated using the 
following equation (Eq. 3.1) (22):  
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    (Eq. 3.1) 
where 
  
   
 is the buffer capacity,     is the concentration of acid or base added 
and     is the pH change produced.  
2.2.1.3 Osmolality  
Osmolality was measured via freezing-point depression method by a micro-
osmometer (Advanced Instruments Inc. micro-osmometer Model 3300, Norwood, 
MA). 20 µl of sample were placed into the sampler, which was then inserted into the 
instrument’s operating cradle, and subsequently lowered to the freezing chamber; 
this initiated the process of super cooling the sample. Following a solenoid-induced 
pulse and subsequent sample freezing, the liberated heat of fusion was related by a 
microprocessor to the sample’s freezing point and osmolality was shown on a digital 
display (26). 
The osmolality values of Bramley’s applesauce (UK), honey and jam were 
quantified based on a set of appropriate dilutions of the vehicles in demineralised 
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water (% (w/w) vehicle/water). Concentration of vehicle (% (w/w)) and osmolality 
value measured were correlated, and the osmolality value of the undiluted vehicle 
(i.e. 100 % (w/w) vehicle/water) was calculated from the linear regression. 
2.2.1.4 Surface tension 
Surface tension was measured with the du Nouy ring method (23), using a ring 
tensiometer (Sigma 700 Force tensiometer, Attension, UK). 10 mL of sample were 
placed into a glass vessel (Ø = 46 mm) and temperature was set to 25 
o
C. The ring 
was submerged below the interface of the sample by moving the stage where the 
vessel was placed. After immersion, the stage was gradually decreased, and the ring 
pulled up the meniscus of the sample. The force required to raise the ring from the 
meniscus was measured and used to determine the surface tension.  
2.2.1.5 Viscosity  
Viscosity of the vehicles was determined using a rheometer (Bohlin Rheometer C-
VOR, Malvern instruments, UK) fitted with a cone and plate geometry (4º cone 
angle, 40 mm diameter). Samples were added to the plate of the rheometer and 
analysis was carried out at 25
o
C. Viscosity was measured at increasing shear stress 
(in the range of 0.1 to 4 Pa) for the drinks (modification of (24)) and increasing shear 
rate (from 0.1 to 85 s
-1
) for the soft foods (modification of (25)), with 10 s delay time 
and 10 s integration time at each shear.  
While the rheological curves for each sample were measured, for simplicity, the 
viscosity value used for statistical analysis was η50 (i.e. the measurement at a shear 
rate of 50 s
-1
), which is the shear rate most often associated with swallowing (11). 
 
2.2.3 Chromatographic conditions 
Drug quantification was performed with HPLC with ultraviolet (UV) detection. 
Samples were analysed with an Agilent HPLC system 1100 series (montelukast) and 
1200 series (mesalazine) (Agilent Technologies, USA). The HPLC method used for 
the analysis of montelukast is a modification of a published method by Raju KN et al 
(27). A revers  ed-phase (RP) J.T. Baker Octadecyl-C18 column (250 mm x 4.6 mm, 
5 µm particle size) was used. The mobile phase was composed of ammonium acetate 
buffer pH 5.6 and methanol (solvents A and B, respectively) delivered at a flow rate 
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of 1 mL min
−1
. The selected gradient started with 10 % of solvent B, which was 
increased linearly to 50 % over 2 min, and linearly to 90 % between 2 and 4 min; at 
11.30 min, the initial conditions of analysis were re-established. Injection volume 
was 100 µL. Analysis was performed at 20 
o
C and the detection wavelength was 284 
nm. The HPLC method used for mesalazine analysis is a modification of a published 
method by Fadda H et al (18). A RP Agilent Eclipse XBD-C18 column (250 mm x 
4.6 mm, 5 µm particle size) was used. The mobile phase was composed of methanol 
and 0.05 % TFA-Water (5:95) delivered at a flow rate of 1 mL min
−1
. Injection 
volume was 20 µL. Analysis was performed at 40 
o
C and the detection wavelength 
was 304 nm.  
The non-presence of a vehicle-matrix effect on drug detection, and HPLC analysis 
validity were confirmed by performing the following protocol: (i.) solution standards 
of the highest and lowest calibration curve concentrations were injected at least 3 
times during each HPLC analysis run, and peak areas were analysed; and (ii.) ‘blank’ 
matrix standards were also injected, corresponding to vehicles exposed to the same 
conditions of the samples but containing no drug (after vehicle opening, and after 
placing vehicle into shaking water bath and collected at 4 and 24h) (data not shown). 
 
2.2.4 Solubility studies 
Solubility studies of montelukast and mesalazine were performed in sixteen food and 
drink vehicles; these included: formula (first milk), milk (whole U.H.T), yoghurts 
(plain flavour, lemon curd and Greek), juices (apple and orange), Coca-Cola, 
squashes (blackcurrant Ribena
®
, orange and blackcurrant Co-Op
®
), honey, jam and 
applesauces (Mott’s natural applesauce US, Bramley’s applesauce UK and Bauck 
Hof applesauce DE). Solubility studies of the two compounds were also performed 
in USP SGFsp pH 1.2, acetate buffer pH 4.5 and phosphate buffer pH 6.8 to compare 
between drug solubility in these media and in different food and drinks of 
corresponding pH and investigate the effect of media pH on the solubility of the 
compounds. 
An excess amount of drug was added to 1.5 g of foods and 1.5 mL of buffers/drinks, 
in centrifuge tubes and stirred with a spatula for 30 s. A pilot study was performed to 
assess the impact of drug excess amount on drug solubility: different amounts of 
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drug were added to selected vehicles (i.e. formula, blackcurrant squash Ribena, 
Greek yoghurt, honey, applesauce DE and jam); results revealed no impact of the 
amount of drug used in the study on the solubility of the two compounds (data not 
shown). Capped tubes were placed in a shaking water bath (37 
o
C) (Grant SS40-2, 
Grant Instruments, UK), under constant shaking rate of 200 strokes/min, and 
protected from light to avoid photodegradation (28, 29). Samples were collected at 4 
h and 24 h. Undissolved drug was removed by centrifugation (Eppendorf Heraeus 
Fresco 17 centrifuge, Thermo Electron LED GmbH, Germany) at 8000 rpm for 15 
min, at 4 
o
C. 1000 µL of acetonitrile (montelukast) or 500 µL of 10 % (v/v) 
TFA/water (mesalazine) were then added to 500 µL (or mg) of the centrifuged 
sample. The mixture was vortexed for 1 min, and centrifuged. The supernatant was 
then filtered through a RC (montelukast) or PTFE (mesalazine) filter (0.45 µm), 
placed into amber HPLC vials and analysed. Honey and jam montelukast samples 
were diluted (dilution 1:2) with a solution of acetonitrile:water (1:1) prior to the 
treatment step.  
Centrifugation technique was confirmed and validated as an efficient separation 
method of undissolved drug after three investigational studies were performed in 
selected vehicles (i.e. whole milk, orange juice, applesauce UK, plain yoghurt, Greek 
yoghurt). These were: (i.) filtration of saturated drink samples and comparison of 
drug solubility results with those obtained with centrifugation technique; (ii.) 
filtration of the supernatant after centrifugation of saturated samples and comparison 
with drug solubility results obtained when the supernatant was not filtered; (iii.) 
different centrifugation conditions (speed and time) and sequential centrifugations 
were tested and compared with drug solubility results obtained with original 
centrifugation conditions (data not shown).  
All experiments were performed in triplicate. Quantification of the concentration of 
drug in samples was performed based on calibration curves. Fresh calibration curves 
(concentration range: 0.2 – 100 μg/mL (montelukast) and 5 – 200 μg/mL 
(mesalazine)) were prepared in the corresponding media (buffer or vehicle), by 
appropriate dilution of a 1000 μg/mL stock solution of the analytical standard in 
methanol (montelukast) or 0.05% TFA/water (mesalazine); the same treatment 
process was applied as described for the samples. 
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2.2.5 Data analysis 
Vehicle characterisation data was analysed with one-way ANOVA using 
Statgraphics Centurion XVII software (Statpoint Technologies Inc, USA). Post hoc 
analysis was performed using Tukey Honest Significant Difference (HSD) test, in 
order to perform pairwise multiple comparison of between vehicles of the same 
subtype (p < 0.05 noting statistical significance). 
Drug solubility results obtained in all studied vehicles were correlated to the 
physicochemical properties (pH, buffer capacity, surface tension, viscosity, 
osmolality) and macronutrient composition (percentage of fat, sugars and proteins) 
of the vehicles and selected interactions by partial least square regression (PLS-R) 
analysis using XLSTAT Software (an Add-In for Excel, Microsoft
 ®
). The 
interactions selected as independent variables were (i.) interactions of vehicle pH 
with all other independent factors (physicochemical properties and macronutrient 
composition of the vehicles), chosen due to the difference between drug solubility in 
simple buffers and in vehicles of corresponding pH; and (ii.) interactions between 
vehicle viscosity and macronutrient composition, chosen due to the differences 
observed between drug solubility in the different soft foods. 
PLS-R analysis is a statistical method which relates multivariate descriptor sets to 
different response sets (30). Four PLS-R models were constructed: one for the 
solubility of each drug at each time point studied (4 and 24 h). The quality of the 




, which measure the fraction of the total 
variation of the response explained by the model and the fraction of the total 





values above 0.5 and 0.8 refer to a model with good fit and prediction power, 
respectively (31). The statistical analysis generates components, based on the 
independent variables set to explain the response. These components are built 
iteratively so as to better explain the variability of the dependent variable (response), 
and their number is lower than the initial variables input into the model (30). The 
PLS-R models were built and evaluated based on full cross-validation (leave-one-out 
procedure). The number of principal components for each model was selected based 
on the optimum Q
2 
value. The variable influence on projection (VIP) function, which 
describes the importance of the factors for the response cumulatively, was used to 
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identify which factors were most relevant for explaining drug solubility (with VIP > 
1 noting statistical significance) (30). The standardised coefficients were used to 
indicate the relative impact (positive or negative) of each factor or interaction on 
drug solubility. 
 
3. Results and discussion  
3.1  Physicochemical characterisation of the food and drink vehicles 
Results from the physicochemical characterisation (pH, buffer capacity, osmolality, 
surface tension and viscosity) of the twenty-six selected vehicles are shown in 
Figures 3.3 to 3.5.  
 
3.1.1 pH 
pH values measured were in the range of 3 to 4 for ‘fruity’ vehicles (i.e. squashes, 
juices, Coca-Cola, applesauce), pH range 4 to 4.5 for ‘milky’ soft foods (i.e. 
yoghurts) and pH range 6 to 7 for ‘milky’ drinks (i.e. milk, formulas) (Figure 3.3a).  
As observed in the results, the pH of food and drinks of the same subtype is usually 
controlled within a specific range of pH, mostly due to their composition (32). For 
example, the pH of yoghurts in the range of 4 to 4.5 can be explained by the use of 
bacteria (normally, lactobacillus acidophillus) in their manufacturing process to 
convert milk sugar/lactose into lactic acid, which ultimately increases the acidity of 
the product (33). The pH of applesauces, orange and apple juice will be close to the 
pH of the corresponding fruits and may be more acidic depending on the presence of 
lemon juice in their composition (32). For example, the pH of the Mott’s natural 
applesauce (US) was lower than the other applesauces due to this.   
Differences in the pH of the vehicles used for medicine co-administration may affect 
the dissolution and absorption of drugs. For example, acidic vehicles such as 
yoghurts, applesauces, jam and honey (pH range 3 to 4.5), have been shown to 
compromise the chemical stability of acid sensitive drugs, especially in the case of 




Figure 3.3. Physicochemical properties of 26 vehicles used for co-administration of drugs: (a) pH; (b) Buffer capacity, per addition of NaOH (upper part) or 
HCl (lower part); (c) Osmolality; (d) Surface tension. Each set of colours represents a subtype of vehicles. 
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3.1.2 Buffer capacity 
Buffer capacity is higher in yoghurts, applesauces and jam, with lower values 
measured in formulas and orange squash (Figure 3.3b). Buffer capacity is especially 
important to the performance of ionisable compounds since a change in pH can 
affect the ionisation percentage of these drugs, and thus influence their solubility and 
dissolution (35). The different results obtained for the buffer capacity of these 
vehicles suggest that co-administration of a drug with the different vehicles may 
have an impact on its solubility.   
 
3.1.3 Osmolality 
The osmolality values of Bramley’s applesauce UK, honey and jam could not be 
directly measured because they were above the maximum value measured by the 
micro-osmometer. Osmolality of these vehicles was obtained by extrapolation of the 
linear regression of the osmolality of a set of vehicle/water mixtures (% (w/w)) at 
various concentrations. Results are presented in Figure 3.4.  
 
 
Figure 3.4. Linear regression of the osmolality values measured for the different mixtures 
vehicle (jam, honey and Bramley's applesauce US)/water (% (w/w)), which was used to 
extrapolate the osmolality value of the undiluted vehicles (dashed lines).  
 
Osmolality of all tested vehicles is presented in Figure 3.3c. Osmolality was 
generally higher in soft foods than drinks, except for soya yoghurt (298.0 mOsm/kg), 
Greek yoghurt (393.0 mOsm/kg) and apple juice (693.3 mOsm/kg). The highest 
osmolality value was observed in honey (6650.0 mOsm/kg) and the lowest in orange 
squash (22.0 mOsm/kg). Significant differences were observed between vehicles of 
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the same subtype, namely between the different squashes and between the 
applesauces (p < 0.05). Osmolality of the orange squash was 4 and 20-fold lower 
than osmolality of the blackcurrant Co-Op and Ribena squashes, respectively. These 
differences can probably be attributed to the higher sugar content of the blackcurrant 
squashes in comparison to the orange squash (42). 
The different osmolality values of the studied vehicles may affect the dissolution 
behaviour of a drug by inducing changes in the swelling behaviour of the 
formulation. When the difference in osmotic pressure between the inner and outer 
(GI environment) part of the formulation decreases, water penetration decreases as 
well, negatively affecting drug release (43).  
 
3.1.4 Surface tension  
Honey and blackcurrant squashes showed the highest surface tension, and soya 
formula the lowest (Figure 3.3d). The similar surface tension values measured for the 
dairy vehicles (except soya-derived products) can be related to the macronutrient 
composition of these vehicles. Dairy vehicles include surface-active constituents in 
their composition, such as fat, proteins and free fatty acids, which can affect the 
surface tension of these products (36). For the case of soya-derived products, these 
differ in composition from the other dairy vehicles due to the absence of milk protein 
and presence of soya protein, which has been shown to lower the surface tension 
(37). The surface tension of the juices and orange squash is lower in comparison to 
the other products due to the higher percentage of water in their composition and to 
the presence of fatty acids and their salts, which are surface active and reduce 
surface tension (38). 
Differences were observed between the surface tension of Infasoy formula (30.0 
mN/m) and the other formulas (40.1 mN/m (Wysoy) and 44.2 mN/m (first milk)) 
and between the surface tension of the squashes (orange squash 44.9 mN/m and 
blackcurrant Ribena and Co-Op squashes 60.1 and 64.2 mN/m, respectively).  
The different surface tension values of the vehicles (including between vehicles of 
the same subtype) may impact the dissolution rate of a drug by influencing the 




The viscosity curves of the studied vehicles are shown in Figure 3.5. All drinks 
exhibited a Newtonian flow whereas the soft foods showed non-Newtonian flow 
(pseudoplastic behaviour), with the exception of honey. The soft foods studied 
contain milk and/or macromolecules (i.e. starch), which results in a significant 
increase in viscosity compared to that of the drinks (p < 0.05) (40).   
 
 
Figure 3.5. Viscosity of the drinks and soft foods measured at increasing shear stress (0.1 to 
4 Pa) for the drinks and increasing shear rate (0.1 to 85 s
-1
) for the foods (left and right 
panels, respectively) are shown in the left and right panels, respectively. 
 
The clear differences in viscosity between the drinks and soft foods and between the 
different soft foods indicate that, depending on the child’s diet, the overall absorption 
of certain drugs may be altered. For example, in infants whose diet consists mostly 
of liquids, the absorption of certain drugs may be increased due to the lower 
viscosity of the ingested food. Moreover, depending on the volume of vehicle 
administered, its viscosity can affect the pharmacokinetics of the drug due to 
alterations of physiological conditions (41). For example, mixing a medicine with a 
vehicle of higher viscosity such as jam may reduce the diffusion rate of the drug and 





3.2  Solubility studies of montelukast and mesalazine 
Solubility of the two drugs differed in the vehicles studied (Figure 3.6). Solubility of 
montelukast in different USP buffers was shown to be pH-dependent (pH 1.2 < pH 
4.5 < pH 6.8; Figure 3.7a), which is in accordance with previous reports (14). This is 
attributed to an increased solubilisation at more basic pHs, corresponding to the 
ionisation of the amino group of the compound (pKa 5.8) (15). Solubility of 
montelukast was generally lower in drinks than in soft foods, except the case of 
‘milky’ drinks and Coca-Cola (Figure 3.4). In drinks, the lowest drug solubility was 
observed in apple juice (9 µg/mL; pH 3) and the highest in ‘milky’ drinks (pH 6.8), 
which is likely due to the pH effect on the solubility of montelukast. In soft foods, 
the lowest solubility of montelukast was measured in the plain yoghurt (1.6 mg/mL) 
and the highest in the Greek yoghurt (14.4 mg/mL). Interestingly, the solubility of 
montelukast in orange squash was 3 and 4-fold lower than in blackcurrant Ribena 
and Co-Op squashes, respectively, and in Mott’s natural applesauce (US) drug 
solubility was around 2 to 3-fold lower than in the other applesauces (p < 0.05). 
Differences in drug solubility observed within vehicles of the same subtype and, 
therefore, same pH range (section 3.1.1), indicate that the solubility of montelukast is 
also driven by other vehicle physicochemical properties (pH, surface tension, 
osmolality, viscosity and buffer capacity) and macronutrient composition differences 
(percentage of sugars, fat and proteins). For example, both sugar content, and 














Figure 3.6. Solubility of montelukast and mesalazine (top and bottom sections, respectively) in the different drink and food vehicles, obtained after 4h (plot 




Figure 3.7. Solubility values (logarithmic scale) of montelukast and mesalazine in the 
selected media (soft foods, drinks) vs (a) pH (including solubility in buffers) (2D plot), and 
vs (b) pH and viscosity, (c) pH and % of fat, (d) pH and % of protein, and (e) pH and % of 
sugars (3D scatter plots). 
 
For mesalazine, solubility was pH-dependent (solubility in pH 1.2 > solubility in pH 
4.5 < solubility in pH 6.8; Figure 3.7a). A similar trend has been observed for the 
solubility of mesalazine in level I and II biorelevant media (44). Lower drug 
solubility at pH 4.5 could be attributed to the ionisation of this amino acid, which is 
the lowest at the isoelectric point (pI) of the compound (pH 4.3) and increases as the 
pH deviates from the pI (45, 46). A clear distinction between the solubility of 
mesalazine in drinks and soft foods could not be made (Figure 3.6). Drug solubility 
was lower in drinks with a pH ~ 4, probably due to the pH effect on drug ionisation 
and, consequently, solubilisation. Although trends could be seen between solubility 
and pH for the drinks, differences between drug solubility in drinks and soft foods of 
the same pH suggested that other vehicle properties, as well as differences in the 
macronutrient composition of the vehicles, influence drug solubilisation. For 
example, in yoghurts and applesauces (pH ~ 4), mesalazine exhibited a higher 
solubility than in drinks of same pH, which could relate to the higher viscosity of 
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these vehicles. For this drug, the highest solubility was obtained in honey (38.4 
mg/mL) and the lowest in orange squash (0.63 mg/mL). 
Overall, these results demonstrate that mixing these two poorly soluble drugs with 
soft foods and drinks significantly affects their solubility. 
 
3D correlations of drug solubility values vs the vehicle composition (percentage of 
fat, sugar and protein)/viscosity and pH are presented in Figures 3.7b-3.7e. Analysis 
of the solubility of montelukast in the different vehicles revealed a crescent shaped 
trend between the pH and the percentages of fat and protein of the vehicles. The 
higher solubility of montelukast in the ‘milky’ products (milk, formula and yoghurts) 
in comparison to its solubility in the other vehicles might be related to the high 
lipophilicity (clogP = 8.79) and high affinity binding of this drug to proteins. This is 
in accordance with drug solubility studies previously conducted in milk which 
showed a positive relationship between drug lipophilicity, affinity binding to 
proteins and drug solubility in milk (47). 
For mesalazine, a positive interplay was observed for vehicle pH, percentage of 
sugars and drug solubility in drinks and soft foods. In soft foods, it was possible to 
observe a positive correlation of drug solubility reliant on an increase of pH and 
viscosity. A positive correlation between drug solubility and media viscosity has 
been previously shown for similar compounds, which can justify the higher 
solubility of mesalazine in soft foods (e.g. honey, jam). 
 
3.3 Statistical assessment of the vehicle-impact on drug solubilisation 
PLS-R analysis was used to understand the vehicle-impact on the solubility of the 
two drugs. The variables and interactions of the PLS-R models constructed are 
presented in Figure 3.8. The PLS-R models developed for the solubility of 
montelukast at 4 and 24 h were defined by 4 and 5 components, respectively, had a 
good predictive power (Q
2
 = 0.66 and 0.78, respectively) and showed a good fit to 
the experimental values (R
2
 = 0.82 and 0.90, respectively). The pH and the 
percentage of fat and proteins were revealed as the factors with the most significant 
(positive) impact on the solubility of montelukast, while the buffer capacity of the 
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vehicles had a significant positive impact on the solubility of montelukast at 4 h but 
not at 24 h (Figure 3.8). Significant effects of the interaction of pH with buffer 
capacity and viscosity with fat (negative) and interaction of pH with osmolality, 
viscosity and fat, sugar and protein content (positive) were observed for this drug.  
For mesalazine, the PLS-R models constructed for drug solubility at 4 and 24 h 
showed a good fit to the experimental values (R
2
 = 0.98 and 0.94, respectively), a 
good prediction power (Q
2
 = 0.95 and 0.91, respectively) and were defined by 3 and 
2 components, respectively. Vehicle viscosity, osmolality and sugar content were the 
significant factors impacting the solubility of mesalazine (all positive effect), while 
significant effects from the interactions of viscosity with protein and fat content 
(negative) and the interaction of viscosity and sugar content (positive) were revealed 
(Figure 3.8).  
 
 
Figure 3.8. Standardised coefficients corresponding to the variables and interactions studies 
for the solubility of montelukast (a, b) and mesalazine (c, d), at 4 h (left panel; a, c) and 24 h 
(right panel; b, d). Blue and red colours denote coefficients with a significant impact on the 
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solubility of montelukast and mesalazine, respectively (VIP >1; data not shown). [BC = 
buffer capacity; ST = surface tension]. 
 
The difference in the vehicle variables (physicochemical properties and/or 
macronutrient composition) that impact the solubility of each drug suggest that the 
effect of the co-administered vehicle also depends on the properties of the drug (e.g. 
lipophilicity, pKa, acid/base properties). Knowledge of the physicochemical 
properties and macronutrient composition of the vehicles and drug/formulation 
physiochemistry could help predict the potential vehicle-impact on drug solubility 
and should be considered during compatibility assessments of the vehicle-drug 
product. For example, for drugs like montelukast, solubilisation may be increased 
when the formulation is mixed with a dairy vehicle than when mixed with juice. 
Moreover, the different results obtained for each drug highlight the importance of 
considering the nature of the vehicle utilised in common practice and possible effects 
of a change in recommendation. This is of particular importance considering that 
even though the recommendations for the administration of Singulair
®
 granules 
(montelukast formulation) are to mix with ‘a spoonful of cold soft foods’, differences 
in drug solubility were observed for soft foods of the same subtype (e.g. the 
solubilisation of montelukast will be 9-fold increased if mixed with the Greek 
yoghurt than if mixed with the plain yoghurt), demonstrating the potential risks of 
this practice. Moreover, the recommended vehicle to mix with Pentasa
®
 granules 
(mesalazine formulation) is orange juice; however, if the juice is substituted for 
another vehicle such as formula, due to the child’s diet/age, the medicine co-
administration practice may result in a different drug solubilisation and, 
consequently, in vivo drug performance.  
Ultimately, medicine co-administration with different vehicles may alter the clinical 
performance of a drug by affecting not only its solubility but also dissolution 
performance and, consequently, bioavailability. Although in some cases this can be 
beneficial, the risk of reduced efficacy and increased toxicity associated with this 





Soft foods and drinks are commonly used to facilitate medicine administration to the 
paediatric population in order to improve palatability and enhance compliance.  
In this study, twenty-six vehicles that are commonly mixed with oral medications to 
facilitate paediatric administration were characterised. Differences between the 
physicochemical properties of the different food and drink vehicles were observed, 
notably not only among vehicles, but also within vehicles of the same ‘subtype’. 
These differences are expected to affect drug behaviour, such as its solubility and 
dissolution, especially in the case of a poorly soluble drug. Solubility studies of two 
model compounds, performed in selected drinks and soft foods resulted in 
considerably different solubility values in each vehicle. The solubility of the drugs 
was significantly affected by the vehicle physicochemical properties and 
characteristics, with the solubility of montelukast driven by pH and protein content 
and the solubility of mesalazine by viscosity, osmolality and vehicle sugar content. 
This vehicle-dependent impact on drug solubility could compromise drug 
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Chapter 4: Evaluating the effect of co-administration with food 
and drinks on the dissolution of paediatric formulations – a 
case study of montelukast sodium and mesalazine 
Abstract 
Objectives: The aim of this study was to use in vitro dissolution testing, under infant 
simulating conditions, to evaluate the effect of co-administration with vehicles on the 
dissolution performance of two poorly soluble paediatric drugs.  
Methods: Dissolution studies of mesalazine and montelukast formulations were 
conducted with mini-paddle apparatus on a two-stage approach: simulated gastric 
fluid without enzymes followed by simulated intestinal fluid. The testing scenarios 
were designed to reflect daily administration practices: (i.) direct administration of 
formulation; (ii.) formulation co-administered with food and drinks, immediately 
after mixing; and 4 h after mixing (iii.).  
Key findings: Drug dissolution was significantly affected by medicine co-
administration with vehicles, compared to the scenario of direct administration of 
formulation with a standard glass of water. Differences were observed on drug 
dissolution when the formulations were mixed with different vehicles of the same 
subtype. The time between preparation and testing of the drug-vehicle mixture also 
had an impact on drug dissolution behaviour. Drug dissolution was shown to be 
significantly affected by the physicochemical properties and composition of the 
vehicles, drug solubility in each vehicle and drug/formulation characteristics.  
Conclusions: It is essential to consider the nature of the vehicles commonly used for 
paediatric drug administration and the possible vehicle-effects on drug product 
performance. Age-appropriate in vitro dissolution testing is a useful 
biopharmaceutical tool for estimating drug dissolution in conditions relevant to the 
paediatric population and evaluate the impact of medicine co-administration with 




Paediatric oral drug development and administration remains challenging due to 
specific age-related problems. Availability of authorised, age-appropriate medicines 
is limited and there is no general rule of how to safely administer oral medicines to 
the paediatric population (1, 2). Therefore, pharmacists and carers often manipulate 
adult dosage forms prior to administration.  
The use of food and drinks as vehicles for medicine co-administration is common 
practice to deliver a specific dose and improve compliance, yet the scientific 
rationale for selecting a particular type of vehicle for mixing with the medicine is 
often not evident (3-5). The majority of vehicles suggested for medicine co-
administration seem to be recommended more on the basis of their taste and texture 
for the paediatric population rather than their impact on in vivo drug product 
performance. In addition to the possible negative effects on dose accuracy (as often 
reported (5-7)), drug manipulation and mixing with different food and drinks can 
also affect drug stability, solubility and bioavailability, ultimately leading to either 
sub-therapeutic or toxic drug levels (8-10). These effects are still often unaddressed.  
It has been shown that different food and drinks can have an effect on paediatric 
medicine performance. For instance, the solubility of two poorly soluble compounds 
(montelukast and mesalazine) commonly administered to children was significantly 
affected by the physicochemical properties (pH, buffer capacity, surface tension, 
osmolality, viscosity) and macronutrient composition (fat, sugar and protein content) 
of commonly used vehicles (11). Similarly, medicine co-administration with 
different vehicles may affect drug dissolution properties to a different extent. 
Dissolution of amlodipine (BCS class I; weak base, pKa 8.6; logP 3.0 (12)) from 
crushed tablets mixed with jam has been shown to be slower in comparison with 
mixing with other vehicles (yoghurt, honey, orange juice and water) (13). 
Dissolution studies of crushed warfarin (BCS class I; weak acid, pKa 5.1; logP 2.7 
(14, 15)) and carbamazepine (BCS class II; neutral compound; logP 2.5 (15, 16)) 
tablets mixed with water or orange juice resulted in a faster drug dissolution in 
comparison to direct administration of whole tablets. In comparison, no differences 
were observed between drug dissolution from crushed tablets mixed with honey, jam 
or yoghurt and the direct introduction of tablets scenario (13). Compatibility studies 
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of tegaserod (BCS class II; weak base, pKa 9.8; logP 2.6 (15, 17)), from crushed 
tablets in food/drinks (water, apple juice, orange juice, and applesauce), revealed that 
while the drug was compatible with the vehicles, the dissolution profiles of the 
crushed tablets mixed with orange juice and applesauce were not comparable with 
those of intact tablets (18). The time between preparation and administration of the 
mixture may also have an effect on drug solubility, drug stability, and consequently 
oral drug absorption (10). This vehicle-impact might be critical for certain 
medications (e.g. when immediate release is needed for a fast-therapeutic action), 
since food-drug interactions can have a significant impact on drug bioavailability 
and, consequently, therapeutic efficacy (19, 20). 
Recently, the FDA issued a draft guidance addressing the recommended approaches 
for determination of the suitability of the vehicles intended for co-administration of 
paediatric medicines (21). Guidance is given on vehicle selection, description of 
standardised in vitro methods for evaluating vehicle compatibility, and suggestions 
on product labelling for communication of acceptability of vehicles (21). It is 
necessary to conduct these investigations in order to fully understand the impact of 
this practice on drug formulation behaviour and better guide healthcare practitioners, 
patients and carers regarding medicine co-administration with vehicles, in the 
paediatric population. 
In vitro dissolution testing is a widely used in vitro tool for drug product 
performance characterisation. Dissolution tests are used for several applications 
including: assessment of batch-to-batch quality process control and quality 
assurance, formulation development, identification of food effects in the dissolution 
and bioavailability of orally administered drugs, and of drug solubility limitations 
and stability issues (22, 23). Dissolution tests have been shown to predict in vivo 
drug behaviour in adults by addressing both medicine administration practices and 
the physiological gastrointestinal (GI) conditions that can affect drug dissolution (22, 
24). However, these tests are unsuitable for assessing drug performance in 
paediatrics. The use of dissolution tests to study the impact of medicine co-
administration with vehicles on paediatric drug performance would require the 
incorporation of age-specific gastrointestinal (GI) tract parameters (namely, pH, 
media volumes and composition and different dosing scenarios) (25).  
111 
 
The aims of this study were two-fold: (i.) to evaluate the effect of the co-
administration with vehicles on the dissolution performance of formulations of two 
poorly soluble compounds; and (ii.) to evaluate the effect of different administration 
practices (i.e. time between preparation and administration of the mixture 
formulation-vehicle) on drug dissolution. Drug dissolution studies were conducted 
with mini-paddle apparatus under relevant conditions (e.g. pH, fluid volumes and 
transit times). Montelukast and mesalazine were selected as model compounds; two 
formulations of each drug were studied (montelukast: Singulair
®
 granules and 
Actavis
® 




 granules).  
 
2. Materials and methods 
2.1 Materials  
Ammonium acetate [High Performance Liquid Chromatography (HPLC) grade], 
37% hydrochloric acid, sodium hydroxide, sodium chloride, glacial acetic acid, 
potassium dihydrogen phosphate, acetonitrile (HPLC grade) and methanol (HPLC 
grade) were purchased from Fisher Scientific (UK). Trifluoroacetic acid [TFA] 
(HPLC grade), montelukast sodium (pharmaceutical secondary standard) and 
mesalazine (≥ 99 %) were obtained from Sigma-Aldrich Company Ltd (UK). Water 
was ultra-pure (Milli-Q) laboratory grade. Regenerated cellulose [RC] membrane 
filters (0.45 µm) (Cronus
®
, UK), and filter papers (0.45 µm), polytetrafluoroethylene 
[PTFE] filters (0.45 µm), and glass microfiber [GF/D] filters (2.7 µm) (Whatman
®
, 
UK) were used. Porous full flow polyethylene cannula filters (10 µm) were obtained 
from Quality Lab Accessories LCC (USA). Nine different soft foods and drinks were 
used as co-administration vehicles. They were chosen based on differences in their 
composition, physicochemical properties, and drug solubility in each vehicle 
(Chapter 3)(11, 26). Orange squash, milk U.H.T. full fat, and orange juice (smooth) 
were from The Co-Operative (UK). Blackcurrant squash was from Lucozade Ribena 
Suntory Ltd (UK). First Infant Milk (cow’s milk-based formula) was from Cow & 
Gate (UK). Applesauces were Bramley applesauce Colman’s of Norwich (referred to 
as ‘applesauce UK’) from Unilever (UK), and Apfelmark applesauce (referred to as 
‘applesauce DE’) from Bauck Hof (Germany). Plain yoghurt from Yeo Valley (UK) 
and Greek yoghurt from Fage (Greece) were also used. The four formulations 
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studied were kindly donated by AstraZeneca (UK). Product information is 
summarised in Table 4.1. 
 












recommendations (27)   
Mesalazine Salofalk
®








Granules should be 
placed on tongue and 
washed down with water 
without chewing. 
     
Pentasa
®









Granules should be 
placed on tongue and 
washed down with water 
or orange juice, without 
chewing. 
Contents of one sachet 
should be weighed and 
divided immediately 
before use; any remaining 
granules should be 
discarded. 
      
Montelukast Singulair
®






4 mg Granules may be 
swallowed or mixed with 
cold, soft foods (not 
liquid), and taken 
immediately. 
     
Actavis
®




5 mg Tablet should not be 
taken with food; should 
be taken at least one hour 




2.2.1 Dissolution media preparation 
Simulated gastric fluid sine pepsin (SGFsp) pH 1.2 and simulated intestinal fluid 
(SIFsp) were prepared according to the USP recipes (28). Double concentrated SIFsp 
containing an additional amount of sodium hydroxide (to neutralize the acid present 





2.2.2 Sample preparation 
Squashes and formula were prepared as per manufacturer’s instructions (formula: 1 
scoop of powder (approximately 4.5 g) was added to 30 mL of boiled cooled water; 
squashes: 25 (orange) or 50 (blackcurrant) mL of concentrated product were diluted 
in 250 mL of water). 
For the direct administration scenario, the formulations were introduced in the media 
without being mixed with a vehicle. For the scenario of mixing the formulations with 
vehicles, each sample was prepared by addition of the formulations (corresponding 
to the ‘dose tested’ in Table 4.1) to 25 mL of drink or 10 mL (approximately 10 g) of 
soft food, at room temperature. All samples were manually mixed with a stainless-
steel spatula, for 30 s, and tested within 5 min of preparation. Actavis
®
 chewable 
tablets were crushed with a spatula prior to being mixed with the vehicles or tested.  
To test different administration practices, samples with vehicles were prepared as 
described above and set aside (at room temperature and protected from direct light) 
and after 4 h they were remixed with a stainless-steel spatula, prior to performing the 
study.  
 
2.2.3 In vitro dissolution studies  
Dissolution studies were performed with a mini-paddle apparatus (Agilent 
Technologies 708-DS apparatus configured with TruAlign 200 mL vessels and 
electropolished stainless steel mini-paddles; Agilent, USA). Experiments were 
conducted in a two-stage approach: in SGFsp pH 1.2 (total volume with sample: 100 
mL), for 1 h, followed by SIFsp pH 6.8 (final volume: 200 mL), for 3 h. A 
dissolution study with a sequential media change mimics the passage of oral dosage 
forms through the GI tract, providing an understanding of the in vivo drug 
performance (29). Experiments were conducted at 37 ± 0.5 
o
C and the agitation rate 
of the mini-paddle was set to 50 revolutions per minute (rpm). Sample collection 
took place at 5, 15, 30, 45, 60, 75, 90, 120, 180 and 240 min. 2 mL samples were 
withdrawn (with volume replacement with the corresponding media), using a 2 mL 
glass syringe (Fortuna Optima
®
 fitted with a stainless tubing) through a cannula 
fitted with a full flow filter (10 µm). All experiments were performed without direct 
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light exposure to avoid photodegradation of the drugs (30, 31). After collection, 
samples were filtered through a GF/D filter (2.7 µm) and treated. Sample treatment 
was as follows: 1000 µL of acetonitrile (montelukast) or 10 % (v/v) TFA/water 
(mesalazine) were added to 500 µL of sample. This mixture was vortexed (HTZ, 
UK) for 1 min and centrifuged (8000 rpm, 15 min, 4 
o
C) (Beckman Coulter J2-MC 
centrifuge, UK). The supernatant was filtered through a RC (montelukast) or PTFE 
(mesalazine) filter (0.45 µm), placed in an HPLC amber vial and analysed. The pH 
of the media was measured at the end of each experiment.  
The effect of different administration scenarios and testing conditions was 
investigated by varying the dissolution test parameters, as described in Table 4.2. 
These were: (1) effect of co-administration of formulation with selected vehicles in 
comparison to direct administration of formulation; (2) effect of different mixing 
patterns (i.e. time between preparation and administration/testing of the formulation-





 granules).  
All experiments were performed in triplicate. Fresh calibration curves (concentration 
range: 0.5 – 100 μg/mL (montelukast) and 0.5 – 200 μg/mL (mesalazine)) were 
prepared in the corresponding media, by appropriate dilution of a 1000 μg/mL stock 
solution of the analytical standard in methanol (montelukast) or 0.05 % TFA/water 
(mesalazine); the same treatment process was applied as described for the samples. 
Results were expressed as mean % drug dissolved ± standard deviation (S.D.), at the 
given sampling time.  
 















1 50 ✓ 
M, OJ, BLS, PY, APSUK, 
F, OS, GY, APSDE 
All 0 
      
2 50 N/A M, OJ, BLS, PY, APSUK All 4 
      








(BLS = blackcurrant squash; OS = orange squash; M = milk; F = formula; OJ = orange juice; PY = 




2.2.4 Chromatographic conditions for drug analysis 
The chromatographic methods used for drug analysis were modifications of 
published methods (32, 33). Drug quantification was performed with HPLC with 
ultraviolet (UV) detection (Agilent HPLC system 1100/1200 series; Agilent, USA). 
A RP Agilent Eclipse XDB C18 column (250 mm x 4.6 mm, 5 µm particle size) was 
used for both drugs. For montelukast, the mobile phase was composed of ammonium 
acetate buffer pH 5.5 and methanol (solvents A and B, respectively) delivered at a 
flow rate of 1 mL min
−1
, on a linear gradient. The selected gradient started with 10 % 
of solvent B, which was increased to 50 % within 2 min, and 90 % within 4 min; at 
11.30 min, the initial conditions of analysis were re-established. Injection volume 
was 100 µL. Analysis was performed at 20 
o
C and the detection wavelength was 284 
nm. Elution time for montelukast was 8.9 min. For analysis of mesalazine, the 
mobile phase was composed of 0.05 % TFA/water and methanol (95:5), delivered at 
a flow rate of 1 mL min
−1
. Injection volume was 20 µL. Analysis was performed at 
40 
o
C and the detection wavelength was 304 nm. Elution time for mesalazine was 4.6 
min. 
 
2.2.5 Statistical analysis of dissolution data 
To describe and compare the dissolution profiles obtained, linear trapezoidal method 
was used to calculate the area under the curve of each profile over 4 h (AUC0-4h). 
This allowed the use of one value representative of drug dissolution to compare the 
different scenarios tested.  
One-way analysis of variance (ANOVA) with a post-hoc Tukey Honest Significant 
Difference (HSD) test was conducted to investigate statistically significant 
differences (p < 0.05 noting significance level) in the AUC0-4h between direct 
administration of formulation and mixing the formulations with the different 
vehicles. T-test analysis was used to compare AUC0-4h results obtained between drug 
dissolution after mixing the formulations with vehicles of same subtype or drug 
dissolution after mixing the formulations with the same vehicle under different 
testing conditions (i.e. agitation rate or time between preparation and mixing) (p < 
0.05 noting significance). The analyses were performed with GraphPad Prism
®
 v.7 
software (San Diego, USA).  
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Partial least squares regression (PLS-R) analysis was used to correlate the AUC0-4h 
values of the different testing scenarios (response factor) with the physicochemical 
properties and macronutrient composition of the vehicles (pH, buffer capacity, 
surface tension, viscosity, osmolality; percentage of fat, sugars and proteins), drug 
solubility in each vehicle, type of formulation and testing conditions (i.e. preparation 
time) (XLSTAT Software; an Add-In for Excel, Microsoft
®
). When analysing both 
drugs together, drug characteristics (logP [log octanol-water partition coefficient] 
and ionisation % [obtained from ACD/Labs
©
 2010-2018]) were also considered as 
variables. The quality of the model was evaluated with the square of the coefficient 
of determination (R
2
) and goodness of prediction (Q
2
), with values close to 1 being 
indicative of good fit and prediction power, respectively (34). Full cross-validation 
(leave-one-out procedure) was used to develop and evaluate the regression model. 
The optimum number of calibration factors for each model was selected based on the 
optimum predictability of the model and predicted residual error sum of squares 
(PRESS). The standardised coefficients of the factors indicated the relative effect 
(positive or negative) of their corresponding variables on the response. The variable 
importance in projection (VIP) value was used to evaluate the importance of each 
factor on the model (34). Model variables with VIP values > 1 were evaluated as the 
most important in explaining the variation in the dependent variable, while values 
between 0.7 and 1 were considered moderately influential for the model. Values < 
0.7 were deemed not of significance for the prediction of the dependent variable 
(34). 
 
3. Results and discussion  
3.1 Effect of medicine co-administration with food and drinks on drug 
dissolution 
Dissolution of montelukast from the two formulations revealed a significant effect of 
medicine co-administration with food and drink vehicles, compared to the direct 
administration scenario (Figures 4.1 and 4.2). For Singulair
®
 granules, the AUC0-4h 
was significantly lower for the direct administration scenario in comparison to when 
the granules were mixed with vehicles, except for orange juice, blackcurrant squash 
and applesauce UK. For the co-administration with drinks scenario, drug dissolution 
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was higher at 4 h when the formulation was mixed with milk (61.9 %), followed by 
when it was mixed with formula, orange squash, blackcurrant squash and orange 
juice (% drug dissolved = 41.1, 16.7, 10.8, and 7.7, respectively). For an ionisable 
compound like montelukast (amphoteric; pKa basic 2.7 and pKa acidic 5.8 (35)) an 
increase in pH can affect the ionisation % of the drug. Therefore, drug solubilisation 
and dissolution are higher when the formulation is mixed with a dairy drink (pH 
between 6.5 and 6.8; Chapter 3) in comparison with other vehicles due to an increase 
in the drug ionisation %. For co-administration with soft foods, the highest drug 
dissolution was observed when the granules were mixed with plain yoghurt (39.3 %) 
and the lowest when the formulation was mixed with applesauce UK (6.4 %). Drug 
dissolution differed when vehicles of the same subtype were tested (AUC0-4h differed 
between milk/formula, and between squashes, yoghurts and applesauces; p < 0.05). 
The lower drug dissolution observed when the granules were mixed with applesauce 
UK, in comparison to when mixed with the other soft foods, is probably due to the 
presence of starch in its composition, which forms a net gel around the formulation 
that is strengthened by fruit pieces and negatively impacts drug dissolution (13). 
Results show that vehicles of the same type (e.g. soft foods) have a distinct impact 
on drug dissolution (e.g. extremely low to no drug dissolution in the case of mixing 
with applesauce UK but not when formulation was mixed with plain yoghurt) and it 
can be hypothesised that this vehicle-impact may, ultimately, affect drug behaviour. 
This is of particular importance considering that the recommendations for 
administration of Singulair
®
 granules are to mix with ‘a spoonful of cold soft foods’ 
(27). Therefore, the differences observed in drug dissolution indicate the potential 
risk of not following vehicle recommendations in clinical practice. Moreover, when 
evaluating vehicle suitability during drug development, the physicochemical 




Figure 4.1. Mean % montelukast dissolved (± S.D.) from Singulair
®
 granules (top panel) 
and Actavis
®
 chewable tablets (bottom panel) after direct administration of formulation, 
after mixing with selected vehicles (full lines) and with vehicles of the same subtype (dashed 
lines). Dotted vertical lines represent the time of medium change. 
 
 
Figure 4.2. Effect of co-administration of formulation with vehicles on % of drug dissolved 
at 4 h from the tested montelukast formulations. * denotes a statistical difference on drug 
dissolution between direct administration (dashed line) and co-administration with vehicles 
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(bars; red: drinks, blue: soft foods). a denotes statistical difference when vehicles of the 
same subtype were tested (p < 0.05). 
 
Dissolution of the crushed Actavis
® 
chewable tablets mixed with vehicles resulted in 
a higher % drug dissolved at 4 h and significantly higher AUC0-4h in comparison to 
direct administration of the crushed formulation. Amongst vehicles, drug dissolution 
was the highest when the crushed tablets were mixed with milk and formula (72.5 
and 67.8 %, respectively) and the lowest when the formulation was mixed with 
blackcurrant squash (11.1 %). Significant differences in AUC0-4h were revealed 
between mixing the formulation with milky vs fruity drinks, and between mixing 
with the different squashes tested. Two-fold differences were observed between 
AUC0-4h when mixing with vehicles of the same subtype (plain in comparison to 
Greek yoghurt and between the applesauce UK and applesauce US; p < 0.05). These 
differences could be attributed to the physicochemical properties (e.g. different pH 
and protein content of dairy and fruity drinks, and different viscosity of the 
applesauces) and macronutrient composition of the vehicles (e.g. different sugar 
content between the squashes), which affect drug solubilisation and may impact drug 
dissolution behaviour (11).  




 granules also revealed a 
significant effect of co-administration with food and drink vehicles (Figures 4.3 and 
4.4). For Pentasa
®
 granules, co-administration with the different vehicles resulted in 
a lower % drug dissolved at 4 h compared to the direct administration scenario. The 
calculated AUC0-4h were significantly lower when the formulation was mixed with 
vehicles, except blackcurrant squash (p < 0.05). For co-administration with drinks, % 
of drug dissolved (4 h) was higher for mixing with blackcurrant squash and formula 
(38.1 and 37.9 %, respectively) followed by orange squash (35.5 %), orange juice 
(24.1 %) and milk (23.4 %). Significant differences in AUC0-4h were revealed 
between mixing the Pentasa
®
 granules with milk and formula (p < 0.05), but not 
between mixing with the different squashes tested. For co-administration with soft 
foods, AUC0-4h significantly differed when mixing with the different applesauces 
demonstrating that vehicles of the same subtype can distinctly affect dissolution of 





Figure 4.3. Mean % mesalazine dissolved (± S.D.) from Pentasa
®
 (top panel) and Salofalk
®
 
granules (bottom panel) after direct administration of formulation, after mixing with selected 
vehicles (full lines) and with vehicles of the same subtype (dashed lines). Dotted vertical 
lines represent the time of medium change. 
 
 
Figure 4.4. Effect of co-administration of formulation with vehicles on % of drug dissolved 
at 4 h from the tested mesalazine formulations. * denotes a statistical difference on drug 
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dissolution between direct administration (dashed line) and co-administration with vehicles 
(bars; red: drinks, blue: soft foods). a denotes statistical difference when vehicles of the 
same subtype were tested (p < 0.05). 
 
The % of mesalazine dissolved from Salofalk
®
 granules (4 h) was also affected by 
the different vehicles used for co-administration. % drug dissolution was the highest 
when the granules were mixed with orange squash (17.3 %), followed by 
blackcurrant squash (16.7 %), formula (16.1 %), milk (12.4%), orange juice (11.7 
%), direct introduction (11.4 %), and soft foods. AUC0-4h was significantly different 
for the direct administration scenario compared to co-administration with vehicles, 
except milk, orange juice and applesauce DE (p > 0.05). For co-administration with 
soft foods, % of drug dissolved at 4 h was the lowest when the formulation was 
mixed with Greek yoghurt (0.6 %) and the highest when mixed with applesauce DE 
(9.9 %), indicating that vehicles of the same type (e.g. soft foods) have a distinct 
impact on drug dissolution. The lower drug dissolution observed when the granules 
were mixed with soft foods was likely due to a physical barrier that these vehicles 
create around the formulation, which prevents mixing with GI fluids and hinders 
drug release, ultimately, reducing drug exposure at the site of absorption (13). 
Dissolution of mesalazine from Salofalk
®
 granules also differed when mixed with 
vehicles of the same subtype; namely, applesauce UK vs US, milk vs formula, and 
plain vs Greek yoghurt (p < 0.05).  
Interestingly, the two mesalazine formulations were oppositely affected when mixed 
with drinks compared to direct introduction of the granules: for Pentasa
®
 drug 
dissolution was lower, whereas for Salofalk
®
 granules was higher. The mode of drug 
release of the two formulations is different; Pentasa
®
 granules have a pH-
independent extended release, whereas Salofalk
®
 granules have a pH-dependent 
delayed release (Table 4.1). Therefore, the vehicle-impact on drug dissolution from 
different formulations will depend not only on vehicle properties, but also on 
formulation properties (e.g. differences in the mode of drug release, type of dosage 
form).  
Overall, it was possible to observe a significant effect of medicine co-administration 
with soft foods and drinks on the dissolution of both drugs from all the formulations 
tested. Results show a vehicle-induced impact on drug dissolution due to changes in 
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drug ionisation % and, consequently, drug solubility (e.g. higher % montelukast 
dissolved when formulation is mixed with milk), changes in formulation 
environment (e.g. higher viscosity of applesauce hindering drug release/dissolution), 
and alteration of formulation factors (e.g. different coating of the tested mesalazine 
granules). 
 
3.2 Assessment of the impact of different administration practices on drug 
dissolution behaviour 
Delaying testing by 4 h after mixture preparation revealed significant differences on 
drug dissolution in comparison to testing immediately after mixing (montelukast: 
Figures 4.5 and 4.6; mesalazine: Figures 4.7 and 4.8). For Singulair
®
 granules, 
delaying testing by 4 h after mixing led to a higher % drug dissolved and a 
significantly higher AUC0-4h for co-administration with milk, orange juice and 
applesauce UK (p < 0.05). This is probably due to the solubility of montelukast in 
these vehicles, which resulted in an increased drug solubilisation and dissolution 
during the 4 h delay (11). From the 3 cases, the differences in drug dissolution 
between the two testing scenarios were most accentuated when the granules were 
mixed with milk. As observed in section 3.1, this is probably due to the pH of milk 
which leads to an increase in drug solubilisation and dissolution, in comparison to 
when the granules are mixed with other vehicles. Results from this test show that this 
increase is even more evident if there is a delay between preparation and 







blackcurrant squash had no effect on drug dissolution, 
whereas delaying the time between mixing with plain yoghurt and testing resulted in 
a significantly lower AUC0-4h. Delaying testing by 4 h after mixing the granules with 
applesauce UK and plain yoghurt led to a drop in drug concentration after the media 
change from SGFsp pH1.2 to SIFsp pH 6.8. This might be related to the sudden 




Figure 4.5. Mean % montelukast dissolved (± S.D.) from Singulair
®
 granules (top panel) 
and Actavis
®
 chewable tablets (bottom panel), under two administration scenarios: testing 
immediately after mixing (dashed lines) and 4 h after mixing (full lines). Dotted vertical 
lines represent the time of medium change. 
 
 
Figure 4.6. Effect of a 4 h delay between mixing and testing of formulation with vehicles on 
drug dissolution from the tested montelukast formulations. * denotes a statistical difference 
on drug dissolution between testing immediately after mixing (dashed bars) and testing 4 h 
after mixing (full bars). 
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For the crushed Actavis
® 
chewable tablets, a 4 h delay between mixing the 
formulation with the vehicles and testing resulted in a higher % drug dissolved for 
co-administration with vehicles, apart from when the formulation was mixed with 
blackcurrant squash, applesauce and plain yoghurt. AUC0-4h was significantly 
different when the crushed chewable tablets were mixed with milk, orange juice 
(both higher) and plain yoghurt (lower), in comparison to immediate administration 
of the vehicle-formulation mixtures (p < 0.05).  
For Pentasa
®
 granules, increasing the time between preparation and testing of the 
granules-vehicle mixtures resulted in a higher % drug dissolved (4 h), and 
significantly higher AUC0-4h, when the formulation was mixed with milk, applesauce 
UK and plain yoghurt.  
 
 
Figure 4.7. Mean % mesalazine dissolved (± S.D.) from Pentasa
®
 granules (top panel) and 
Salofalk
®
 granules (bottom panel) under two administration scenarios: testing immediately 
after mixing (dashed lines) and 4 h after mixing (full lines). Dotted vertical lines represent 




Figure 4.8. Effect of a 4 h delay between mixing and testing of formulation with vehicles on 
drug dissolution from the tested mesalazine formulations. * denotes a statistical difference 
on drug dissolution between testing immediately after mixing (dashed bars) and testing 4 h 




 granules, increasing the time between mixing the formulation with 
milk and testing resulted in a significantly higher AUC0-4h and 3-fold increase on % 
drug dissolved (4 h), observed from the beginning of dissolution (pH 1.2). The 
Salofalk
®
 granules have a pH-dependent modified release coating (due to the 
presence of the coating polymers Eudragit L and NE 40 D which only disintegrate at 
pH ≥ 6), and therefore no release is intended during the gastric passage. A 4 h delay 
between mixing the granules with milk (pH 6.8) and testing resulted in a pH-induced 
loss of integrity of the coating and, consequently, earlier drug release and 
dissolution. In contrast, the 4 h delay between mixing the Salofalk
®
 granules with the 
other vehicles (pH between 2 and 4.5; Chapter 3) and testing did not alter drug 
dissolution in the first hour of the test (pH 1.2) due to the polymer coating. AUC0-4h 
was significantly higher when delaying testing after mixing the formulation with 
plain yoghurt (pH 4.5) (p < 0.05). This testing scenario was also associated with 
large variation in dissolution between replicate tests, probably due to the loss of 
integrity of the formulation during the mixing which resulted in an unimpaired 
release.  
Overall, results indicate that when medicines are co-administered with vehicles, the 
mixtures should be administered as soon as possible after preparation, unless specific 
data is available and indicated, not only due to risk of dosing errors and potential 
microbiological contamination, but also due to other vehicle-effects on drug 
dissolution (e.g. increased drug solubilisation, potential stability issues). Depending 
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on the formulation, and particularly for enteric-coated dosage forms (case study, 
Salofalk
®
), delaying administration of the prepared formulation-vehicle mixture 
could result in changes in drug absorption and, consequently, drug safety and 
efficacy. Other potential consequences of delaying the administration of the drug-
vehicle mixture are an increase of the risk of adverse side effects, depending on the 
drug category (e.g. for nonsteroidal anti-inflammatory drugs, it might lead to 
irritation of the GI mucosa and, ultimately, ulcers) (13).  
 
3.3 Assessing the impact of in vitro hydrodynamics  





 granules) was influenced by the hydrodynamic 
conditions, for all the scenarios tested (Figures 4.9 and 4.10). For Singulair
®
 
granules, higher agitation conditions resulted in a higher % drug dissolved (4 h) 
when the formulation was mixed with milk, orange juice, applesauce and plain 
yoghurt (drug dissolved = 78.0 %, 35.3 %, 7.8 % and 47.9 %, respectively). Analysis 
of the AUC0-4h revealed significant differences when comparing low (50 rpm) and 
high (100 rpm) testing agitation rates in all cases, apart from the direct introduction 
scenario. A significantly higher AUC0-4h was observed when the granules were 
mixed with milk, orange juice, applesauce UK and plain yoghurt and tested at 100 
rpm, in comparison to 50 rpm (Figure 4.10). This is probably related to the effect of 
the increased hydrodynamics, which result in a better dispersion of the drug product-
vehicle mixture and, consequently, facilitate drug dissolution from the vehicles (36). 
For the scenarios of direct administration and mixing with blackcurrant squash, drug 
dissolution was likely limited by the drug solubility in the media and not as affected 
by the increase in agitation rate (11).   
Testing at 100 rpm also resulted in a higher drug dissolution and significantly higher 
AUC0-4h, when the Pentasa
® 
granules were mixed with milk, orange juice, plain 




Figure 4.9. Mean % drug dissolved (± S.D.) of montelukast from Singulair
®
 granules (top 
panel) and mesalazine from Pentasa
®
 granules (bottom panel), after testing under two 
agitation rate conditions: 50 rpm (dashed bars) and 100 rpm (full bars). Dotted vertical lines 
represent the time of medium change. 
 





 (mesalazine) granules. * denotes a statistical difference in AUC0-4h between 
drug dissolution when agitation rate was set at 50 (dashed bars) and 100 rpm (full bars). 
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In comparison to the results obtained when testing at 50 rpm, increasing the agitation 
rate to 100 rpm resulted in a reduced discrimination between drug dissolution 
profiles. Nevertheless, comparison of AUC0-4h of the dissolution profiles obtained at 
100 rpm still revealed significant differences between direct introduction of the 
formulation and mixing with vehicles (p < 0.05). Therefore, the differences in drug 
dissolution for co-administration with vehicles in comparison to direct 
administration of formulation were not due to the agitation speed set (50 rpm) since 
they were still observed when testing at a higher agitation rate. 
 
3.4 Statistical evaluation of the factors impacting in vitro drug dissolution 
Results from the PLS-R analyses, conducted to understand the vehicle impact on the 
dissolution of the two drugs, are shown in Figure 4.11. For the dissolution of 
montelukast from the granules and crushed chewable tablets, the PLS-R model 
developed was defined by 3 components and showed a good fit to the experimental 
values (R
2 
= 0.83) and a good predictive power (Q
2 
= 0.79). The statistical analysis 
revealed that vehicle pH and percentage of fat and drug solubility in each vehicle 
were the factors with the most significant positive impact on drug dissolution from 
the two montelukast formulations tested, with a moderate negative impact from 
vehicle osmolality, viscosity, percentage of sugar and of protein.  
For dissolution of mesalazine, the model constructed was defined by 2 components 
and showed a good fit to the experimental values (R
2 
= 0.70) and a good prediction 
power (Q
2
 = 0.64). PLS-R analysis revealed that the type of formulation was the 
factor with the most significant positive impact on drug dissolution, while significant 
negative effects from vehicle viscosity, percentage of protein and buffer capacity 
were observed. Moderate negative effects from vehicle osmolality, percentage of 
sugars and drug solubility were also observed. 
For dissolution of both drugs (all formulations), the PLS-R model built was defined 
by 6 compartments, had good predictive power and showed a good fit to the 
experimental values (Q
2 
= 0.62 and R
2 
= 0.70, respectively). PLS-R analysis showed 
that the drug characteristics (logP and ionisation %), and the pH of the vehicles were 
the factors with a significant negative effect on drug dissolution. A moderate 
negative effect from vehicle buffer capacity was also observed. In contrast, 
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significant positive effects from the type of formulation, drug solubility in each 
vehicle and percentage of fat of the vehicle were observed. Moderate positive effects 
from vehicle osmolality, viscosity and percentage of protein were also observed. 
 
 
Figure 4.11. Standardised coefficients corresponding to the variables studied for dissolution 
of montelukast, mesalazine and both drugs. Colour denotes coefficients with a moderate 
(lighter colour) and significant (darker colour) impact on the response (VIP > 0.7 and 1, 
respectively). [B.C. = buffer capacity; ST = surface tension] 
 
Overall, PLS-R results showed that knowledge of the physicochemical properties 
and macronutrient composition of the food and drinks and drug/formulation 
properties can help understand the potential vehicle-impact on drug dissolution. This 
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impact should be taken into consideration during compatibility assessments of the 
vehicle-drug product and could be used to predict potential alterations on drug 
product behaviour.  
 
4. Conclusions 
For poorly soluble drugs, in vivo dissolution is likely to be the rate-limiting step of in 
vivo drug absorption and bioavailability. This study aimed to assess the impact of 
practices of medicine co-administration with food and drinks on the dissolution 
behaviour of two compounds. Results show that vehicle-induced changes on drug 
ionisation % and solubility (affected by the pH of the different vehicles), formulation 
environment (e.g. higher viscosity of the soft foods), and alteration of formulation 
factors (e.g. different coating of the mesalazine granules) affect drug dissolution 
behaviour. Drug dissolution was significantly affected by both the different vehicles 
as well as the timing between preparation and testing of the vehicle-drug product 
mixtures. The use of different vehicles may impact the pharmacokinetic profile of 
the drug, ultimately altering its clinical performance. For example, alterations in drug 
bioavailability related to reduced dissolution rates are of concern for drugs that 
display dissolution as a rate limiting step of absorption, and have a narrow 
therapeutic index (as the absorbed concentration needed to induce a therapeutic 
effect may not be reached) or when immediate release is required for fast therapeutic 
action. Increased drug bioavailability may lead to drug toxicity and adverse clinical 
side effects. Therefore, it is essential to consider the nature of the vehicles commonly 
used in practice and the possible effects of different administration recommendations 
on product performance and, ultimately, clinical performance.  
The age-appropriate in vitro dissolution test used in this study is a useful 
biopharmaceutical tool for estimating drug dissolution in conditions relevant to 
infants. Due to the simplistic experimental setup, it is possible to address paediatric 
administration scenarios (as done in the current study), as well as testing parameters 
representative of the different paediatric subgroups (e.g. by using different volumes, 
agitation rate and media change times). Although it cannot entirely replace in vivo 
testing, the dissolution setup described has the potential to provide information on 
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the impact of medicine co-administration with vehicles on paediatric formulation 
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Chapter 5: Predictive biorelevant dissolution testing of montelukast 
formulations administered with drinks and soft foods to infants 
Abstract 
Objectives: The aim of this study was to develop a predictive biorelevant dissolution 
test in order to investigate the impact of medicine co-administration with soft food 
and drinks on the dissolution performance of a poorly soluble compound. Relevant 
in vitro dissolution conditions simulating the in vivo gastrointestinal environment of 
infants were used to establish in vitro-in vivo relationships with corresponding in 
vivo data.  
Methods: Dissolution studies of two montelukast formulations were conducted with 
the mini-paddle apparatus on a two-stage approach: infant fasted state simulated 
gastric fluid (Pi-FaSSGF; for 1 h) followed by either fasted state or infant fed state 
simulated intestinal fluid (FaSSIF-V2 or Pi-FeSSIF, respectively; for 3 h). The 
dosing scenarios tested reflected in vivo paediatric administration practices: (i.) 
direct administration of formulation; (ii.) formulation co-administered with vehicles 
(formula, milk or applesauce).  
Key findings: In comparison with direct administration of formulation, drug 
dissolution was significantly affected by co-administration with vehicles. Drug 
dissolution was significantly higher when testing under fed state intestinal conditions 
in comparison to the fasted state. A good relationship was revealed between the in 
vitro drug dissolution (Pi-FaSSGF/Pi-FeSSIF conditions) and the in vivo drug 
performance in all subgroups when testing the granules with milk, and in the 1 to 3 
months subgroup with the granules-formula mixture. Moreover, although the in vivo 
prandial state of the infants was not evident, findings indicate that the studies were 
either performed in the fed state or the practice of co-administration with vehicles 
might trigger fed state conditions in vivo. 
Conclusions: Ultimately, this study supports the potential utility of the biorelevant in 
vitro dissolution approach proposed to predict the in vivo formulation performance 





Understanding the dissolution profile of a pharmaceutical dosage form and linking it 
to its in vivo pharmacokinetic (PK) profile is a vital requirement for ensuring product 
quality and safety of use (1-3). Dissolution profiles can be analysed through different 
approaches: using model-dependent methods where experimental data are fitted 
using mathematical equations, model-independent methods (single values such as 
mean dissolution time and area under the dissolution curve (AUC) are used for data 
evaluation), and/or statistical methods (e.g. ANOVA and multivariate analysis) (4, 
5).  
Drug dissolution profiles may be used to establish in vitro-in vivo correlations 
(IVIVC). The development of an IVIVC for a pharmaceutical dosage form is of great 
interest to the pharmaceutical industry and plays a key role in the pharmaceutical 
development of dosage forms (1). It can serve as a surrogate for in vivo 
bioavailability and be used to request biowaiver status for formulations or production 
changes within a product lifecycle (1-3). This reduces the need for expensive 
bioequivalence (BE) testing in humans. 
Defining appropriate biorelevant drug dissolution conditions requires an 
understanding of the relationship between the various physicochemical and 
physiological factors that have an impact on the rate and extent to which an orally 
administered dosage form is absorbed (4). Since clinical research with adults cannot 
simply be generalised or extrapolated to the paediatric population, research involving 
paediatric patients is essential (6). Age-related PK studies are normally required due 
to differences in anatomy or drug handling/manipulation practices, which might lead 
to different dose requirements to achieve efficacy or to avoid adverse effects (7). 
Moreover, changes in developmental physiology throughout childhood complicate 
pharmacotherapy, due its impact on drug absorption, distribution, metabolism and 
excretion of drugs and excipients (8). Thus, better understanding of physiological 
developmental changes is important for paediatric drug testing. Challenges in 
paediatric medicine development include: (i.) the need for appropriate outcome 
measures for paediatric patients, (ii.) the complexities of paediatric administration 
practices (e.g. drug manipulation and mixing with food and drinks (vehicles)), (iii.) 
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the parental involvement, and (iv.) the adaptations of required research procedures 
and settings to accommodate paediatric anatomic/cognitive development (8).  
Development of a physiologically relevant in vitro dissolution setup would be crucial 
for the prediction of the in vivo performance after the administration of a formulation 
to a paediatric patient. Moreover, it would be beneficial for the investigation of 
formulation sensitivity to different foods and drinks, so that the risks associated with 
its co-administration can be predicted. In 2018, the FDA issued a draft guidance 
addressing the recommended approaches for determination of the suitability of the 
vehicles intended for co-administration of paediatric medicines. In this guidance, 
standardised in vitro methods for evaluating possible vehicle-effects on in vivo 
product performance were described (9). These tests could help reduce the number 
of in vivo studies required for paediatric formulation development, and ultimately 
help tackle ethical issues related to paediatric clinical research (10). To this extent, in 
vitro test conditions should address the parameters relevant to drug release and 
dissolution in the paediatric gastrointestinal (GI) tract, including media composition, 
prandial state, hydrodynamics and current administration practices. The possible 
effect of these parameters on the in vivo drug behaviour should be considered during 
paediatric drug development (6, 11). Recently, in vitro dissolution studies, 
performed with a mini-paddle apparatus and a two-stage approach, showed that this 
setup could be a useful biopharmaceutical tool for estimating drug 
release/dissolution in paediatric conditions (Chapter 4). With this setup it is possible 
to address pH, fluid composition and volumes and transit times representative of the 
GI tract of infants, as well as different paediatric administration practices such as 
medicine co-administration with food and drinks.  
The aims of this study were (i.) to investigate the impact of co-administration of 
montelukast formulations (granules and chewable tablets) with food and drinks on 
drug dissolution performance, under paediatric physiological relevant conditions, 
and (ii.) to evaluate the in vitro dissolution studies in terms of their predictability of 
the in vivo formulation performance.  
Montelukast was chosen as the model drug; it is an amphoteric compound, with a 
high lipophilicity (clogP 8.79), and classified as BCS class II (12). Montelukast is a 
potent leukotriene receptor antagonist that has demonstrated efficacy and tolerability 
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in the treatment of patients with chronic asthma (13-15). For approved paediatric 
use, it is available in two dosage forms (granules and chewable tablets) and is used in 
very young ages from 1 month old (15). The PK profile of montelukast is dose 
proportional and not substantially altered by age (16). As shown in different in vivo 
studies in infant subgroups, montelukast formulations are often mixed with drinks or 
soft foods to facilitate administration (7, 14, 15, 17). 
 
2. Materials and methods 
2.1 Materials  
Ammonium acetate [High Performance Liquid Chromatography (HPLC) grade], 
37% hydrochloric acid, sodium hydroxide, sodium chloride, glacial acetic acid and 
maleic acid were purchased from Fisher Scientific (UK). Dichloromethane, 
acetonitrile (HPLC grade) and methanol (HPLC grade) were from VWR Chemicals 
(UK). Montelukast sodium (pharmaceutical secondary standard), sodium oleate and 
pepsin from porcine gastric mucosa (Ph. Eur.) were obtained from Sigma-Aldrich 
Company Ltd (UK). Sodium taurocholate (Prodotti Chimici Alimentari S.P.A., 
Italy), egg lecithin Lipoid EPCS (Lipoid E PCS, Phosphatidylcholine from egg; from 
Lipoid GmbH, Germany) and glyceryl monooleate – Rylo Mg 19 (Danisco, 
Denmark) were used. Water was ultra-pure (Milli-Q) laboratory grade. Regenerated 
cellulose [RC] membrane filters (0.45 µm) (Cronus
®
, UK), filter papers (0.45 µm) 
and glass microfiber [GF/D] filters (2.7 µm) (Whatman
®
, UK), and porous full flow 
polyethylene cannula filters (10 µm) (Quality Lab Accessories LCC, USA) were 
used. Full fat U.H.T. milk was purchased from The Co-Operative (UK), First Infant 
Milk (cow’s milk-based formula) was from Cow & Gate (UK) and Bramley 
applesauce Colman’s of Norwich from Unilever (UK). Singulair
®
 Pediatric granules 
(4 mg, 28 sachets; from Merck Sharp & Dohme Ltd, UK), and Actavis
®
 chewable 
tablets (5 mg, 28 chewable tablets; from Actavis, UK) were kindly donated by 






2.2.1 Dissolution media preparation 
Paediatric biorelevant media representative of infants were freshly prepared for each 
experiment, as described by Maharaj et al (18). Infant Fasted-State Simulated 
Gastric Fluid (Pi-FaSSGF, pH 1.6), and Fasted-State Simulated Intestinal Fluid 
(FaSSIF-V2, pH 6.5) or infant Fed-State Simulated Intestinal Fluid (Pi-FeSSIF, pH 
5.8) were used. Both fasted and fed intestinal state were simulated since the prandial 
state of the infant patients in the in vivo studies was not reported, and in order to 
investigate if medicine co-administration with a vehicle would induce a food effect 
in the infant. Double concentrated simulated intestinal fluids were prepared for the 
two-stage dissolution studies performed (section 2.2.3). 
 
2.2.2 Sample preparation 
Formula was prepared as per manufacturer’s instructions: 1 scoop of powder 
(approximately 4.5 g) was added to 30 mL of boiled cooled water. Two formulations 
were tested: Singulair
®
 granules (4 mg), and Actavis
®
 chewable tablets (5 mg) which 
were crushed prior to mixing (following reported practices (7)). For the direct 
administration scenario, formulations were tested in the simulated GI fluids without 
prior mixing with a vehicle. For the mixing with vehicles scenario, each sample was 
prepared by addition of the formulation to milk (25 mL; as previously investigated 
(Chapter 4)), applesauce (15 g) or formula (5 mL), followed by mixing with a 
stainless-steel spatula. Mixing with formula was performed only for the Singulair
®
 






2.2.3 Biorelevant in vitro dissolution studies  
Dissolution studies were performed with a mini-paddle apparatus (Agilent 
Technologies 708-DS apparatus configured with TruAlign 200 mL vessels and 
electropolished stainless steel mini-paddles; Agilent, USA). Experiments were 
conducted at 37 
o
C, and agitation rate was set to 50 revolutions per minute (rpm). A 
two-stage approach was followed: gastric conditions were simulated for 1 h (Pi-
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FaSSGF pH 1.6; total volume with sample: 100 mL), followed by intestinal 
simulated conditions (FaSSIF-V2 pH 6.5 or Pi-FeSSIF pH 5.8; final volume: 200 
mL), for 3 h. Sample collection took place at 5, 15, 30, 45, 60, 75, 90, 120, 180 and 
240 min. 2 mL samples were withdrawn (with volume replacement with the 
corresponding media), using a 2 mL glass syringe (Fortuna Optima
®
 fitted with a 
stainless tubing) through a cannula fitted with a full flow filter (10 µm). All 
experiments were performed without direct light exposure to avoid photodegradation 
of montelukast (19). After collection, samples were filtered through a GF/D filter 
(2.7 µm), treated, placed into amber HPLC vials and injected into the HPLC. 
Treatment was as follows: 1000 µL of acetonitrile were added to 500 µL of the 
filtered sample, the mixture was vortexed (HTZ, UK) for 1 min, centrifuged (8000 
rpm, 15 min, 4 
o
C) (Beckman Coulter J2-MC centrifuge, UK) and the supernatant 
was filtered through a RC filter (0.45 µm). The pH of the media was measured at the 
end of each experiment.  
The effect of different administration scenarios on drug dissolution was investigated 
by varying the mode of the introduction of the formulation in the simulated gastric 
fluid in the dissolution vessel: direct administration of the formulation or 
administration of the formulation after mixing with drinks (formula and milk) or soft 
food (applesauce). These vehicles were selected based on their impact on the 
dissolution of montelukast (Chapter 4) and/or to mimic the in vivo studies performed 
in infants (14, 15, 17, 20).  
All experiments were performed in triplicate. Fresh calibration curves (concentration 
range: 0.5 – 60 μg/mL) were prepared in the corresponding media, by appropriate 
dilution of a 1000 μg/mL stock solution of montelukast analytical standard in 
methanol. Results were expressed as mean percentage (%) drug dissolved ± standard 
deviation (S.D.) at the given sampling time.  
 
2.2.4 Chromatographic conditions for drug analysis 
The chromatographic method used for quantification of montelukast was a 
modification of the method by Raju NK et al (21). Drug quantification was 
performed with HPLC with ultraviolet (UV) detection (Agilent HPLC system 
1100/1200 series; Agilent, USA), using a C18 column (RP Agilent Eclipse XDB, 250 
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mm x 4.6 mm, 5 µm particle size), and ammonium acetate buffer pH 5.5 (A) and 
methanol (B) as mobile phase, delivered on a linear gradient. The selected gradient 
started with 10 % of solvent B, which was increased to 50 % within 2 min, and 90 % 
within 4 min; at 11.30 min, the initial conditions of analysis were re-established. 
Injection volume was 100 µL, flow rate was 1 mL min
−1
, run time was 12.30 min, 




2.2.5 Data analysis and calculations 
2.2.5.1 In vitro data analysis and calculations 
The linear trapezoidal method was used to calculate the area under the curve of each 
in vitro % drug dissolved over 4 h profile (AUC0-4h in vitro). One-way analysis of 
variance (ANOVA) with a post-hoc Tukey Honest Significant Difference (HSD) test 
was conducted to investigate differences in the AUC0-4h in vitro calculated from the 
dissolution studies, after direct administration of formulation and after mixing the 
formulation with the different vehicles (p < 0.05 noting significance level). T-test 
analysis was used to compare experimental results under fasted gastric conditions, 
followed by fasted or fed intestinal conditions (represented as Pi-FaSSGF/FASSIF-
V2 and Pi-FaSSGF/Pi-FeSSIF, respectively) (significance p < 0.05). Analyses were 
performed with GraphPad Prism
®
 v.7 software (USA).  
2.2.5.2  In vivo data analysis and calculations 
Published data of plasma concentration profiles of Singulair
®
 granules (4 mg) co-
administered to different infant subgroups with formula or applesauce (formula: 1 to 
3 months; applesauce: 3 to 6 months and 6 to 24 months) were digitalised with 
WebPlotDigitalizer
®
 v4.1 software (USA) (14, 15, 17, 22).  
The corresponding in vivo drug absorption profiles were obtained after 
deconvolution of the oral data using the Wagner-Nelson equation (Eq. 5.1) (Excel, 
Microsoft
®
) (23).  
            
    
    
       
       ∫       
 
   
  ∫       
 
   
       (Eq. 5.1) 
142 
 
where,      is the amount of drug in the system at time   and   is the first order 
elimination rate constant (23). The elimination rate constant was obtained from the 
slope of the terminal logarithmic concentrations of the in vivo montelukast oral data. 
The linear trapezoidal method was used to calculate the area under the curve of each 
in vivo % drug absorbed over 4 h profile (AUC0-4h in vivo). 
2.2.5.3 In vitro/in vivo relationship 
An in vitro–in vivo relationship for Singulair
®
 granules (4 mg) was investigated by 
comparing the in vitro dissolution (AUC0-4h in vitro) and the in vivo absorption data 
(AUC0-4h in vivo). Average differences between the obtained AUC0-4h in vitro and the 
AUC0-4h in vivo of the different subgroups were expressed as a ratio (%) (AUC0-4h in 
vitro/AUC0-4h in vivo x 100). For evaluation of the results, ratios lower than 100 % 
indicate that AUC0-4h in vitro was lower than the AUC0-4h in vivo and higher values 
represent the opposite. To denote relevant discrepancies between the AUC0-4h in 
vitro and AUC0-4h in vivo, reference points corresponding to ratios of 80 and 125% 
were used. Mean ratios falling inside this reference range were estimated to represent 
an in vitro-in vivo relationship, whereas when mean ratios were outside the reference 
range in vitro dissolution results were deemed not related to in vivo drug 
performance.   
 
3. Results and discussion  
3.1 Biorelevant in vitro drug dissolution studies for the assessment of the 
impact of medicine co-administration with food and drinks  
Dissolution of montelukast from both formulations in the administration scenarios 
tested is presented in Figure 5.1. In gastric conditions (Pi-FaSSGF), dissolution of 
montelukast was higher when the formulations were mixed with milk, in comparison 
to direct administration and when mixed with applesauce. In intestinal conditions, 
differences in drug dissolution were observed for both formulations when testing 
under fasted or fed conditions (FaSSIF-V2 pH 6.5 or Pi-FeSSIF pH 5.8). These are 
probably attributed to an increase in drug solubilisation (drug solubility = 8 µg/mL 
and 53 µg/mL in FaSSIF-V2 and Pi-FeSSIF, respectively) due to the presence of a 
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higher concentration of bile salts and lecithin in the fed intestinal simulated fluid, as 
shown in solubility studies of montelukast in different paediatric media (12, 18, 24). 
In addition, the vehicle-impact on drug dissolution varied depending on the vehicles 
used for co-administration and the formulation tested. For example, when both 
formulations were mixed with applesauce, the impact of testing under fed intestinal 
conditions was higher for the crushed chewable tablets than for the granules.  
 
 
Figure 5.1. Mean % montelukast dissolved (± S.D.) from Singulair
®
 granules and Actavis
®
 
chewable tablets after direct introduction of the formulation and mixing with selected 
vehicles, under fasted gastric conditions, followed by fasted (full lines) or fed (dashed lines) 
intestinal conditions. Dotted vertical lines represent the time of medium change. 
 
Comparison of the AUC0-4h in vitro of the dissolution profiles (4 h) is presented in 
Figure 5.2. Results of the AUC0-4h in vitro confirmed that dissolution of montelukast 
from the two formulations tested was significantly affected by co-administration 
with vehicles, compared to the direct administration scenario. The AUC0-4h in vitro 
was also shown to be significantly higher when testing under fed state intestinal 





Figure 5.2. AUC0-4h in vitro (% dissolved*h) of montelukast dissolution profiles after direct 
administration of formulation and after mixing with the vehicles. a denotes statistical 
difference between direct administration (blue bars) and co-administration with vehicles 
(other colours); * denotes a statistical difference on drug dissolution between testing under 
fasted gastric conditions, followed by fasted (dashed bar) or fed (full bar) intestinal 




 granules, the AUC0-4h in vitro of the direct administration of 
formulation scenario was significantly lower compared to the co-administration with 
drinks (milk and formula), and significantly higher than the co-administration with 
applesauce. Drug dissolution (4 h) was higher when the formulation was co-
administered with milk (74.3 and 93.0 % drug dissolved in Pi-FaSSGF/FaSSIF-V2 
and Pi-FaSSGF/Pi-FeSSIF, respectively), than when mixed with formula (% drug 
dissolved = 37.4 (Pi-FaSSGF/FaSSIF-V2) and 55.3 (Pi-FaSSGF/Pi-FeSSIF)). These 
results confirm that vehicles of the same subtype (i.e. dairy drinks) can have 
different effects on drug dissolution, in accordance with what was observed in 
Chapter 4 and previous studies (20, 25, 26). The lower dissolution of montelukast 
observed when the granules were mixed with formula compared to the drug 
dissolution when mixed with milk, relates to the differences in the solubility of 
montelukast in the two vehicles (milk: 13.3 mg/mL; formula: 12.0 mg/mL) (Chapter 
2). It can be hypothesised that these differences were accentuated by the use of 
different volumes of the two drinks mixed with the formulation (15 mL milk and 5 
mL formula). This is of particular importance considering that the recommendations 
for medicine co-administration with drinks/soft foods often do not specify the 
volume of vehicle to use (7). These results indicate the risk of unspecific 
recommendations for vehicle choice and volume, and further confirm the importance 
of the FDA draft guidance on vehicle selection and in vitro methods for product 
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quality assessment (9). The lowest % drug dissolution (4 h) was observed for the 
mixing with applesauce scenario (% drug dissolved = 9.8 (Pi-FaSSGF/FaSSIF-V2) 
and 18.1 (Pi-FaSSGF/Pi-FeSSIF)). As mentioned in Chapter 4, it is possible that this 
relates to the presence of starch in the composition of applesauce, which forms a net 
gel around the formulation and negatively affects drug release and dissolution (27).  
The AUC0-4h in vitro for the crushed Actavis
® 
chewable tablets mixed with 
applesauce was not significantly different from the direct introduction scenario, 
whereas a higher AUC0-4h in vitro was observed after mixing with milk (Figure 5.2). 
The higher drug dissolution when the formulation was mixed with milk is probably 
related to the higher drug solubilisation in milk, due to the high drug affinity for 
protein and fat globules in milk, as well as the higher pH and buffer capacity of this 
vehicle (Chapter 3)(24, 28). 
Overall, it was observed that co-administration with food and drink vehicles 
significantly affects the dissolution of montelukast from both formulations. Results 
showed the influence of drug ionisation and solubility (e.g. higher % montelukast 
dissolved when formulations were mixed with milk), vehicle viscosity (e.g. higher 
viscosity of applesauce hinders the dissolution of the Singulair
®
 granules), and 
alteration of formulation factors (granules and crushed chewable tablets displayed 
different dissolution behaviour when mixed with applesauce), on drug dissolution 
behaviour. In addition, simulated intestinal prandial conditions were shown to affect 
drug dissolution behaviour, with higher % drug dissolved (4 h) achieved when 
testing under Pi-FaSSGF/Pi-FeSSIF conditions. These results indicate that the 
impact of the practice of medicine co-administration with food and drinks will be 
higher if the vehicle used triggers a food effect in vivo or if medicine co-
administration with vehicles is performed under fed conditions.  
 
PK parameters will influence the extent of the vehicle-impact on drug dissolution 
and, consequently, drug behaviour and clinical outcomes. One of these parameters is 
the half-life of the drug, which will influence the Cmax achieved. In this study, 
montelukast was chosen as a proof-of-concept molecule to understand the possible 
vehicle-impact on dissolution of a poorly soluble drug. It is a BCS class II drug, with 
a half-life of 4 h, which should be administered once-daily (12, 13, 15). The possible 
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vehicle-impact on drug dissolution may be significant in cases where drug has low 
permeability, low dissolution and short half-life (< 120 min) or if a fast onset 
therapeutic action is required. Vehicles that slow down drug dissolution might cause 
issues in vivo, because the drug can be metabolised and/or eliminated before it 
reaches therapeutically relevant systemic concentrations. For example, the Cmax of a 
high-permeability and short half-life drug such as ibuprofen can be sensitive to the 
dissolution profile, as this drug requires frequent administration in order to maintain 
blood concentration levels within a therapeutically effective concentration range (29, 
30). Vehicles that cause an increase in drug dissolution rate compared to the rate of 
absorption (limited by permeability restrictions) might be problematic if the drug 
achieves higher concentrations in the GI lumen than its equilibrium solubility, as this 
might lead to precipitation (31). Absorption is a complicated process and other GI 
physiological parameters might play a role, such as GI transit rates and volumes 
(31). Thus, the influence of these parameters should also be considered during 
evaluation of a possible vehicle-effect and could be captured if evaluated in a 
physiologically based pharmacokinetic model.  
 
3.2 In vivo drug absorption  
In published in vivo studies of Singulair
®
 granules (4 mg) administered to infant 
patients, medicine administration was conducted by mixing the formulation with 
different vehicles: formula (5 mL) for the subgroup 1 to 3 months, and applesauce 
(15 g) to infants from 3 to 24 months (two subgroups: 3 to 6 and 6 to 24 months). 
However, the prandial state of the patients in these studies was not disclosed and no 
significant vehicle-induced differences on drug behaviour were considered (14, 15, 
17, 22). 
PK parameters of montelukast Cmax and AUC0-24 h after the administration of the 4 
mg dose to infants of 1 to 3 months were higher and more variable than for older 
infants (3 to 24 months) (14, 15, 17). The higher systemic exposure in the younger 
subgroup when given the dose of montelukast was attributed to their smaller body 
weight, and to the levels of CYP3A4, which are only about 30 to 40 % of adult 
levels in ages younger than 3 to 12 months (15).  
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The in vivo % absorbed profiles of montelukast after administration of Singulair
®
 
granules, in the different subgroups of infants (calculated from the Wagner-Nelson 
equation of the plasma profiles (14, 15, 17, 22)), are shown in Figure 5.3.  
 
 
Figure 5.3. % of montelukast absorbed in vivo after administration of Singulair
®
 granules (4 
mg) to: (a) 1 to 3 months infants with formula (15); (b) 3 to 6 months infants with 
applesauce (14); and (c) 6 to 12 months infants with applesauce (17). The % absorbed was 
calculated with the Wagner–Nelson equation. 
 
3.3 In vitro-in vivo relationships for Singulair
®
 granules 
The ratios between the AUC0-4h in vitro and the AUC0-4h in vivo are presented in 
Figure 5.4. The ratios were calculated from the AUC0-4 h in vitro of the in vitro 
dissolution profiles of Singulair
®
 granules directly administered or mixed with milk, 
formula or applesauce, under fasted gastric conditions followed by fasted or fed 
intestinal conditions, and the AUC0-4 h in vivo in infants (3 subgroups: 1 to 3 months, 





Figure 5.4. Ratio (%) between each AUC0-4h in vitro and AUC0-4h in vivo (AUC0-4h in 
vitro/AUC0-4h in vivo x 100) for: (a) in vitro fasted gastric followed by fasted intestinal 
conditions; and (b) in vitro fasted gastric followed by fed intestinal conditions. Grey area 
represents the range criteria (80 – 125 %) set for prediction of in vivo drug performance. 
   
In the cases of direct introduction of Singulair
®
 granules and mixing with 
applesauce, the in vitro drug dissolution was much slower than the in vivo absorption 
of montelukast, in all subgroups (% AUC0-4h in vitro/AUC0-4h in vivo ratio lower than 
80%). In these cases, as in vitro drug dissolution was slower than in vivo absorption, 
it might be hypothesised that the in vitro test must be improved (1).  
For the mixing of Singulair
®
 granules with formula scenario, when testing under 
fasted gastric conditions followed by fed intestinal conditions, the AUC0-4h in 
vitro/AUC0-4h in vivo ratio fell inside the 80 – 125 % limits for one of the subgroups 
tested in vivo (1 to 3 months old), even though it was under the limits for the other 
subgroups. Conversely, the in vitro-in vivo ratio was lower than the 80 % limit for all 
subgroups when testing under fasted gastric conditions followed by fasted intestinal 
conditions. These results indicate that the biorelevant in vitro dissolution test under 
fasted gastric conditions followed by fed intestinal conditions gives a good 
prediction of the in vivo product performance for the 1 to 3 months subgroup. 
For the Singulair
®
 granules mixed with milk, when testing under fasted gastric 
conditions followed by fed intestinal conditions and comparing to in vivo results in 
infants from all subgroups, the AUC0-4h in vitro/AUC0-4h in vivo ratio fell inside the 
80 – 125 % limits. However, under in vitro fasted gastric conditions followed by 
fasted intestinal conditions, the AUC0-4h in vitro/AUC0-4h in vivo ratio only fell inside 
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the 80 – 125 % limits when using the in vivo data from the studies conducted in 
infants from 1 to 3 months old. These results indicate that the biorelevant in vitro 
dissolution test (fasted gastric conditions followed by fed intestinal conditions) using 
milk gives the best prediction of the in vivo product performance for all the tested 
subgroups. A good relationship was also found between the in vivo performance, for 
the 1 to 3 months subgroup, and the in vitro setup when using milk and testing under 
fasted gastric conditions followed by fasted intestinal conditions.  
Overall, even though in the in vivo studies the prandial state of the infants is not 
evident, results suggest that these were likely performed in the fed state or that the 
practice of medicine co-administration with food and drinks might trigger fed state 
conditions in vivo. Nevertheless, further investigations would be needed to confirm 
and refine the dissolution testing parameters (e.g. media volume and composition, 
and dissolution hydrodynamics), and ensure the establishment of predictive, 
physiologically relevant methodology (1, 2). To this extent, characterisation of 
paediatric GI contents of different age groups in vivo is warranted for validation of 
paediatric biorelevant media and to allow the establishment of certainty and 
confidence in these paediatric biopharmaceutical methods.  
 
4. Conclusions 
The practice of mixing medicines with food and drinks may affect drug behaviour, 
leading to potential clinical implications. As emphasized in the recent FDA draft 
guidance on the use of vehicles for drug administration, this potential impact should 
be assessed during formulation development/evaluation by using different 
biopharmaceutical tools. In this study,  
Dissolution of montelukast was significantly affected when mixing the tested 
formulation with vehicles in comparison to the scenario direct administration of 
formulation. Moreover, drug dissolution was significantly higher when testing under 
fed state intestinal conditions in comparison to the fasted state.  
The biorelevant in vitro dissolution test (fasted gastric conditions followed by fed 
intestinal conditions) of the Singulair
®
 granules mixed with milk scenario led to the 
best prediction of the in vivo drug performance in infant subgroups (1 to 3 months, 3 
150 
 
to 6 months and 6 to 24 months). Moreover,  results from this study suggest that they 
were performed in the fed state or that the practice of medicine co-administration 
with food and drinks might have triggered fed state conditions in vivo. 
The good relationship between the in vitro drug dissolution and in vivo absorption 
demonstrates the potential utility of biorelevant in vitro dissolution testing to 
understand the potential impact of co-administration of paediatric medicines with 
vehicles on drug performance. Ultimately, the use of in vitro tools like the one 
described could help understand the impact of this administration practice and avoid 
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Chapter 6: BCS-based biowaivers: extension to paediatrics  
Abstract 
Objectives: The aims of this study were to: (i.) identify compounds which would 
change drug solubility classification in the paediatric population, and (ii.) to assess 
the risk of extending BCS-based biowaiver criteria into paediatric products of these 
compounds.  
Methods: Amoxicillin, prednisolone and amlodipine were selected as the model 
compounds. Dissolution studies of IR formulations of these compounds were 
conducted with USP II (paddle) and mini-paddle apparatus, in media of three pHs 
(pH 1.2, 4.5 and 6.8). Three dissolution setups were tested: (1) ‘typical’ BCS-based 
biowaiver conditions, (2) setup derived from BE study protocols (volume: 250 mL), 
and (3) extrapolation of a volume representative of the paediatric population (50 
mL). 







) would qualify for a biowaiver 
status, under all setup scenarios tested. In view of these results, it was shown that 
extension of regulated BCS-based biowaiver criteria for paediatric application is not 
straightforward and cannot be based on direct assumptions (i.e. simple scaling 
down). It was further shown that BCS-based biowaiver criteria should not be applied 
when there is a risk of a change of the drug solubility class, from the adult to 
paediatric populations.  
Conclusions: Drug solubility considerations for adult BCS might not directly apply 
to paediatric subpopulations and extrapolation of BCS-based criteria into paediatric 
formulations should be undertaken with caution. A deeper knowledge of the 
paediatric GI environment is still lacking and would assist in refining the 
biopharmaceutical tools needed to appropriately evaluate formulation performance 
across age groups. This would not only be of great scientific interest but also 
potentially reduce the number of clinical studies required and speed up formulation 




Biopharmaceutical tools are extensively used in the design and development of 
pharmaceutical formulations, namely in risk assessment and optimisation of 
formulation performance. The application of these tools in paediatric medicines is 
currently still limited (1). Despite the increased effort put into improving the safety 
and effectiveness of paediatric medicines, development of medicines for this 
population is hindered by ethical considerations and technical constraints (e.g. 
physiological and anatomical changes), leading to knowledge gaps (2-5). 
Consequently, the tools currently used to undertake biopharmaceutical risk 
assessment of paediatric formulations are based on adult tests, addressing adult 
physiology and anatomy (1). However, the paediatric population has distinct needs 
with respect to formulation design and performance and thus adult formulations may 
not be suitable. Due to the challenges faced during paediatric medicine development, 
regulations have been reformed to address paediatric drug development in parallel to 
adult formulations (2, 3). Preliminary enabling formulations might be used in early 
paediatric studies, followed by a confirmatory study in which better-designed market 
formulations are introduced (6). Supportive clinical studies (e.g. relative 
bioavailability (BA) or bioequivalence (BE)) or in vitro techniques may then be used 
to establish the bridge from adult and/or enabling formulations to the final paediatric 
formulation.  
From a regulatory perspective, during drug development a BE study should be 
conducted for a new formulation that has not been tested in efficacy trials. 
Pharmacokinetic (PK) parameters of two formulations (i.e. area under the curve 
(AUC), maximum plasma concentration (Cmax) and time to maximum concentration 
(Tmax)) are compared; if the rate and extent of drug absorption fall within predefined 
limits, comparable in vivo drug exposure is ensured. BE studies of paediatric 
products are currently conducted in adults, with subsequent extrapolation to the 
target age group and a dose determination/confirmation study (6). 
Bioequivalence studies may be exempted if in vitro dissolution testing can be used as 
a surrogate to adequately predict the in vivo drug performance (biowaivers). The 
biopharmaceutics classification system (BCS) is a scientific tool which categorises 
drugs according to their (high or low) solubility and intestinal permeability (7). This 
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system has been adopted as a very useful tool for in vivo drug design and 
development, particularly in terms of regulatory standards. BCS-based biowaivers 
have become an important and cost-saving tool in the development of new 
medicines, formulation bridging and generic drug approval. When combined with in 
vitro dissolution, BCS-based biowaivers consider the three major factors that govern 
the rate and extent of oral drug absorption from immediate release (IR) dosage 
forms. An IR oral solid formulation (test product) is eligible for a BCS-based 
biowaiver if the drug satisfies solubility criterion (high solubility; BCS class I/III), 
and the dosage form is pharmaceutically equivalent to the reference product (8-10). 
BCS-based biowaiver criteria are detailed in regulatory guidance documents (8-10). 
In the USA, it is required that at least 85 % of the labelled amount of drug substance 
should dissolve from the product within 15 min (BCS class III drugs) or 30 min 
(BCS class I drugs), in 900 mL media (500 mL or less can be allowed with scientific 
justification) cross a pH range (pH 1.2, 4.5 and 6.8), using USP apparatus I (100 
revolutions per minute [rpm]) or II (50 rpm or 75rpm, if justified). The time frame 
criterion for BCS class I drugs, is subdivided into very rapidly and rapidly dissolving 
products (time-limits of 15 and 30 min, respectively), in guidelines from the World 
Health Organisation (WHO) and the European Medicines Agency (EMA) (8-10). 
There are no equivalent guidance documents for paediatric products, and the 
relevance of the defined criteria in this population is unknown.  
Currently, biowaiver decisions are based on the drug properties related to the adult 
population. However, a BCS-biowaiver approach for paediatric products would be 
beneficial towards producing age-appropriate medicines, whilst 
minimising/eliminating scientific regulatory risks. Potentially this could be explored 
if both the reference (e.g. adult formulation or enabling paediatric formulation) and 
test formulations are pharmaceutical equivalents exhibiting rapid and similar 
dissolution profiles.  
The use of the BCS in paediatrics is limited due to several biopharmaceutical 
particularities regarding paediatric physiology and PK parameters, therefore BCS-
based biowaivers are not feasible for this population (4, 11). These particularities 
include gastrointestinal (GI) pH and volumes, which can influence drug solubility 
and ionised fraction. Additionally, permeability changes occur as function of the 
relative size of the small intestine, weight gain and maturation of GI transporters 
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(e.g. P-glycoprotein) (3, 12). Thus, the role of BCS and biowaivers in paediatric 
medicine development is unclear (13, 14).  
In this context, it is important to investigate the possible changes on the 
biopharmaceutical characteristics of the drug as a function of the different age 
groups. Age-related physiological and/or anatomical changes may be responsible for 
shifts in the BCS classification of a drug due to changes in its solubility and 
permeability classification (15). Recent studies have shown that a drug which 
exhibits a high dose/solubility ratio in adults (i.e. highly soluble drugs) might not 
show the same ratio in paediatric patients, and unfavourably shift into poorly soluble 
classification. Consequently, these drugs would not be eligible for BCS-based 
biowaivers among pediatric populations (15, 16).  
The aims of this study were to assess the risk of extending the biowaiver criteria for 
IR formulations from adults to paediatrics, and to identify bioinequivalence risks 
when comparing the performance of different formulations in age-appropriate BCS-
conditions. The biowaiver decision was then discussed not only in terms of the 
formal requirements set out in existent guidance, but also in the context of the risks 
associated with an incorrect biowaiver decision. Drugs were selected based on the 
identified risk of shifting into poorly soluble classification in the different paediatric 
age groups and, consequently, not being eligible for a BCS-based biowaiver. 
Amoxicillin, amlodipine and prednisolone were selected as the model compounds. 
 
2. Materials and methods 
2.1 Materials  
Sodium hydroxide, 37 % hydrochloric acid, sodium chloride, glacial acetic acid, 
potassium dihydrogen phosphate, sodium acetate trihydrate and sodium phosphate 
anhydrous were purchased from Fisher Scientific (UK). Water was ultra-pure (Milli-
Q) laboratory grade. Regenerated cellulose [RC] membrane filters (0.45 µm) were 
from Cronus
®
 (UK). Amoxicillin trihydrate (98 %) was purchased from VWR (UK). 
Prednisolone (99 %) and amlodipine besylate (pharmaceutical secondary standard) 
were obtained from Sigma-Aldrich (UK). Details of the formulations used are 
presented in Table 6.1.  
158 
 
Table 6.1. Information of the formulations used in this study. 









250 mg (2398) 
500 mg (X54F) 
Magnesium stearate E572, 
gelatine, erythrosine E127, 
titanium dioxide E171, 
indigotine E132, iron oxide 















magnesium stearate, sunset 
yellow E110, carmosine 
E122, brilliant blue E133, 
Quinoline Yellow E104, 
















Magnesium stearate, maize 
starch, gelatine, erythrosine 
E127, quinoline Yellow 
E104, titanium dioxide 












Potato starch, lactose, talc, 








5 mg (4F46) 
25 mg (YK13) 
Lactose monohydrate, 
pregelatinized starch, 
sodium starch glycolate 
type A, iron oxide yellow 









Pfizer Ltd  
(UK) 
5 mg (2398) 




















sodium starch glycolate 















phosphate, sodium starch 








2.2.1 Drug and dose selection 
Amoxicillin (trihydrate), prednisolone and amlodipine (besylate) were selected as the 
model compounds. They are included in the Model List of Essential Medicines for 
Children, with two dose strengths specified for each drug (17). Two doses (one 
paediatric and one adult) were selected for this study; these were: 250 and 500 mg 
for amoxicillin, 5 and 25 mg for prednisolone and 5 and 10 mg for amlodipine.  
The BCS allows the classification of drugs as highly soluble when the highest drug 
dose (or dose unit, D0) is soluble in 250 mL of an aqueous liquid at a relevant 
physiological pH range of 1.2 – 6.8 (7). According to this criterion, the three drugs 
(all doses) selected are classified as highly soluble drugs (18-20). The key factors 
that define drug dose unit (i.e. highest dose strength, initial gastric volume available 
(V0) and drug solubility) have been shown to vary amongst the different populations 
(15, 16, 21). The paediatric D0 of these drugs were estimated across the different 
paediatric age groups (average age in each subpopulation was used for the 
calculations; Table 6.2), using the following equation (Eq. 6.1) (15): 
   
                                               
               
 (Eq. 6.1) 
where, aqueous drug solubility data was obtained from the literature (22), and the 
reference volumes for paediatric groups were determined using the equation (Eq. 
6.2): 
                                 
                   
  
      (Eq. 6.2) 
where, 0.56 mL/kg and 40 mL are estimates of fasted gastric fluids volumes in 
paediatrics (23) and adults (24), respectively, and 250 mL is the reference volume 
used in the BCS (8-10). 
All drugs were shown to change D0 (Table 6.2) and consequently BCS class, with a 
shift from high drug solubility classification in adults to low drug solubility 
classification (given by D0 > 1 (4)) in certain paediatric age groups. The BCS‐based 
biowaiver status claimed in adults may therefore not be safely extended to the 




Table 6.2. Dose unit in different age groups from early infancy through to 
adulthood. High and low drug solubility classification are denoted by red (D0 > 1) 
and black (D0 < 1) colours, respectively. Paediatric reference volumes were 










3 Years / 
V0 = 54 mL 
6 Years / 
V0 = 79.2 
mL 
10 Years / 
V0 = 121 
mL 
17 Years / 
V0 = 245 
mL 
Adult / 





250 1.350 0.920 0.602 0.297 0.292 
500 2.699 1.841 1.205 0.595 0.583 
Prednisolone 0.223 
5 0.415 0.283 0.185 0.092 0.0897 




5 1.230 0.838 0.549 0.271 0.266 
10 2.459 1.677 1.098 0.542 0.531 
(D0 = dose unit; V0 = gastric volume available) 
 
2.2.2 In vitro dissolution studies 
In vitro dissolution studies were conducted with USP II apparatus or mini-paddle 
apparatus (Agilent 708-DS Dissolution apparatus; Agilent, USA). For the mini-
paddle setup, TruAlign 200 mL vessels and electropolished stainless steel mini-
paddles were used (Agilent, USA). Experiments were conducted at 37 ± 0.5 
o
C in 
three media; simulated gastric fluid sine pepsin (SGFsp) pH 1.2, acetate buffer pH 
4.5 and phosphate buffer pH 6.8 (25). Three different setups were developed for the 
assessment of formulation performance and equivalence, in dissolution conditions 
representative of both adults and paediatric populations (Figure 6.1). Setup 1 was 
conducted in USP II apparatus, using 900 mL of dissolution media and an agitation 
of 50 rpm (prednisolone and amlodipine) or 75 rpm (amoxicillin) (setup 1, old 
‘typical’ BCS-based biowaiver conditions). Setup 2 was conducted in USP II 
apparatus, using 250 mL of media and an agitation rate of 50 rpm (prednisolone and 
amlodipine) or 75 rpm (amoxicillin) (setup 2, derived from BE study protocols that 
prescribe administration of a drug product to fasting human volunteers with a glass 
of water of 250 mL). Setup 3: was conducted in mini-paddle apparatus, using 50 mL 
of dissolution media and an agitation rate of 125 rpm (prednisolone and amlodipine) 
or 187.5 rpm (amoxicillin) (setup 3, where a 50 mL volume representative of the 
paediatric population was used). The agitation rate for setup 3 in the mini paddle 
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apparatus (125 or 187.5 rpm) was set based on the speed factor of 2.5 between 
paddle and mini-paddle hydrodynamics [i.e. Agitation rate mini-paddle = 2.5 * 
agitation rate paddle] to reflect the agitation rate used in the USP II apparatus (50 or 
75 rpm, respectively) (26). Other requirements for granting the biowaiver status (i.e. 
pH range for testing and time frame limits for rapid dissolution of the formulations) 








Figure 6.1. Schematic representation of the different dissolution setups tested: (1) 900 mL, 
USP II apparatus; (2) 250 mL, USP II apparatus; (3) 50 mL, mini-paddle apparatus. 
 
For amoxicillin capsules, slow dissolution was observed when testing at 50 rpm in 
media of pH 4.5 and 6.8. To explore the dissolution performance of the drug 
products and investigate if there were experimental issues of coning, dissolution tests 
were performed with Amoxil
®
 250 and 500 mg capsules (reference product), in 
media of pH 4.5 and 6.8 at three agitation rate conditions; 50, 75 and 100 rpm. Two 
volumes were tested: 900 mL (setup 1) and 250 mL (setup 2).  
Experiments were conducted for 60 min or 120 min, depending on whether complete 
dissolution was reached within 60 min. For amoxicillin testing, capsules were put in 
sinkers (Quality Lab Accessories LCC, USA). Sample collection took place at 5, 10, 
15, 20, 30, 45, 60, 75, 90 and 120 min. 2 mL samples were withdrawn (with volume 
replacement) using a 2 mL glass syringe (Fortuna Optima
®
 fitted with a stainless 
tubing) through a cannula (Quality Lab Accessories LCC, USA). Each sample was 
filtered with a RC filter (0.45 µm), and appropriately diluted prior to quantitative 
analysis. All experiments were performed in triplicate. Samples were analysed at 272 
(amoxicillin), 246 (prednisolone) and 239 (amlodipine) nm, using an UV 
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spectrophotometer (Thermo Scientific Helios Gamma UV-Vis Spectrophotometer, 
Thermo Fisher Scientific, UK) equipped with a cuvette. 
Drug quantification was performed based on calibration curves prepared in the 
corresponding media for each experiment. Freshly prepared standard solutions 
(concentration range: 5 – 120 μg/mL (amoxicillin) or 2 – 30 μg/mL (prednisolone 
and amlodipine)) were prepared by appropriate dilution of a 1000 μg/mL stock 
solution of the analytical standard in water (amoxicillin) or methanol (prednisolone 
and amlodipine). The interfering effect of formulation excipients on the maximum 
absorption of the compounds was deemed insignificant, after scanning and 
comparing the spectrum of each stock solution with the spectrum of a solution of 
same concentration of the dissolved dosage forms in water (amoxicillin) or methanol 
(prednisolone or amlodipine) (data not shown). Results were expressed as mean 
percentage (%) drug dissolved ± standard deviation (S.D.), at the given sampling 
time. 
 
2.2.3 Treatment of dissolution data 
To qualify for a BCS-based biowaiver, both the test product and reference should 
display a mean % drug dissolved above 85 % within 15 or 30 min, and similar in 
vitro dissolution characteristics, under all the defined conditions (i.e. agitation rate, 
pH range). When > 85% of the label amount of drug was dissolved in 15 min (for 
both test and reference products), the dissolution profiles were considered similar. If 
this was not the case, the similarity factor f2 was estimated for comparison of 
dissolution profiles, by using the following equation (Eq. 6.3) (27): 
         (
   
√  
∑                 
 
) (Eq. 6.3) 
where,   is the number of time points,      is the mean percent of reference drug 
dissolved at time t after starting the study; and      is the mean percent of test drug 
dissolved at time  .  
DDsolver
®
 software (an Add-In for Excel, Microsoft
®
) was used to determine the 
similarity factor f2. The evaluation of the similarity factor was based on three 
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conditions: (i.)  a minimum of three time points was used, (ii.) the time points used 
were the same for the two products compared, (iii.) not more than one mean value of 
≥ 85% dissolved for any of the products was included in the analysis. The coefficient 
of variation was less than 20 % at early time points and less than 10% at other time 
points, thus allowing the use of mean values for evaluation of the similarity factor 
(8). Two dissolution profiles were considered similar when the f2 value was ≥ 50 
(27).     
 
3. Results and discussion  
3.1 Amoxicillin 
Amoxicillin can be classified as a BCS class I drug, according to drug solubility and 
permeability studies (18). According to regulations for BCS-based biowaivers, 
dissolution studies should be performed with USP II paddle apparatus at 50 rpm. 
Amoxicillin capsules had a slow and incomplete dissolution when dissolution testing 
was performed at this agitation rate in media of pH 4.5 and 6.8. At an agitation rate 
of 75 rpm and 100 rpm, dissolution of amoxicillin from the Amoxil
®
 capsules 
(reference product; 250 and 500 mg) was rapid and reached completion, with low 
variability between replicates. These results revealed that at lower agitation rate (50 
rpm) a coning effect was taking place (Figure 6.2). Therefore, the dissolution tests 
for the amoxicillin capsules were performed at 75 rpm (setup 1 and 2 conditions) and 





Figure 6.2. Mean % amoxicillin dissolved (± S.D.) from Amoxil
®
 capsules 250 mg (full 
lines) and 500 mg (dashed lines), in acetate buffer pH 4.5 (top) and phosphate buffer pH 6.8 
(bottom), under two testing scenarios: setup 1 (USP II apparatus, 900 mL) and setup 2 (USP 
II apparatus, 250 mL) (left and right panels, respectively). Three agitation rates were tested: 
50 rpm (blue), 75 rpm (red) and 100 rpm (black). 
 







) is presented in Figure 6.3 and f2 similarity factors estimated for 
comparison of the dissolution profiles in Table 6.3. For the 250 mg amoxicillin 
capsules, under setup 1 conditions at pH 1.2, more than 85 % of amoxicillin was 
dissolved from the tested formulations within 15 min. In the acetate (pH 4.5) and 
phosphate (pH 6.8) buffers, dissolution of all the tested products was not rapid (% 
drug dissolved within 30 min was less than 85 %). Dissolution of amoxicillin was 
complete within 15 min in pH 1.2 media, 90 min in pH 4.5 media and 45 min in pH 





similar to the dissolution profile of the reference product (Amoxil
®
) (f2 ≥ 50; Table 
6.3). Consequently, the products would not qualify for biowaiver status. These 
results are in agreement with dissolution studies recently conducted based on USP 
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methodologies and BCS-based biowaiver dissolution studies, which have showed 
high failure rates for amoxicillin products (28-30). In these studies, the discrepant 
dissolution profiles were thought to be caused by poor manufacturing techniques or 
variation in the API particle size, and thus with appropriate content uniformity 
assays in addition to in vitro drug dissolution testing, this risk should be easily 
identified (28-30). This could also be the case in this study, as the formulations 
selected do not contain any excipients known to affect the bioavailability of 
amoxicillin (Table 6.1), according to the available literature (18). Under setup 2 
conditions, more than 85 % of the labelled amount of amoxicillin was dissolved in 
less than 15 min at pH 1.2, and under 30 min at pH 4.5 and 6.8 for all products 
tested. Complete dissolution was achieved within 20 min in pH 1.2 media, and 45 





products with the reference product showed that biowaiver status would be granted 


















Since in vitro equivalence was shown between Amoxil
®





 capsules would be assumed as therapeutically 
equivalent to the reference product, under these testing conditions. With setup 3 
conditions, the criterion for rapid dissolution was not met within the pH range tested. 
Dissolution was complete at pH 1.2 and 6.8 (within 15 and 75 min, respectively), but 
not at pH 4.5. Therefore, even though the products were shown to be similar (f2 ≥ 50; 
Table 6.3), they would not qualify for biowaiver status. The different results 
obtained with setups 1 and 3 in comparison to setup 2 testing conditions may be 
related to the dissolution setup. When using a dissolution volume of 250 mL in USP 
II dissolution (setup 2), the paddles are very close to the medium surface, which not 
only requires careful sampling as it may lead to result variability but also shows that 
the different hydrodynamics impact drug dissolution, ultimately affecting the 











 capsules 250 mg (left panels) and 500 mg (right panels), in SGFsp pH 1.2 
(blue), acetate buffer pH 4.5 (green) and phosphate buffer pH 6.8 (red). Three setup 
scenarios were tested: (1) 900 mL, USP II apparatus; (2) 250 mL, USP II apparatus; (3) 50 
mL, mini-paddle apparatus (from top to bottom). Dotted grey lines represent the limit for 






Table 6.3. f2 similarity factor values for the comparison between drug dissolution 
from the test and the reference formulation (f2 ≥ 50 noting similarity; red values: f2 < 
denoting non similarity between profiles). (-) % drug dissolved > 85% within 15 
min. 
f2 value 
Amoxicillin - 250 mg Amoxicillin - 500 mg 




































 - 51.17 51.09 - 63.28 62.40 
 
Prednisolone - 5 mg Prednisolone - 25 mg 





















 - - - 83.83 73.09 81.59 
 
Amlodipine - 5 mg Amlodipine - 10 mg 




































 - - - - - 52.71 
 
For the 500 mg capsules, the amoxicillin products would not qualify for a BCS-
biowaiver under any of the setup conditions tested. Even though similarity was 
shown between the test and reference products (f2 ≥ 50; Table 6.3), the criterion for 
rapid dissolution was not met in any of the setups tested (setup 1 to 3; pH 1.2: all 
products rapidly dissolved; pH 4.5: % drug dissolved within 30 min was less than 85 
%; pH 6.8: drug dissolved within 30 min was less than 85 % under setup 2 and 3 
conditions). Under setup 1 conditions, complete dissolution was achieved in all 
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media pH (100 % drug dissolved reached within 15, 90 and 45 min at pH 1.2, 4.5 
and 6.8, respectively). Under setup 2 conditions, complete dissolution was achieved 
in pH 1.2 and 6.8 media within 10 and 90 min, respectively, but not in pH 4.5 media. 
Under setup 3 conditions, complete dissolution was only achieved in pH 1.2 media, 
at pH 4.5 and 6.8 the maximum % dissolved within 2 h was 60 and 80 %, 
respectively. These results show a clear impact of the pH-drug solubility profile on 
drug dissolution behaviour. Amoxicillin is an amphoteric compound (18); in acidic 
pH it is protonated, in a pH typical of the upper small intestine it exists primarily as a 
zwitterion, and in the distal small intestine (pH 6.5) it will exist both as zwitterion 
and as deprotonated acid. It has been shown to exhibit a pH-dependent, U-shaped 
solubility curve (drug solubility in buffers of pH 1.2, 4.5, and 6.8 was 7.7, 3.6 and 
5.4 mg/mL, respectively) (18). Accordingly, drug dissolution rate was higher at pH 
1.2, which can be correlated with the higher drug solubility in acidic conditions due 
to an increase in the ionisation % of the drug. For the 250 mg products (setup 3) and 
500 mg products (all setups), sink conditions were not achieved during the 
dissolution studies (i.e. having a volume of medium at least three times above the 
volume required to form a saturated drug solution (31)). Sink conditions are critical 
to ensure that reproducible dissolution occurs; however, although these conditions 
are desirable, accordingly to BCS-based biowaiver regulations, they are not 
mandatory and the important is to have a discriminative method (8-10, 31).   
Overall, the 250 mg amoxicillin products tested would fail to meet the in vitro 
dissolution criterion associated with the BCS-based biowaiver requirements in setups 
1 and 3 conditions and would pass in setup 2 conditions. As previously mentioned, 
the difference in outcomes between setup 2 conditions and the other setups is likely 
related to the impact of hydrodynamics.  For the 500 mg amoxicillin capsules, the 
tested products would fail to meet BCS-based biowaiver requirements in all the 
setup scenarios tested.  
Amoxicillin is a broad spectrum, beta-lactam antibiotic, mainly used in an 
ambulatory setting for infections of mild-to-moderate severity (18, 32). Since it has a 
wide therapeutic range (33), the possibility of life-threatening toxic reactions with 
supra-therapeutic doses of amoxicillin is very low. On the other hand, the risk 
associated with subtherapeutic blood levels is unknown; a false-positive biowaiver 
decision, particularly if the products are severely below the accepted level of 
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bioequivalence, could possibly lead to prolongation of illness, and even to the 
development of resistance if the drug content significantly differs from the labelled 
amount (34). In this study, since in setup 1 conditions the products do not exhibit 
rapid dissolution in pH 4.5, then it would not be possible to get a biowaiver for an 
adult formulation. Moreover, since the paediatric population undergoes 
developmental changes (e.g. gastric pH and emptying, intestinal transit time, 
membrane permeability, body water, distribution and metabolism), which may lead 
to a significant alteration of the plasma concentration profile and of key 
bioequivalence parameters (e.g. Cmax and AUC), bioinequivalence risks might be 
increased in this population (12, 35). Consequently, a BCS-based biowaiver status of 
these products could not be applied for administration in paediatrics. 
 
3.2 Prednisolone  





) are presented in Figure 6.4 and f2 similarity factor results are shown 
in Table 6.3. Results of dissolution studies of the 5 mg prednisolone tablets revealed 
that more than 85 % of the labelled amount of prednisolone was dissolved in less 
than 15 min, under all the setup scenarios tested. Under setup 1 and 2 conditions, 
complete dissolution was achieved in pH 1.2 and 6.8 media within 15 min and in pH 
4.5 media within 20 min. Under setup 3 conditions, complete dissolution was 
achieved in all pH within 30 min. Due to having met very rapidly dissolution 





 tablets, in all the setup testing conditions performed. The test product can 
be assumed as therapeutically equivalent to the reference, with no need for in vivo 
bioequivalence studies.  
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Figure 6.4. Mean % prednisolone dissolved (± S.D.) from Pevanti
®
 and prednisolone 
Actavis
®
 tablets 5 mg (left panels) and 25mg (right panels), in SGFsp pH 1.2 (blue), acetate 
buffer pH 4.5 (green) and phosphate buffer pH 6.8 (red). Three setup scenarios were tested: 
(1) 900 mL, USP II apparatus; (2) 250 mL, USP II apparatus; (3) 50 mL, mini-paddle 
apparatus (from top to bottom). Dotted grey lines represent the limit for ‘very rapid 
dissolution’ classification (> 85 % dissolved within 15 min). 
 
For the 25 mg tablets, under setup 1 conditions, complete dissolution was achieved 
in pH 1.2 media within 20 min and in pH 4.5 and 6.8 media within 45 min. 
Comparison of the dissolution studies of the test (Actavis
®





) products showed that following BCS-based dissolution testing conditions, 
biowaiver status would be granted (rapidly dissolved products; f2 ≥ 50; Table 6.3). 
Under setups 2 and 3 dissolution conditions, the products would not qualify for 
biowaiver status. Under setup 2 dissolution conditions, although more than 85 % of 
the labelled drug amount in the dosage form was dissolved in less than 30 min, f2 





) = 47.5 and 38.0, respectively). Under these conditions, 
complete dissolution was achieved within 20 min in pH 1.2 media and within 45 min 
in pH 4.5 and 6.8 media. When testing under setup 3 dissolution conditions (mini-
paddle apparatus, 125 rpm, 50 mL), the test product would not qualify for BCS-
based biowaiver status since rapid dissolution criterion (> 85 % dissolved in less 
than 30 min) was not met, even though f2 analysis revealed similarity between test 
and reference products (f2 > 50; Table 6.3). Sink conditions in dissolution testing of 
both products were not achieved with this dose (25 mg) in 50 mL, as revealed by the 





, respectively).  
Overall, the 5 mg prednisolone products tested would meet the in vitro dissolution 
criterion associated with the BCS-based biowaiver requirements, in all the setup 
conditions tested. For the 25 mg tablets, the products would meet BCS-based 
biowaiver requirements in setup 1 conditions, but not under setup 2 and 3 conditions 
tested.  
According to drug solubility and permeability studies, prednisolone can be classified 
as a BCS Class I drug (19). When calculating the D0 for the 25 mg tablets, 
prednisolone was shown to change solubility class to low solubility in younger age 
groups (Table 6.2). This is reflected in the results obtained when testing the 25 mg 
formulations, under setup 2 and 3 conditions. In this context, formulation bridging 
into paediatrics could result in a false biowaiver decision (i.e. wrongly declaring the 
test formulation bioequivalent to the reference formulation in the paediatric 
population). This could affect the in vivo drug behaviour, resulting in changes in the 
AUC and/or Cmax of the drug. If resulting in a lower AUC, the products might be 
clinically less effective in paediatric patients and/or potentially lead to serious 
clinical consequences when acute treatment is required for severe, life-threatening 
diseases. In this case, as prednisolone is a prescription-only drug, therapy should be 
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periodically reviewed a dose adjustment/ substitution would be required. If the drug 
became supra-bioavailable (i.e. resulted in a higher AUC than intended), the risk of 
toxicity and/or side effects would increase (19, 36). Lastly, if bioinequivalence was 
caused by a difference in Cmax, clinical implications could be expected since 
prednisolone IR tablets are usually used in chronic therapeutic regimes (37). 
 
3.3 Amlodipine  







) and f2 similarity factor results are presented in Figure 6.5 and Table 6.3, 
respectively. For the 5 mg tablets, under setup 1 testing conditions, more than 85 % 
of amlodipine was dissolved within 15 min, in the pH 1.2 and pH 4.5 media. At pH 
6.8, although f2 analysis revealed similarity between the dissolution profiles of the 
tested products in relation to the reference, the criterion for rapid dissolution was not 
met (i.e. 85% of drug dissolution within 30 min). Therefore, the products would not 
qualify for biowaiver status. Complete dissolution was achieved in pH 1.2 and 4.5 
media within 10 min and in pH 6.8 media within 60 min. The lower dissolution rate 
observed at pH 6.8 could be explained by drug characteristics; since amlodipine is a 
weak base (pKa 8.7 (38)), it is affected by changes in pH and exhibits pH-dependent 
solubility (20, 38). Under setups 2 and 3 conditions, more than 85 % of the labelled 
amount of amlodipine was dissolved in less than 15 min. Having met the very 
rapidly dissolution criterion, in vitro equivalence was shown between the test 












 tablets 5 mg (left panels) and 10 mg (right panels), in SGFsp pH 1.2 
(blue), acetate buffer pH 4.5 (green) and phosphate buffer pH 6.8 (red) under three testing 
scenarios. Three setup scenarios were tested: (1) 900 mL, USP II apparatus; (2) 250 mL, 
USP II apparatus; (3) 50 mL, mini-paddle apparatus (from top to bottom). Dotted grey lines 
represent the limit for ‘very rapid dissolution’ classification (≥ 85 % dissolved within 15 
min). 
 
For the 10 mg tablets, under setup 1 (BCS-based dissolution testing) and setup 2 
conditions, % drug dissolved was higher than 85 % under 15 min at pH 1.2 and 4.5, 
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and under 30 min at pH 6.8, for all products tested. Under both setup conditions, 
complete dissolution was achieved within 15 min in media of pH 1.2 and 4.5, and 





 (reference) tablets showed that biowaiver status would be granted 





) = 50.7 and 64.3 for setups 1 and 2, respectively). On the contrary, 
comparison of Sandoz
®
 and reference (Istin
®
) tablets showed that biowaiver status 
would not be granted for the test product (pH 1.2 and 4.5: rapidly dissolved 




) = 48.4 and 40.0 for setups 1 and 2, 
respectively). In the case of the formulations tested (10 mg tablets), dissolution of 
amlodipine could be affected by the excipients used and/or manufacturing methods. 
Since the excipients included in the selected formulations would not be expected to 
affect drug behaviour (Table 6.1), it is more likely that the differences observed in 
drug dissolution from the tested formulations are due to manufacturing methods 
causing variability in the results. Under setup 3 conditions (mini-paddle, 50 mL, 125 
rpm), complete dissolution was achieved in pH 1.2 and 4.5 media within 10 min and 
in pH 6.8 media within 45 min. % drug dissolved was higher than 85 % under 15 
min at pH 1.2 and 4.5, and under 30 min at pH 6.8 for all products tested, and f2 
analysis revealed similarity between all products (pH 1.2 and 4.5: rapidly dissolved 








= 52.7)). Therefore, 
biowaiver status would be granted for all products. 
Overall, results revealed that the 5mg amlodipine tablets tested would fail to meet 
the in vitro dissolution criterion associated with the BCS-based biowaiver 
requirements in setup 1 conditions and would pass in setup 2 and 3 conditions. 







qualify for a BCS-based biowaiver status under all setup scenarios tested, while the 
Sandoz
® 
products would not qualify for a biowaiver status in setup
 
1 and 2 
conditions but would qualify in setup 3 conditions.  
Regarding evaluating patient risks associated with bioinequivalence, a false-positive 
biowaiver decision for amlodipine IR dosage forms could result in subtherapeutic 
plasma concentrations (which may lead to a therapeutic failure) or to concentrations 
above the recommended upper therapeutic concentrations (which may result in 
adverse drug reactions). Amlodipine is indicated for hypertension (38-40). In 
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general, drug dose is individualized depending on the severity of disease, tolerance 
and responsiveness of the patient to the drug (40). In these situations, it is necessary 
to ensure BE of the product, so that the therapeutic outcome from treatment with test 
products could be well predicted during the management of pharmacological 
indications. As far as supra-therapeutic drug levels, mild to moderate side effects 
have been reported (40). Patient risks associated with the sub-therapeutic levels pose 
more serious consequences because of therapeutic insufficiency; these can be 
exacerbated in very young age groups as a recent study has shown that amlodipine 
dosing has a significant inverse relationship with patient age, with the youngest 
children requiring the highest doses of amlodipine (39). 
 
3.4 Risk assessment of extending BCS-based biowaiver criteria into 
paediatrics 
A summary of the results obtained in this study and of whether the biowaiver status 
(as currently defined) would be granted in each situation is presented in Figure 6.6. 







) would qualify for a biowaiver status, under all 
setup scenarios tested. In view of these results, it seems clear that extrapolation of 
the BCS-based biowaiver criteria into paediatrics is not straightforward and cannot 











Figure 6.6. Risk assessment of extending the biowaiver for IR formulations of 3 model compounds from the adult to the paediatric population. (N/A: not 




When analysing the risk of extending BCS-based biowaiver testing criteria into 
products for the paediatric population, it is important to consider the factors that 
would affect BCS-based biowaiver decisions and the relevance of the criteria within 
the paediatric population. BCS-based biowaiver decisions are allowed for highly 
soluble drugs, which are expected to exhibit fast dissolution rates. Currently, drugs 
are classified as highly soluble if the highest dose strength is soluble in at least 250 
mL of aqueous liquid at a relevant physiological pH range of 1.2 – 6.8, however 
these aspects concern adult physiology. Age-related changes in anatomy and 
physiology will impact the classification of drug solubility and permeability 
properties within the different paediatric subpopulations. Several issues arise 
regarding drug solubility classification amongst the paediatric population, including 
the definition of the highest single dose, the initial gastric volume, and the luminal 
solubility of the drug. Moreover, with respect to drug permeability classification, 
drugs are classified as highly permeable when the extent of oral absorption (i.e. 
fraction of dose absorbed) is greater than 85 % of the administered dose. However, 
using adult permeability data for paediatric subjects is controversial and information 
regarding permeability in younger paediatric subgroups is still lacking, which has 
hindered the establishment of meaningful permeability criteria for this population. 
Thus, a drug that exhibits a high dose/solubility ratio in adults (i.e. highly soluble 
drug) might not show the same ratio in paediatric patients, and unfavourably shift 
into poorly soluble classification. In this study, except for the case of prednisolone in 
a dose of 5 mg, the chosen model compounds selected would change from high drug 
solubility classification in adults to low drug solubility class in paediatric age groups 
(D0 > 1; Table 6.2). These drugs would not be eligible for BCS-based biowaiver 
status, as the solubility criterion was not satisfied. In this context, a p-BCS approach 
could provide a simplistic tool to help understand possible age-related physiological 
and/or anatomical changes in oral drug performance, and identify risks associated 
with a change in BCS class of a compound and eligibility for BCS-based biowaivers 
for paediatric products.  
Regarding testing methodology, dissolution testing with USP I/II apparatus is 
commonly used to define the classification of a drug when rapid dissolution across a 
pH range is required (which is the case for BCS-based biowaivers). The basis of this 
approach is that the dosage form is agitated at a fixed rate within a fixed media 
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volume, representative of the GI environment. Some limitations associated with this 
apparatus have been reported, including the impossibility of using small testing 
volumes (26, 41). This is of importance as the fluid volumes available in the GI tract 
of younger age groups are smaller than adults (35). In the present study, an 
adaptation of standard USP II apparatus to a mini-paddle apparatus was tested as an 
appropriate method to address the need for small volume testing. The mini-paddle 
apparatus is already commonly used when screening for critical quality attributes of 
rapid dissolving tablets, in cases where it is difficult to detect differences using 
standard working conditions (41). Regarding agitation rate criterion, rates of 50 and 
100 rpm have been defined for paddle and basket apparatus, respectively (1, 8, 14). 
A direct extrapolation was made from the agitation rates set for the USP II apparatus 
(50 or 75 rpm) to the mini-paddle following a speed factor, which allowed the 
maintenance of discriminatory conditions.  
The dissolution media volume was considered in this study and its effect on drug 
dissolution was evaluated by comparison of different setup conditions. Since there is 
currently no guidance on appropriate volumes to use within paediatric dissolution 
testing, a direct extrapolation from the adult value of 250 mL utilised in USP II 
dissolution was conducted for the mini-paddle apparatus (50 mL; setup 3). As 
previously mentioned, an important factor in BCS-style bridging is that dissolution 
rate of paediatric medicines needs to be rapid to ensure adequate exposure in this 
population and guarantee that GI transit dictates drug absorption rather that drug 
dissolution. In this context, BCS-based biowaiver would be granted for the 5 mg 







all the amoxicillin products (250 and 500 mg), the lowest dose amlodipine products 
and the highest dose products of prednisolone would fail to be classified as rapidly 
dissolved. In the case of the amlodipine 5 mg tablets, the products would fail the 
criterion of rapid dissolution under setup 1 conditions (current requirements for 
BCS-based biowaivers) due to slow dissolution in pH 6.8 but would pass when the 
volume was scaled down (setups 2 and 3). In the case of the prednisolone 25 mg 
tablets, the products would meet the criterion of rapid dissolution under setup 1 
conditions (current requirements for BCS-based biowaivers), but would fail when 
the volume was scaled down, likely due to the solubility of the drug.   
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The time limits set to define rapid dissolution criteria might also affect the biowaiver 
status, as subsequent analysis of the dissolution profiles differs accordingly. For 
example, in the present study it was shown that when the products did not meet the 
criteria for very rapidly or rapidly dissolving products, it was because both the test 
and reference products did not exhibit fast dissolution and not due to dissimilarity 
between profiles (except for the case of the Sandoz
®
 amlodipine 10 mg tablets). This 
could indicate that the time frame for rapid drug dissolution should be further 
evaluated, and potentially refined when considering the paediatric population. A 
minimum of 50 % of drug release within 15 min has been recently suggested to 
support a biowaiver decision for paediatric formulations (21). With this criterion, the 
formulations studied in mini-paddle setup would be considered as rapidly dissolved, 
except for the case of amoxicillin 500 mg capsules for which drug dissolution was 
shown to be limited by drug solubility. Nevertheless, the scientific basis for such 
alterations regarding the most appropriate time frames for evaluating dissolution 
rates, would need to be further evaluated. 
Overall, the risk of using the BCS adult classification in paediatric drug development 
lies in shifts in BCS classification of drugs due to growth and maturation of 
paediatric subpopulations. Results from this study reveal the need for the 
development and establishment of a p-BCS, as a simplistic tool to help understand 
possible changes in oral drug performance in the paediatric population. The 
development and establishment of a p-BCS could meaningfully impact the paediatric 
biopharmaceutical field and guide the production of age-appropriate medicines and 
facilitate formulation bridging. While such a tool remains to be developed, 
extrapolation of the adult BCS classification should be performed with care.  
 
4. Conclusions 
The use of BCS-based biowaivers for paediatric products needs to be undertaken 
with caution due to differences in the drug D0 between adults and paediatrics.  
In this study, the risk of directly extrapolating BCS-based criteria into paediatrics 
was assessed. A dissolution setup potentially representative of the paediatric 
population in terms of the lower volumes required was tested (setup 3), with the 
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criteria limits used in BCS-based biowaiver guidance being applied for product 
evaluation/risk assessment. Results revealed that only the 5 mg prednisolone and the 






) would qualify for a 
biowaiver status, under all setup scenarios tested. Thus, it was shown that a simple 
scaling down of the dissolution testing volume stipulated on BCS‐based biowaiver 
dissolution criteria may not be adequate for paediatric products. Knowledge of the 
solubility classification of a drug across different age groups would assist on 
assessing the development of a biowaiver as BE testing surrogate in the different age 
groups. Therefore, a consensus on a p-BCS needs to be reached and should address 
the heterogeneity of the paediatric population.  
Overall, the establishment of a p-BCS would contribute to formulation bridging (e.g. 
surrogate the need for future clinical BE testing) and risk assessment decisions, thus 
promoting paediatric drug development. This would result in a smaller discrepancy 
between technologies available for the different age groups and provide better 
support for the development and testing of age-appropriate medicines, ultimately 
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Conclusions and future directions 
Conclusions 
Development of oral medicines for young patients is more challenging than for 
adults. Despite the increased effort put into improving the safety and effectiveness of 
paediatric medicines, formulation development is hindered by ethical considerations 
and technical constraints including physiological and anatomical changes. The tools 
currently used to undertake biopharmaceutical risk assessment of paediatric 
formulations are based on adult tests, addressing adult physiology and anatomy. 
Consequently, paediatric medicines are not always age-appropriate, leading to 
problems with dosing, acceptability and adherence.  
In this project, research was conducted towards the development of in vitro 
predictive tools, to aid understanding of formulation performance and facilitate 
bridging in paediatrics. An emphasis was placed on co-administration of medicines 
with food and drinks (vehicles), and on a potential extension of Biopharmaceutical 
Classification System (BCS)-based biowaiver criteria into paediatric products. 
Mixing oral dosage forms with food and drinks was revealed to be a common 
practice to facilitate paediatric medicine administration in order to improve 
palatability and enhance patient compliance. However, studies often fail to assess its 
impact on drug bioavailability, safety and efficacy. To reduce the need for 
manipulation and co-administration of medicines with vehicles, continuous efforts 
should be made towards developing age-appropriate medicines, whilst providing 
dosing flexibility and acceptable taste. Nevertheless, since this remains the most 
practiced strategy for paediatric oral administration, more elaborate and explicit 
information regarding vehicle suitability is warranted. In this context, the use of in 
vitro biopharmaceutical techniques to guide vehicle selection and assessment and 
predict in vivo performance in the paediatric population, could help understand the 
possible clinical outcomes associated with this practice, whilst allowing the 
availability of information for appropriate vehicle decisions. 
First, a statistical model was developed which provided an understanding on which 




Commonly recommended vehicles for medicine co-administration were then 
selected, and their physicochemical properties were studied, with differences 
observed not only among vehicle type, but also within vehicles of the same subtype. 
Solubility studies of two model compounds in commonly used vehicles was shown 
to be significantly affected by the physicochemical properties (pH, osmolality, buffer 
capacity, surface tension and viscosity) and macronutrient composition (percentage 
of fat, sugars and protein) of the vehicles.  
Age-appropriate in vitro dissolution tests were to predict the impact of different 
administration practices of medicine co-administration with vehicles on drug 
behaviour. An in vitro dissolution testing setup under infant simulating conditions 
was developed, which could be used to evaluate drug dissolution, whilst addressing 
typical dosing conditions (e.g. co-administration with vehicles) and allowing the 
investigation of factors that could affect drug dissolution. Drug dissolution was 
shown to be significantly affected by medicine co-administration with vehicles, in 
comparison to the scenario of direct administration of formulation, and the time 
between preparation and testing of the drug-vehicle mixture. Prior knowledge of the 
properties of the vehicles was shown to be useful towards predicting their possible 
impact on drug behaviour. To predict in vivo formulation performance, paediatric 
biorelevant media was used in combination with the in vitro dissolution setup 
developed. The biorelevant in vitro dissolution test predicted the in vivo drug product 
performance in infant subgroups. Additionally, it was revealed that the practice of 
medicine co-administration with food and drinks might trigger fed state conditions in 
vivo. Ultimately, the potential of physiologically relevant dissolution studies with 
mini-paddle to mimic paediatric administration practices and predict drug 
performance was highlighted. 
The use of BCS-based biowaivers in paediatrics was also investigated. A simple 
extension of current biowaiver criteria into the paediatric population was shown not 
to be feasible. Moreover, a discussion of factors that hinder the establishment of a 
paediatric-BCS in paediatrics identified knowledge gaps regarding the paediatric 




Overall, work was conducted towards identifying the areas where further 
information is needed to support knowledge around the paediatric biopharmaceutical 
field. It was demonstrated that the biopharmaceutical basis for the recommendation 
of co-administration of paediatric medicines with vehicles should be considered 
during administration practices and formulation testing, mainly due to the possible 
negative therapeutic outcomes. The need for unified mandatory guidelines on 
paediatric administration practices, including appropriate training of parents, carers 
and healthcare professionals and assessment methodologies, was emphasised and 
should be regulatory priority. Ultimately, it was shown that in vitro 
biopharmaceutical tools for investigation of drug product performance in paediatrics 
need further development, refinement and validation, which is still hindered by 
knowledge gaps and ethical and technical constraints. In this context, a combination 
of in vitro and in silico methods would be a stronger approach to ensure the 
prediction of paediatric drug product performance, having the potential to largely 
overcome the need to conduct in vivo research in this population. 
We developed in vitro age-appropriate predictive tools to aid understanding of 
formulation performance in paediatrics. Our emphasis was on the impact of medicine 
co-administration with food/drinks and age-related factors on in vitro drug 
behaviour. We showed that knowledge of the composition and physiochemistry of 
food/drinks in combination with drug/formulation properties can appropriately guide 
their selection for medicine co-administration. In vitro testing can be used to predict 
the impact of different medicine co-administration practices on drug behaviour. 
Ultimately, these tools could be used to predict in vivo clinical outcomes. 
 
Future directions 
In this thesis, age-appropriate biopharmaceutical tools were defined in order to 
predict the impact of administration practices on drug product behaviour. 
Commonly reported techniques of medicine co-administration with vehicles revealed 
the need for a unified mandatory regulation on administration practices, vehicle 
selection and assessment. This involves better training of healthcare professionals, 
and consequently patients, parents and carers, on the possible clinical outcomes of 
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this practice, supported by globally available platforms and unified databases. 
Initiatives such as the pan-European formulary are crucial, however further work 
should be conducted towards including information on this practice in these 
emerging platforms to better support paediatric pharmacotherapy. 
In this project, a statistical model was developed which provided an understanding 
on which vehicle is recommended for use with drugs/formulations, with basis on 
their biopharmaceutical properties. This is a first approach towards generating 
awareness and discussion concerning co-administration practices of paediatric 
medicines, within the clinical and scientific communities. In the future, it would be 
useful to include information from other formularies not included to further refine 
and validate the model constructed. 
Future experiments with different drugs and formulations (namely, of different BCS 
class, solubility, pKa, logP) would be valuable towards revealing the extent of the 
vehicle-impact on formulation performance. When combined with the 
physicochemical properties and composition of the vehicles, these could 
consequently be used to develop and establish a regulatory framework to guide 
administration practices, vehicle selection and assessment, and predict potential food 
effects. In addition, vehicles from the same subtype and different countries should be 
evaluated to expand the database created in Chapter 3. Ultimately, this would 
provide a useful tool for guidance both during paediatric formulation development 
and in clinical settings. The impact of co-administration with food/drinks on the 
solubility of a wide range of drugs should be assessed in order to develop a roadmap 
which could be used as a risk assessment tool for paediatric drug clinical studies and 
administration practices. 
In vitro dissolution testing conditions that predict the in vivo performance are 
advantageous, especially for the paediatric population for which clinical testing is 
hindered by ethical and technical considerations. In this project, the factors that 
could affect drug dissolution were investigated and related to the in vivo drug 
performance. Overall, it is recognised that a deeper knowledge of the paediatric GI 
environment is still lacking and would assist in refining the predictive 
biopharmaceutical tools needed to appropriately evaluate formulation performance 
across age groups.  
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Regarding the applicability of BCS-based biowaiver criteria into paediatrics, it is 
evident that a consensus on a paediatric BCS needs to be reached and should address 
the heterogeneity of the paediatric population and the possible risks of 
bioinequivalence in vulnerable paediatric populations. 
Future work is needed towards conducting clinical studies in paediatric patients in 
order to obtain more complete information on paediatric biopharmaceutics. This 
work should evaluate pharmacokinetics (PK), pharmacodynamics (PD), side effects 
and acceptance of medicines. Future studies should be performed simulating closely 
the conditions in which patients receive therapy, including practices of medicine co-
administration with food and drinks. In addition, although the in vitro dissolution 
approaches described in this study have the potential to provide an alternative to 
clinical paediatric studies, especially after refinement, a combination of in vitro and 
in silico methods would be a stronger approach to ensure the prediction of paediatric 
drug product behaviour. In this context, the development of more complex in silico 
models for this population, such as physiologically based pharmacokinetic (PBPK) 






















Solution, Tablet Weak base 1.21   X food  
Abacavir and 
Lamivudine 












Tablet Amphoteric 108.0   X meal  


















Acetylcysteine I (4) Solution Weak acid 5.09 
X cola, orange 
juice, or other 
soft drink 

























Tablet  Amphoteric 2.02   X food*  
Albendazole II (3) Tablet  Amphoteric  0.0228   X food*  
Albuterol I (3) Syrup, Tablet Amphoteric  -   X food*  
Alcohol (ethyl) - Ampoule Neutral  - X water, juice    

















Tablets Weak base 1.22 X milk  X food  
Aminocaproic Acid - 
Solution, Tablet, 
Syrup  
Amphoteric  505   X food*  
Amiodarone II (7) Tablet  Weak base 0.00476   X meal 
Do not administer with 
grapefruit juice 
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Drinks Soft foods Others 
Amoxicillin and 
clavunate 
- Tablet, Suspension - - 
X formula, 
milk, juice 




Tablet, Suspension Weak base 1.74   X food*  




Capsule  - 0.0194   X food*  






Amphoteric  0.00777 X liquid    
Artemether and 
lumefantrine 
- Tablet - - X water  X meal 
Crush tablet and mix with 
water, followed with food, 
milk, formula, pudding, 














Powder Amphoteric  0.00327 X beverage
1




e.g. milk, water, formula 
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Tablet  Weak base  13.3   X food  
Atomoxetine I (3) Capsule Weak base 0.0039 
X water, 
liquids 
 X food  
Atorvastatin II (3) Tablet  Weak acid 0.00063   X food  
















Drinks Soft foods Others 
Auranofin - Capsule  - 0.151   X food  
Azithromycin II (7) Tablet  Weak base  0.514   X food  
Baclofen - Tablet Amphoteric 0.712 X milk  X food  
Balsalazide - Capsule, Tablet Weak acid 0.0621  
X applesauce 
(capsule) 
X food  
Benazepril I (3) Tablet  Amphoteric 0.0022   X food  
Benztropine  - Tablet  Weak base 0.0012   X food  
Betaine - Powder  Weak base 1.56   X food  
Biotin - Capsule, Tablet Weak acid 0.22   X food  
Bosentan - Tablet Amphoteric 0.00904 
X non-acidic 
liquid 
 X meal 
Avoid grapefruit and 
grapefruit juice 
Brivaracetam - Tablet Amphoteric 46.8 X liquid   X food  
Bromocriptine - Capsule, Tablet Amphoteric  0.0858   X food*  
Budesonide II (4) Capsule Neutral 0.0457  
X applesauce 
(capsule) 
X meals  
Bumetanide - Tablet Amphoteric 0.0257   X food*  
Bupropion I (3) Tablet  Weak base 312   X meal  
Buspirone I (3) Tablet Weak base 0.588   X food*  




- Tablet, Capsule  - -   X food  
Caffeine  I (12) Solution, Tablet Neutral  21.6   X meal  
















Drinks Soft foods Others 
Calcium acetate - Capsule, Tablet - 147 X fluids   X meal  
Calcium carbonate - 
Capsule, Tablet, 
Suspension 
- 128 X fluids   X meal  
Calcium citrate - 
Capsule, Tablet, 
Suspension 
- 4.12 X fluids  X food   
Calcium glubionate - Syrup - 47.2 X fluids   X meal  
Calcium gluconate - Capsule, Tablet - 44.2 X fluids   X meal  
Calcium lactate - Capsule, Tablet  - 191 X fluids   X meal  
Candesartan  II (3) Tablet  Amphoteric  0.00667   X meal  
Carbamazepine II (3) 
Chew tablet, 
suspension, Tablet 
ER, Capsule ER 








X food, meal* 
(tablet) 
1
 e.g. applesauce 







Castor oil - Oil (discontinued) - - 
X milk, juice, 
carbonated 
beverage 


















Weak acid 0.0878   X food*  






































Tablet, Suspension  Weak acid  0.284   X food   
Celecoxib II (3) Capsule  Weak acid  0.00503  X applesauce 
X food (doses 













Amphoteric  0.101   X food  
Charcoal, activated - 
Liquid, 
Suspension 
- 0.0 X orange juice   
X chocolate 
syrup 
Avoid adding chemicals, 
dairy products, syrups 
(Actidose) 
Chenodiol  - Tablet  Weak acid 0.0899   X food  
Chloral hydrate - 
Capsule 
(discontinued) 
Weak acid  43.4 
X water, fruit 
juice, ginger 
ale, formula 
   
























Tablet, Suspension Weak acid 0.398   X food  
Chlorpheniramine I (3) 
Liquid, Tablet, 
suspension 
Weak base 0.0519   X food  
Chlorpromazine II (3) Solution, Tablet  Weak base 0.00417 X water, milk  X food  
Chlorthalidone - Tablet  Weak acid  0.0528   X food  
Chlorzoxazone - Tablet  Weak acid 2.96   X food  
Cholecalciferol  - 
Capsule, Liquid, 
Tablet  
Neutral  0.00038   X food  
Choline magnesium 
trisalicylate 
- Tablet, Liquid  - - 
X milk, fruit 
juice 








Tablet, Suspension Amphoteric  1.35   X food* 
Dairy foods reduce 
absorption 
Citalopram  I (3) Tablet, Solution  Weak base  0.0059   X meal  
Clarithromycin  II (3) Tablet, Suspension Weak base  0.0003   X meal, food  
Clemastine - Tablet, Syrup  Weak base  0.0004   X food  
Clindamycin  I (4) Solution, Capsule  Amphoteric  0.031   X meal  
Clobazam - Tablet  Neutral  0.164  X applesauce    
Clomipramine I (17) Capsule  Weak base  0.014   
X food, cherry 
syrup* 
 






















Drinks Soft foods Others 
Clopidogrel  II (3) Tablet  Weak base 0.051   X food  
Clorazepate - Tablet  Amphoteric  0.025   X food  








Tablet, Capsule  Neutral  45   X meal  
Colesevelam - Granules, Tablet  - Insoluble 
X liquid 
(tablet) 
 X meal  










 e.g. pineapple, peaches, 
pears
 
Cortisone - Tablet  Weak acid 
0.0278 
(acetate) 





Liquid, Tablet  - 12.5   X food 
 
Cycloserine  - Capsule  Amphoteric  877   X meal 
 
Cyclosporine II (4) Solution Weak acid  - 
X milk, 
chocolate milk, 
orange or apple 
juice 
   
Danazol - Capsule  Amphoteric  0.0176   X fatty meal  
Dantrolene - Capsule  Weak acid  0.0805 
X juice or 
liquid 
   
Darunavir - Tablet  - 0.0668   X food 
If co-administered with 
















Drinks Soft foods Others 
Deferasirox II (4) Tablet  - 0.0343 
X water, other 
liquids 
   
Desipramine - Tablet  Weak base  0.0396   X food*  




Tablet, Solution  Weak acid  0.0505 X milk   X food, syrup  
Dexchlor-
pheniramine  
- Syrup  - 0.0519   X food  
Dexmethylphenidate - Capsule (ER) - 0.182  
X applesauce 
(ER) 
X food  
Dextroamphetamine 
and amphetamine 









Weak base  0.00851   X meal  
Diazepam II (3) Tablet, Solution  Weak base  0.0122   X food, water  
Diclofenac II (3) Tablet, Capsule  Weak acid  0.00447 X milk  X food*  




Dimenhydrinate - Tablet  Weak base  0.00125   X food  
Diphenhydramine - 
Capsule, Solution, 
Syrup, Liquid  
Weak base 0.0752   X meal  
Diphenoxylate and 
atropine 
- Tablet, Solution  - -   X food*  
         
















Drinks Soft foods Others 
Docusate - Liquid, Syrup  Weak acid  - 
X milk, fruit 
juice, formula 
   




 X food (tablet)  
Doxazosin I (3) Tablet  Weak base 0.79   X food, meal   
Doxepin I (19) Solution  Weak base  0.0319 













Amphoteric  0.63 





X food*  
Dronabinol  - Capsule  - 2.8   X meal  

















- Tablet - -   X food  






























- Tablet - -   
X meal (> 500 
kcal) 
 
Enalapril  I (3) Tablet, Solution  Amphoteric  16.4   X food  






Neutral 0.05   X meal  
Ergotamine  I (21) Sublingual tablet  Amphoteric 0.223   X meal  
Ergotamine and 
caffeine 
- Tablet  - -   X meal  
Escitalopram  I (22) Solution, Tablet  - 0.00588   X food  
Esomeprazole - Capsule  Amphoteric  0.353  X applesauce   
Estradiol I (13) Tablet Weak acid  0.0213   X food, meal*  
Estrogens - Tablet Weak acid  -   X food*  




Tablet Weak base  7.58 X apple juice X applesauce X food 
Do not mix with other juices 
or syrups (not stable) 






















Weak acid  101 X milk  X food*  
Etodolac II (7) Capsule, Tablet Weak acid  0.0392   X food*  
Etoposide II (7) Ampoule Weak acid  0.978 
X orange or 
apple juice, 
lemonade 
   
Etravirine - Tablet - 0.0169 
X water, milk, 
orange juice 
 X meal 
Not grapefruit juice or 
carbonated beverages 
Everolimus  IV(3) Tablet  - 0.00163   X food  
Ezetimibe  II (3) Tablet  Neutral  0.00846   X meal  
Ezetimibe and 
Simvastatin 




















Felbamate  II (7) Tablet, Suspension Weak base 0.742   X meal  
Felodipine II (7) Tablet Weak base  0.00715   X light meal  
Ferrous gluconate - Tablet - - X water, juice  X food* 
Do not administer with milk 
products 
Ferrous sulfate - 
Tablet, Syrup, 
Solution  
- - X water, juice  X food* 
Do not administer with milk 
or milk products 
Fexofenadine I (3) Tablet, Suspension Amphoteric  0.00266   X food 

















Drinks Soft foods Others 
Flecainide I (22) Tablet Amphoteric  0.0324   X food  
Avoid administration with 




Tablet, Suspension Weak base 0.001   X meal  
Fluoxetine  I (3) 
Capsule, Tablet, 
Solution  
Weak base  50   X food  
Flurazepam  - Capsule  Weak base 500   X meal  







Capsule, Tablet  Weak acid 0.00046   X meal  




Capsule, Tablet  Amphoteric  0.0016   X meal  
Fosamprenavir II (4) Tablet, Suspension Amphoteric  0.685   X food* 
*food in paediatric patients 
and no food in adults 
(suspension) 














e.g. orange juice  
2
e.g. applesauce 
Glycopyrrolate  - Tablet  Weak base 0.000944   X meal  
Guaifenesin - Tablet, Liquid  Neutral  14.9 
X fluid (large 
amount) 
   























X fluid (large 
amount) 







X fluid (large 
amount) 
   
Haloperidol II (3) Tablet, Solution  Amphoteric  0.00446 
X water, acidic 
beverage,  
milk* 















- - X milk  X food*  
Hydrocodone and 
chlorpheniramine  
- Capsule - -   X meal  
Hydrocortisone - Tablet Neutral  0.199 X milk  X food*  
Hydromorphone - Capsule  Amphoteric  4.39 X milk (IR)  X food (IR)*  
Hydroxyzine  II (3) 
Tablet, Capsule, 
Solution, Syrup 





- Tablet   - -   X meal  
Ibuprofen II (3) 
Tablet, Capsule, 
Suspension 
Weak acid  0.0684 X milk  X food*  
















Drinks Soft foods Others 
Imatinib II (4) Tablet  Weak base  0.0146 




 X meal 
1
50 mL -100 mg tablet 
200 mL -400 mg tablet 




Capsule  Amphoteric  0.015 
X water, 
liquids
1  X light snack
2 
1




 e.g. dry jelly toast, 
cornflakes w/ skim milk 
Indomethacin II (7) 
Capsule, 
Suspension 








Irbesartan II (3) Capsule  Amphoteric  0.00884  
X applesauce 
(capsules) 
X food  
Irinotecan - Ampoule Amphoteric  0.11 
X cranberry 
grape juice 
   
Isotretinoin II (3) Capsule Weak acid  0.00477 X liquid  X meal  
Isradipine - Capsule, Tablet  Weak base  0.23   X meal  
Itraconazole II (3) Capsule  Weak base  0.00964   X food  
Ivacaftor - Granules - 0.002 




   
1
e.g. pureed fruit/vegetable, 
applesauce, yoghurt  
Mix should be consumed 
within 1 hour 
Ketamine I (27) Ampoule Weak base  0.046 
X cola, cherry 
juice, other 
beverages 
   
















Drinks Soft foods Others 
Ketoconazole II (7) Tablet Weak base  8.66*10






e.g. soda pop 
Ketorolac I (19) Tablet Weak acid  2.5 (salt) X milk  X food*  
Labetalol I (13) Tablet Amphoteric  0.117   
X meal, cherry 
syrup 
 
Lacosamide  I (28) Solution, Tablet  - 0.465   X food  
Lactobacillus - 
Granules, 
Capsules, Powder  
-  - 
X milk, fruit 
juice, water 
 X cereal, food  
Lactulose II (4) Solution  Weak acid  792 
X milk, fruit 
juice, water 




Tablet  Weak base  70   X meal   
Lamivudine and 
Zidovudine 
- Tablet  - -   X meal  




 X meals  
Lansoprazole II (7) Capsule  Amphoteric  0.00097 






















Tablet Neutral  298 X liquid    
















Drinks Soft foods Others 
Levocarnitine - Solution  Amphoteric  2500 
X beverages, 
liquid food 




Tablet, Solution  Amphoteric  0.0658   X food  
Levofloxacin  I (3) Tablet  Amphoteric  1.44   X food  
Levothyroxine I (3) Tablet Amphoteric  0.105 











Tablet, Suspension Amphoteric  3   X food  




Tablet  Amphoteric  97   X food  




Weak acid  -   X meal*  
Lopinavir and 
ritonavir 
- Tablet, Solution  - -   X food
1 
1
Adm with sweet foods, 
chocolate syrup, or peanut 





Syrup, Solution  
Weak base  0.000011   X meal  
Lorazepam I (22) Solution  Amphoteric  0.08 




  X food* 
1
 e.g. applesauce, pudding 
Losartan  I (13) Tablet  Amphoteric  0.00082   X food  
       





















- Granules  - - X water, juice    




Tablet  Weak base 0.00883   X meal  




Tablet Weak base  0.001   X food*  
Medium chain 
triglycerides 
- Emulsion oil - - 












Tablet Neutral  0.0021   X food  
Mefloquine II (4) Tablet Amphoteric  0.038 















Weak acid 0.00715 X milk  X food*  




Capsule  Amphoteric  0.84  




X food with a 








Tablet Weak base  1.38   X meal*  

















Drinks Soft foods Others 
Methadone I (31) Tablet, Solution  Weak base  0.0059 X juice, water    









Tablet  Amphoteric  10   X food  
Methylphenidate I (4) Tablet, Capsule  Weak base  1.25 
X water, milk 
or juice 















Methylprednisolone - Tablet Weak acid  0.120 X milk  X food Not grapefruit juice 



























X food*  
Mexiletine I (3) Capsule  Weak base  8.25 X milk  X food*  




Tablet  Weak base 2.2   X food  
Mitotane - Tablet Neutral  0.0001   
X MCT oil, 
then solution 
























Tablet Neutral 0.622   X food  















 a spoonful 
Cold or at room temp. 




Tablet Weak base  8.33   X meal  




Nefazodone  - Tablet Weak base  0.0698   X food  
Nelfinavir II (3) Tablet Amphoteric  0.00191   X food  
Neostigmine  I (3) Tablet Weak base 0.0677   X food  
Nevirapine II (3) Tablet Weak base 0.0007 
X milk, water 
or soda (IR) 






Amphoteric  18 X milk  
X food*, low 
fat snack 
 
Nicardipine I (3) Capsule  Weak base  0.0022   X meals Avoid high fat meals 
Nifedipine II (3) Capsule  Weak base  0.0177   X food  
Nitisinone - Capsule  Weak acid  0.00811 
X water, 
formula 









 X food  





































Do not administer or mix 
with apple juice 
Norethindrone I (3) Tablet Neutral  0.0069   X food  
Nortriptyline I (22) Capsule, Solution  Weak base  0.00087   X food  




Tablet Weak base 0.0105   X food  
Omeprazole II (4) Capsule  Amphoteric  0.359  X applesauce   
Ondansetron I (3) Tablet, Solution  Weak base  0.248   



















e.g. chocolate syrup, corn 
syrup, caramel topping, light 
brown sugar dissolved in 
water 




Tablet, Suspension Neutral  0.308   X meal  
Oxybutynin I (3) 
Tablet, Syrup,  
Capsule  
Amphoteric  0.01 
X liquid 
(capsules) 




























- - X milk  X food*  
Oxycodone and 
aspirin 




Tablet Weak base  0.297 
X liquids (ER 
tablets) 
   
Pancrelipase - Tablet, Capsule   - 1 
X liquid, 






X snacks, meal 
1
e.g. applesauce, prepared 
baby food 
 
Infants: avoid mixing with 





suspension (DR) Amphoteric  0.495 X apple juice
1







Do not administer with other 
liquids or foods 
Paricalcitol - Capsule  Neutral  0.0068   X food  
Paromomycin - Capsule  Amphoteric  79.7   X meal  
Paroxetine I (3) 
Capsule, Tablet, 
suspension 




Capsule  Amphoteric  111 X fruit juice 







Tablet, Solution  Weak acid  0.454   X food*  
Pentobarbital - Ampoule Weak acid  6.78   X cherry syrup  
Pentoxifylline - Tablet Neutral  77   
X food or 
antacids* 
 
Perampanel - Tablet, Suspension - 0.0056   X meal  
















Drinks Soft foods Others 
Phenazopyridine II (7) Tablet Weak base  0.202   X food*  
Phenobarbital I (19)  Solution Weak acid  1.1 
X water, milk 
or juice 
   
Phenoxybenzamine - Capsule  Weak base 0.0103 X milk*    
Phenytoin  II (3) Capsule (ER) Weak acid 0.032   X meal  
Phytonadione  - Tablet Neutral 5.92e05   X food  
Pimozide  II (3) Tablet Amphoteric 0.01   X meal  




Tablet Amphoteric  0.012   
X food (DR 
tablets) 
 





















and citric acid 
- Powder - - 






at least 6 ounces 


























- Solution  - - 
X water, fruit 
juice or milk 































Tablet Weak acid 0.242   X meal  
Prazosin  I (26) Capsule  Weak base 0.5   X meal  
Prednisolone I (35) 
Tablet, Solution, 
Suspension 
Weak acid  0.223 X milk  X food, meal*  
Prednisone I (36) Tablet, Solution  Weak acid  0.111 X milk  X food*  
Primaquine I (21) Tablet Weak base  0.0564   X food*  
Primidone II (7) Tablet Weak acid  0.5   X food*  




Tablet Weak base 0.015 X water  X food  
Promethazine I (26) 
Tablet, Syrup, 
Solution  
Weak base  0.0156 X milk, water  X food*  
Promethazine and 
phenylephrine 




- Syrup  - - X water  X food*  
Propranolol I (3) Solution, Capsule  Neutral  0.0617 
X water, fruit 
juice, liquid 
(oral solution) 
X semi solid 
food (oral 
solution) 
X food (ER 
capsules)  
 
Protriptyline - Tablet Weak base  0.00104   X food* 



























Tablet, Capsule  
- -   X food  
Psyllium - Granules, Powder - - 
X water or 
juice
1   
1 
8 ounces 
Pyrantel pamoate - Tablet Weak acid  0.118 
X milk or fruit 
juice 








Tablet Weak base  0.121   X meal  
Quetiapine II (3) Tablet Weak base  0.0403   X light meal   
Quinapril  I (3) Tablet  Amphoteric  0.001   X food  













Capsule Amphoteric  0.336 X liquid  X  
1 
e.g. formula, apple juice, 
paediatric electrolyte solution 
(small amount) 
2 
e.g. applesauce, fruit or 
vegetable-based baby food, 




Tablet  Weak acid -   X meal  


























Tablet, Capsule,  
Solution  
Neutral  33.2   X food  




Capsule  Amphoteric  0.19  X applesauce   







Tablet  Amphoteric  0.00738   X food  




  X food  


















Other techniques: dulling the 
taste buds by chewing ice, 
giving popsicles of partially 
frozen orange or grapefruit 
concentrates, coating the 
mouth with peanut butter, 
administration of strong-
tasting foods immediately 
after a dose. 
















Drinks Soft foods Others 








Tablet  Neutral  0.642   X food  
Sacrosidase - Solution  - - 
X water, milk, 
formula 








X water, apple 
juice, formula 
X (powder)  
2
applesauce or pudding 
(small amount) 
Saquinavir I (3) Capsule  Amphoteric  0.00765  X jam





 15 mL 
Senna - Syrup - - X juice or milk X ice cream   








Do not administer with 
grapefruit juice 
 













Tablet  Neutral  0.0122   X meal  


















Drinks Soft foods Others 
Sirolimus II (4) Solution  Weak acid  0.00173 
X water, 
orange juice 
   
Sodium 
phenylbutyrate 
- Powder  - 18 X  
X food, meal 
or feeding 
Avoid mixing with acidic 
beverages  
Sodium phosphate - Tablet - 121 X clear liquids
1
   
1 
water, flavoured water, 
pulp-free lemonade, ginger 
ale or apple juice (8 ounces) 
Sodium polystyrene 
sulfonate 
- Powder  - -   X syrup Do not mix with orange juice 
Sotalol  I (13) Solution, Tablet  Amphoteric  5.51   X meal  
Spironolactone II (3) Tablet Neutral  0.022   X food  
Stavudine  I (26) Capsule Weak acid  40.5   X food  
Succimer - Capsule  Weak acid  2.43 X fruit juice X
1




and trimethoprim  
- Tablet, Suspension - -   X meal  




Tablet Amphoteric  21.4 
X water, other 
fluids 
   
Tamoxifen  II (3) Tablet, Solution  Weak base 0.00102   X food  




yoghurt or pudding 













Do not mix with liquids 
















Drinks Soft foods Others 







pudding, mashed potatoes. 
Do not use fruit-based foods 
Terbutaline  - Tablet  Amphoteric  213   X meal  




Tablet, Capsule  Weak base  500   X food  





1  X food* 
1
oral concentrate 
Thiothixene - Capsule  Weak base  0.0139 X water  X food  
Tiagabine - Tablet Amphoteric  0.0211   X food  





























e.g. apple, grape or orange 
juice (30 mL) 
Torsemide  - Tablet  Weak acid  0.0596   X meal  
Tramadol  I (3) 
Capsule, Tablet, 
Suspension 
















Drinks Soft foods Others 
Tranexamic acid I (44) Tablet  Amphoteric  167   X meal  
Tretinoin - Capsule  Weak acid  0.0048 X warm milk X
1 
 X meal  
1
one spoonful 
Triamterene II (3) Capsule  Weak base  0.0482   X food*  
Trifluoperazine - Tablet  Weak base 0.0122   X food*  
























Tablet Amphoteric  4.79   X meal  
Valproic acid and 
derivatives 







e.g. pudding, applesauce 
(small amount) 
Do not administer with 
carbonated drinks  
Valsartan  II (3) Tablet  Weak acid 0.0234   X food  











X food   
        
 


















Drinks Soft foods Others 

















1 tbs  
2
only 2 of the commercial 
formulations 
Vigabatrin  I (4) Tablet  Amphoteric  55.1   X food  
Vitamin A - Capsule Neutral  0.00067 X milk  X food  





   X food  
Warfarin  I (46) Tablet  Weak acid 0.017   X food  





Weak base  0.00718   X food  
Zonisamide - Capsule Weak acid  0.8   X meal   
■   Drug included in the UK formularies but without recommendations of medicine co-administration with vehicles 
■   Drug included in both the UK formularies and the Lexicomp Handbook with recommendations for medicine co-administration with vehicles 
(underlined)   Recommendations are to mix ‘with or without food/meals’ or ‘without regards to food/meals’ 
¥        
Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 1994-2016 ACD/Labs) 
* To avoid GI distress              α for extemporaneous preparations                                                            
ER: Extended release          DR: Delayed release 
Tbs: tablespoon                   mL: millilitre
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